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 In addition to increased intake of sweet solutions by mammals, learning, 
particularly classically-conditioned “Pavlovian-like” learning, also plays an important 
role. An orosensory conditioned flavor preference (CFP) can be elicited by pairing one 
novel flavor (conditioned stimulus, CS+) with a fructose solution and a second novel 
flavor (CS-) with a saccharin solution. Rats will prefer the CS+ flavor in a subsequent 2-
bottle choice test with both flavors mixed in saccharin.  Previous pharmacological 
analyses revealed that systemic administration of dopamine (DA) D1 and D2 as well as 
NMDA, but not opioid, receptor antagonists eliminated the acquisition (learning) of 
fructose-CFP.  Further, expression of an already-acquired fructose-CFP was significantly 
reduced by systemic DA D1 or D2, but not NMDA or opioid receptor antagonists.  This 
dissertation research extended the pharmacological substrates of fructose-CFP by 
examining whether systemic administration of muscarinic (scopolamine: SCOP) and 
nicotinic (mecamylamine: MEC) cholinergic receptor antagonists, or a GABAB receptor 
agonist (baclofen: BAC) affected the learning and maintenance of fructose-CFP.  
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Whereas fructose-CFP acquisition was eliminated by SCOP, but not MEC or BAC, 
fructose-CFP expression was only marginally reduced by SCOP, MEC and BAC.  
 In addition to sugars, fats can also elicit CFP by pairing two novel flavors with 
different concentrations (e.g., 3.5% and 0.9%) of corn oil (CO).  Previous studies 
indicated that acquisition of CO-CFP was eliminated by NMDA recptor antagonistm, it 
was significantly reduced by DA D1 and D2, but not opioid receptor antagonists. 
Expression of CO-CFP was mildly reduced by DA D1, DA D2, NMDA or opioid 
receptor antagonists.  In similar fashion, the effects of SCOP, MEC and BAC were 
evaluated upon acquisition and expression of CO-CFP.  Interestingly, a similar pattern of 
results emerged for fat-CFP as was found for fructose-CFP.  Thus, whereas CO-CFP 
acquisition was eliminated by SCOP, but not MEC or BAC, CO-CFP expression was 
significantly but marginally reduced by SCOP, MEC and BAC. 
In addition to learned preferences, a conditioned flavor avoidance (CFA) can be 
produced by pairing a CS+ flavor with the bitter taste of quinine. The present studies 
evaluated whether fructose-CFP, CO-CFP and quinine-CFA share common 
neurochemical substrates by determining the systemic effects of DA D1 (SCH23390: 
SCH), DA D2 (raclopride: RAC), NMDA (MK-801), opioid (naltrexone: NTX), 
muscarinic (mAch: SCOP) or nicotinic (nAch: MEC) receptor antagonists as well as 
GABAB (BAC) agonists on the acquisition of quinine-CFA. We first demonstrated that 
DA D1, NMDA and opioid, but not DA D2 receptor antagonism enhanced the CFA 
produced by the bitter taste of quinine, and then subsequently found that whereas MEC 
and BAC enhanced this avoidance, SCOP failed to alter quinine-CFA. 
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Therefore, this dissertation demonstrated the differential involvement of major 
neurotransmitter systems in two forms of preference-based and one form of avoidance-
based learning.  Accordingly, whereas the acquisition of sugar- and fat-preferences is 
primarily mediated by DA D1, DA D2, NMDA and mAch receptors, and their expression 
is primarily mediated by DA D1, DA D2, mAch and nAch receptors, the acquisition of 
quinine-avoidance is primarily mediated by DA D1, NMDA, opioid, nAch and GABAB 
receptors. 
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Chapter 1: Introduction 
Significance and Specific Aims: 
 
Humans and animals learn to use orosensory cues (e.g., taste, odor, texture) to signal 
approach to energy-dense and nutritious substances (Capaldi, 1996; Sclafani, 1995), and 
avoidance to toxic substances (Dwyer, 2011; Fanselow and Birk, 1982; Freeman and Riley, 
2009). Associative learning influences food-related preferences and avoidances, dissociating 
behavioral, neurochemical and neuroanatomical differences among four forms of food-related 
learning: conditioned flavor preferences (CFP) promoted by either the orosensory (flavor-flavor 
CFP (Sclafani and Ackroff, 1994)) or post-ingestive (flavor-nutrient CFP (Sclafani et al., 1999; 
Sclafani et al., 1999)) qualities of sugars and fats, conditioned taste-aversions (CTA), elicited by 
post-ingestive gastrointestinal malaise (Chambers and Bernstein, 1995; Garcia et al., 1974), or 
conditioned flavor avoidances (CFA) elicited by the negative orosensory qualities of quinine 
(flavor-flavor CFA (Dwyer, 2011). 
One primary focus of this dissertation examines whether the pharmacological effects 
affecting orosensory-mediated flavor-flavor CFP produce similar patterns of effects upon flavor-
flavor CFA in adult male Sprague-Dawley rats.  The behavioral pharmacology mediating the 
acquisition and expression of sugar (fructose) and/or fat (corn oil) flavor-flavor CFP has been 
investigated using antagonists of dopamine (DA) DA D1 (SCH23390), DA D2 (raclopride), N-
methyl-D-aspartate (NMDA: MK-801), or opioid (naltrexone: NTX) receptors (Baker et al., 
2003; 2004; Dela Cruz et al., 2012a; 2012b; Golden and Houpt, 2007). The major forebrain 
targets (nucleus accumbens (NAc), amygdala (AMY) and medial prefrontal cortex (mPFC) of 
the meso-limbic and meso-cortical DA system originating in the ventral tegmental area (VTA) 
(Swanson, 1982) have been implicated in the mediation of the orosensory and post-ingestive 
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substrates of sugar-CFP (Amador et al., 2014; Bernal et al., 2008; 2009; 2010; Khaimova et al., 
2004; Malkusz et al., 2012; 2014; 2015; Touzani et al., 2008; 2009a; 2009b; 2010b). However, 
the abilities of these receptor antagonists to alter the acquisition of quinine-CFA are unknown, 
and are examined in the present specific aims. 
A second primary focus of this dissertation examines two additional neurotransmitter 
receptor systems in the acquisition and expression of fructose-CFP and fat-CFP and in the 
acquisition of quinine-CFA: the cholinergic muscarinic and nicotinic receptor systems and the 
GABAB receptor system. The cholinergic system, acting through muscarinic (mAch) and 
nicotinic (nAch) receptor signaling, has been implicated both directly and as a modulator of 
overlapping limbic and cortical DA circuits previously assessed in these flavor-flavor CFP 
studies (see review: Avena and Rada, 2012).  The γ-Aminobutyric acid (GABA) system, and 
particularly its GABAB receptor, mediates both primary stimulatory (e.g., Ebenezer, 1995; Echo 
et al., 2002; Khaimova et al., 2004; Miner et al., 2010) and inhibitory (Buda-Levin et al., 2005; 
Wojnicki et al., 2006; Wong et al., 2009) behavioral effects upon food and palatable intake, and 
has also been shown to mediate responses within this same limbic DA circuit (Johnson and 
North, 1992).    Therefore, additional specific aims examine the pharmacodynamic roles of 
GABAB, mAch and nAch receptors in mediating the associative learning processes conditioned 
by either primary appetitive stimuli (e.g., sugar or fat, CFP) or primary avoidant stimuli (e.g., 
quinine: CFA) in rats. 
Specific Aim 1: Will muscarinic or nicotinic cholinergic receptor antagonism mediate the 
acquisition and expression of sugar (fructose)-CFP? 
 Previous pharmacological analyses have evaluated the neurochemical substrates of the 
acquisition (learning) and expression (maintenance) of the flavor-flavor component of sugar-
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CFP. Systemic administration of either DA D1 (SCH23390) or D2 (raclopride) receptor 
antagonists eliminated both acquisition and expression of fructose-CFP in real-feeding, food-
restricted rats and sucrose-CFP in sham-feeding, food-restricted rats (Baker et al., 2003; Hsiao 
and Smith, 1995; Yu et al., 2000a; 2000b).  Subsequent studies revealed that systemic 
administration of the non-competitive NMDA receptor antagonist (MK- 801) eliminated 
acquisition, but not expression of fructose-CFP (Golden and Houpt, 2007). In contrast, systemic 
administration of NTX, a general opioid receptor antagonist, reduced sweet intake, but failed to 
alter flavor-flavor-mediated sugar-CFP (Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). 
Therefore, DA D1, DA D2, and NMDA, but not opioid receptor signaling is required for the full 
learning (acquisition) and maintenance (expression) of fructose-CFP. 
Evidence implicating cholinergic involvement in complex aspects of food intake appears 
to be due to activity in a limbic circuit (specifically the VTA and NAc) in which cholinergic 
signaling can act directly upon preferences and avoidances either in and of itself, or through 
interactions with brain DA (see review: Avena and Rada, 2012).  Therefore, Specific Aim 1 
investigates the role of muscarinic and nicotinic cholinergic receptor signaling in mediating the 
expression and acquisition of flavor preferences conditioned by fructose in rats by examining the 
ability of muscarinic (scopolamine: SCOP) and nicotinic (mecamylamine: MEC) receptor 
antagonists to block the expression and acquisition of fructose-CFP.  
In addition to sugars, rodents are attracted to the flavor of fats (e.g., corn oil: CO) which 
may be partly mediated by taste receptors for fatty acids (Ackroff and Sclafani, 2007; 2009; 
Passilly-Degrace et al., 2009), as well as rewarding post-ingestive and orosensory properties, and 
can condition a flavor preference (Ackroff and Sclafani, 2009; Sclafani, 1999; 2004). The second 
Specific Aim addresses this corollary. 
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Specific Aim 2: Will muscarinic or nicotinic cholinergic receptor antagonism mediate the 
acquisition and expression of fat (corn oil)-CFP? 
   In contrast to fructose-CFP, systemic administration of DA D1 and D2 receptor 
antagonists produced marginal reductions in the expression of fat (CO)-CFP, and DA D2, but not 
DA D1 receptor antagonism hastened the extinction of fat-CFP acquisition (Dela Cruz et al., 
2012a). Further, systemic administration of NMDA receptor antagonists significantly reduced 
the acquisition, but not the expression of fat-CFP. Finally, opioid receptor antagonism was 
ineffective in altering this fat preference similar to that observed for fructose-CFP (Dela Cruz et 
al., 2012b). Consequently, Specific Aim 2 addresses the potential involvement of muscarinic or 
nicotinic cholinergic receptor signaling in a parallel paradigm employed for the assessment of 
DA D1, DA D2, NMDA and opioid receptor signaling in the mediation of fat-CFP elicited by the 
ingestion of a flavor (e.g., cherry) paired with a higher (3.5%) CO concentration relative to a 
flavor (e.g., grape) paired with a lower (0.9%) CO concentration.  This aim expands on the 
behavioral pharmacological relationships of the above neurochemical substrates beyond sugar 
preferences to that of fat preferences and thereby making a unifying statement about preferences 
in general. Thus, it is hypothesized that both subtypes of cholinergic receptor antagonists will 
influence the expression of fructose-CFP (Specific Aim 1) and fat-CFP (Specific Aim 2). 
However, only antagonism of the muscarinic subtype will modulate the acquisition of fructose- 
(Specific Aim 1) or fat- (Specific Aim 2) CFP. 
 The first two Specific Aims examine cholinergic receptor involvement in fructose- and 
fat-CFP. The next two Specific Aims evaluate GABAB receptor involvement. 
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Specific Aim 3: Does systemic pharmacological stimulation of GABAB receptors influence 
the acquisition and expression of sugar (fructose)-CFP?  
 Studies of reward- or aversive-related learning revealed that regions within the 
mesolimbic DA system (e.g., VTA) are in turn modulated by and receive inputs from a number 
of other neurotransmitter systems including GABA using receptor activation rather than 
inhibition in influencing reward- and/or aversive-related learning (Johnson and North, 1992; Tan 
et al., 2012; van Zessen et al., 2012).  Therefore, this specific aim addresses the specific effects 
of GABAB receptor stimulation rather than inhibition. 
There are two major receptor families for GABA: GABAA and GABAB. Systemic 
administration of the GABAA receptor agonist, muscimol, interferes with memory consolidation 
processes in forms of inhibitory avoidance learning (Castellano and McGaugh, 1990) and 
conditioned taste aversions (DiSorbo et al., 2009). However, the timing of these effects suggests 
that the effects were due to retrograde amnesic effects (Salinas and McGaugh, 1995).  In these 
studies, muscimol was most effective in interfering with learning when administered after the 
conditioning procedures (Castellano and McGaugh, 1990; DiSorbo et al., 2009). This approach is 
fundamentally different from the procedure employed in CFP studies.  Further, the systemic 
effects of GABAA agonism initially produce profound behavioral inhibitory effects associated 
with a cataleptic state followed by periods of hyperactivity (Vyazovskiy et al., 2007), which 
could potentially confound the learning effects of interest, similar to the reward-confounding 
behavioral effects of DA antagonists (Wise and Schwartz, 1981).  The mechanism of action of 
such GABAA agonists as muscimol occurs through stimulation of ionotropic GABA receptors, 
leading to a relatively quick hyperpolarization of the neuron and resulting in general depression 
of neuronal activity (see review: Johnston, 2014).  Moreover, central muscimol is very 
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commonly used as a tool in producing generalized depression in addition to its GABAA actions. 
On the other hand, GABAB agonists such as baclofen act via stimulation of metabotropic GABA 
receptors, leading to a longer term cellular cascade of events resulting in a much slower 
depression and modulation of neuronal (particularly DA) activity (Kuba et al., 2000). 
In addition, central stimulation of both subtypes of the GABA receptor (e.g., muscimol: 
GABAA and baclofen: GABAB) stimulate food intake in a receptor-specific manner (Miner et al., 
2010). However, each seem to be expressed on different clusters of neurons (Sugita et al., 1992).  
Accordingly, GABAA receptors are located mainly on non-DA-containing neurons (Churchill et 
al., 1992), while GABAB receptors are located mainly on DA-containing neurons (Margreta-
Mitrovic et al., 1999; Wirtshafter and Sheppard, 2001).  Given the proposed interactions between 
GABA and DA in the modulation of CFP and CFA, this specific aim focuses on GABAB 
signaling via systemic agonism of these receptors. 
 Another rationale for limiting our investigation to GABAB receptors is their specific 
involvement in animal psychopathological models of food intake dysregulation (e.g., binge-
eating: Berner et al., 2009; Broft et al., 2007; Buda-Levin et al., 2005; Corwin et al., 2012; de 
Beaurepatre et al., 2015; Wojnicki et al., 2006). However, the effects of peripheral GABAB 
receptor activation (via baclofen: BAC) on food intake vary.  In non-deprived rats, increases in 
food intake depend on time of consumption (Ebenezer and Patel, 2011), route of administration 
(Ebenezer and Prabhaker, 2007; Patel and Ebenezer, 2008a; 2008b), and acute tolerance (Bains 
and Ebenezer, 2013).  In contrast, BAC can also decrease food intake in diabetic and diet-
induced obese mice (Sato et al., 2007), as well as reduce intake of pure fat emulsions relative to 
chow under normal, limited-access and “binge-type” conditions in rats (Buda-Levin et al., 2005; 
Rao et al., 2008; Wang et al., 2011; Wojnicki et al., 2014; but see: Bains and Ebenezer, 2013) 
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and suppress intake of either a pure fat or a sugar-fat mixture (Avena et al., 2014; Berner et al., 
2009; Corwin et al., 2009; Wojnicki et al., 2013; Wong et al., 2009). 
Evidence implicating GABAB receptor involvement in complex aspects of food intake 
appears to be due to activity in a previously mentioned limbic circuit (specifically the VTA and 
NAc).  Additional research suggests GABAB signaling mediates both medium spiny NAc GABA 
and VTA DA outputs, possibly interacting with DA-Ach activity here (Avena and Rada, 2012; 
Hoebel et al., 2007).  Behavioral evidence also suggests the interaction of GABAB stimulation 
and DA-Ach involvement through baclofen’s ability to reduce nicotine self-administration in 
rats, in addition to being extended to glutamate (mGluR5) signaling (Markou et al. 2004).  
Therefore, Specific Aim 3 examines the roles of GABAB receptor signaling by determining 
whether the systemic GABAB (baclofen) receptor agonist will alter the acquisition and/or 
expression of fructose-CFP in an identical paradigm employed for the assessment of Specific 
Aim 1. As with the evaluation of the cholinergic system, the next Specific Aim examines 
GABAB receptor involvement in fat-CFP.  
Specific Aim 4: Does systemic pharmacological stimulation of GABAB receptors influence 
the acquisition and expression of fat (corn oil)-CFP?  
 GABAB receptor stimulation has also been implicated in the mediation of fat intake. BAC 
administered into limbic and hypothalamic sites increased food intake (e.g., Arnt et al., 1979; 
Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993), and 
was reported to be mediated through GABA receptor interactions between the VTA and NAc 
(Miner et al., 2010). Systemic BAC increased fat intake under normal conditions (e.g., Bains and 
Ebenezer, 2013; Ebenezer and Patel, 2011), but suppressed fat intake under “binge-type” 
conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al., 2005; Corwin and 
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Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al., 2009).  Furthermore, the 
reinforcing effects of rewards as well as cues associated with those rewards mediated by 
mesolimbic circuitry is modulated by GABAB receptor stimulation in optogenetic studies of food 
intake (van Zessen et al., 2012). Indeed, given that many of the animal psychopathological 
studies were mimicking binge-eating with strong effects on diets containing fat, it would be 
expected that BAC effects should exert more powerful effects on acquisition and expression of 
fat-CFP if these learning processes are intimately related to the psychopathological model. 
 The first four Specific Aims relate to the second primary focus of the research. The first 
primary focus addresses the question as to whether CFA might utilize the same pharmacological 
systems and patterns of effects as CFP. Thus, the fifth and sixth Specific Aims examine this 
possibility. 
Specific Aim 5: Can DA D1, DA D2, opioid and NMDA receptors, involved in mediating 
appetitive associative learning processes (e.g., sugar- and fat-CFP), similarly modulate 
underlying associative processes contributing to the behavioral effects of conditioned flavor 
avoidance (CFA) associative learning processes induced by primary avoidant stimuli (e.g., 
quinine, CFA)? 
 Flavor–taste avoidance learning occurs when an arbitrary flavor (CS, conditioned 
stimulus) is paired with a naturally non-preferred taste (US, unconditioned stimulus, e.g., bitter: 
quinine), and similar distinctions between flavor-flavor and flavor-nutrient processes with 
respect to avoidance and aversive conditioning have been assessed.  Former studies elucidating 
the taste-specific (US: quinine) rather than post-ingestive (US: lithium chloride) effects of 
avoidance and aversive conditioning, respectively, have suggested that it is possible for rats to 
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learn to associate negative orosensory qualities (e.g., bitter) with that of neutral flavors 
(Fanselow and Birk, 1982; Dwyer, 2011). 
 Although there is much literature elucidating the pharmacology of flavor-toxin CTA 
elicited by the pairing of a neutral flavor (CS) with that of gastrointestinal malaise (US), flavor–
taste CFA learning conditioned via non-visceral US’s (e.g., taste) has not been the subject of 
pharmacological analysis.  Thus, Specific Aim 5 addresses this gap by examining the roles of 
those pharmacological substrates assessed previously for other forms of primarily taste-mediated 
learning (e.g., fructose- and fat-CFP), including DA D1, DA D2, NMDA and opioid receptor 
signaling in flavor avoidance conditioned by the bitter taste of quinine. One simple hypothesis is 
that pharmacological effects on CFP and CFA produce parallel effects. In this model, given that 
DA D1, DA D2 and NMDA, but not opioid receptor antagonism effectively block fructose-CFP 
acquisition (Baker et al., 2003; 2004; Golden and Houpt, 2007), it would be hypothesized that 
blockade of DA D1, DA D2 and NMDA, but not opioid receptors would systematically reduce 
the magnitude of quinine-CFA acquisition. An alternate hypothesis is that pharmacological 
antagonist effects would drive CFP and CFA in the same direction. In this model, given that DA 
D1, DA D2 and NMDA, but not opioid receptor antagonism effectively block fructose-CFP 
acquisition, it would be hypothesized that blockade of DA D1, DA D2 and NMDA, but not 
opioid receptors would systematically enhance the magnitude of quinine-CFA acquisition. 
Specific Aim 6: Extending on the previous pharmacological assessments of fructose- and 
fat- CFP, will muscarinic or nicotinic cholinergic as well as GABAB receptors also mediate 
avoidance learning? 
A. Cholinergic receptors have also been previously implicated in certain forms of CFA such 
as in lithium chloride-(LiCl) induced CFA (Coil et al., 1978; Ossenkopp and Giugno, 1990; 
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Ossenkopp et al., 1986).  With respect to flavor-taste CFA, avoidant tastants such as quinine 
have been demonstrated to modulate Ach activity in itself (Ballestero et al., 2005) and influence 
adrenal catecholamine release stimulated by Ach (Jang et al., 2001). Further, nicotine depressed 
quinine-evoked responses in the nucleus tractus solitarius that were blocked by MEC (Simons et 
al., 2006).  Nicotine and quinine CFA generalized to each other in three mouse strains (Gyekis et 
al., 2012), with MEC blocking this ability in behavioral and electrophysiological assays 
(Oliveira-Maia et al., 2009). 
These data appear to implicate cholinergic receptor signaling in flavor–taste CFA and 
therefore Specific Aim 6 addresses the pharmacological roles of muscarinic (SCOP) and 
nicotinic (MEC) receptor signaling in mediating the acquisition of quinine-induced CFA.  Due to 
much behavioral evidence implicating muscarinic receptor signaling in the formation of learned 
associations conditioned by primary appetitive stimuli (Nisanov et al., 2016; Sharf et al., 2006; 
Sharf and Ranaldi, 2006), it is hypothesized that only manipulation of the muscarinic subtype 
will modulate the acquisition of quinine-CFA and that these effects will oppose those seen in 
fructose-CFP studies such that muscarinic cholinergic receptor blockade will enhance the 
magnitude of quinine-CFA. 
B. Furthermore, given the inconsistent effects of GABAB receptor agonism on various forms 
of food-related approach type learning (Berner et al., 2009; Broft et al., 2007; Buda-Levin et al., 
2005; Corwin et al., 2012; de Beaurepatre et al., 2015; Wojnicki et al., 2006), we assess the roles 
of GABAB receptor signaling in food-related avoidance type learning, thereby shedding some 
light on these inconsistencies.  As such, Specific Aim 6 also tests hypotheses as to the roles of 
GABAB receptor signaling in the acquisition of quinine-CFA.  Similar to the rationale noted in 
Specific Aims 3 and 5, if GABAB receptor signaling is interacting with DA and/or muscarinic 
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Ach at integral limbic sites, it is hypothesized that agonism of GABAB receptors will modulate 
quinine-CFA in a manner opposite to that of DA and/or muscarinic receptor antagonism for 
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Chapter 2: Background and Rationale 
General Background: 
To promote normal growth and development, humans require the intake of a multitude of 
substances including carbohydrates, fats, proteins, vitamins, minerals, fiber, and water. However, 
government data in 2015 indicated that the average diet was high in calories, added sugars, and 
saturated fats, but low in essential nutrients such as vitamin D, calcium, potassium, and fiber 
thereby posing health risks for a majority of the population (Dietary Guidelines Advisory 
Committee, 2015). This factor has contributed to increases in diet-related nutrition and metabolic 
disorders and diseases including obesity, type II diabetes, cardiovascular diseases and certain 
cancers (Dietary Guidelines Advisory Committee, 2015). 
As an example, although obesity may be due partially to genetic factors (Choquet and 
Mayre, 2011), the presence of unlearned preferences and aversions (Menella and Beauchamp, 
2005; Roitman et al., 2008; Sclafani, 2004), as well as the abundance of processed, energy dense 
and cost-efficient, yet nutrient-sparse foods (Dietary Guidelines Advisory Committee, 2015; 
Drenowski and Specter, 2004), another significant contributing factor to non-compliance with 
dietary guidelines and the development of diet-based nutrition and metabolic disorders is 
learning (Gibson and Brunstrom, 2007; Roitman et al., 2008; Scalfani, 2004; Yeomans, 2008). In 
addition to these factors, substantial animal research has shown that fats and sugars are both 
recognized as contributing to the palatability of foods, overeating, and diet-induced obesity 
through their inherent positive hedonic properties as well as learning processes associated with 
the preferences for fat- and sugar-rich foods (Sclafani, 1999).  It has also been proposed that 
sugars, much like other substances of abuse such as alcohol, are able to elicit several components 
of addiction such as bingeing, withdrawal and craving in animal models (Avena et al., 2008a), 
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possibly contributing to the development of diet-induced obesity.  Evidence supporting the 
inherent negative hedonic qualities and learning processes associated with the unpalatability and 
avoidance of bitter substances is far less conclusive (Dwyer, 2011; Fanselow and Birk, 1982).  
These preferences, and to a lesser extent, avoidances (Dwyer, 2011; Fanselow and Birk, 1982; 
Rotella et al., 2014; 2015), are based, in part, on learned associations between the various flavor 
elements in foods (e.g., flavor–flavor conditioning), and between flavor cues and post-ingestive 
consequences (e.g., flavor–nutrient/flavor-toxin conditioning). 
Elucidating the neurochemical substrates of orosensory associative processes with an 
array of primary appetitive as well as aversive stimuli is critical to our understanding of 
dysregulations both in brain and bodily nutritional homeostatic mechanisms as well as 
conditioned goal-directed and consummatory behaviors associated with preventable nutritional 
and metabolic disorders.  This research provides further insight as to alternate potential 
neurochemical substrates modulating traditional neurotransmitter systems (such as DA) in 
addition to mediating the activity of reward-related and/or limbic structures within the brain in 
and of themselves during orosensory associative processes.  The series of Specific Aims were 
addressed by incorporating systemic pharmacological manipulations on our well-established 
flavor-flavor paradigms. 
The remainder of the Background section is organized to cover the following topics: 1) 
conditioned flavor preferences (CFP) for sugars and fats and 2) pharmacological and 
neuroanatomical substrates of CFP.  Based on these preliminary findings, the rationale for the 
studies of the dissertation research is then presented: 3) potential roles of cholinergic receptor 
systems in mediating CFP; 4) potential roles of GABAB receptors in mediating CFP; and 5) 
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conditioned flavor avoidances (CFA) and their potential pharmacology. This will be followed by 
Section 6 describing how these six specific aims are organized into the series of research studies. 
1. Conditioned Flavor-Flavor Preferences (CFP): 
1A. Sugar-CFP (Flavor-Flavor vs. Flavor-Nutrient Conditioning) 
 Rats use flavor cues (taste, odor, texture) to guide their selection of nutritious foods 
(Capaldi, 1996). Sugar-induced conditioned flavor preferences (CFP) occur when a novel flavor 
(CS+) is paired with a more-preferred sucrose (16%) or fructose (8%) and saccharin (0.2%) 
solution relative to a flavor (CS-) paired with a less-preferred saccharin (0.2%) solution. These 
sugar-CFPs are based on learned associations between food flavor elements (flavor-flavor 
conditioning) as well as between flavor and post-ingestive consequences (flavor-nutrient 
conditioning) (Sclafani, 1995). Flavor-flavor conditioning has been studied for sucrose in sham 
feeding rats (Yu et al., 1999; 2000a; 2000b), and for fructose in real-feeding rats (Baker al., 
2003; 2004), given the inability of fructose to condition preferences after intragastric (IG) 
administration (Sclafani and Ackroff, 1994; Sclafani et al., 1993; 1999). In contrast, glucose is 
capable of producing CFP following oral and IG administration (Dela Cruz et al., 2014; Sclafani 
and Ackroff, 1994; Sclafani et al., 1993; 1999).  Specific Aims 1 and 3 will expand our 
knowledge of the pharmacological substrates of sugar (e.g., fructose) flavor-flavor conditioning.  
 Conditioned flavor preferences (and subsequent description of conditioned flavor 
avoidance) is described throughout this dissertation as “Pavlovian-like” conditioning rather than 
true Pavlovian conditioning.  For all studies, multiple UCSs were paired with a neutral stimulus 
(NS) as opposed to a single US and NS pairing in traditional Pavlovian conditioning studies.  
Thus, in sugar-CFP studies, the CS+ was operationally defined as the more preferred solution 
containing one NS (e.g. cherry Kool Aid) paired with two UCSs (fructose + saccharin: having 
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both orosensory and post-ingestive consequences) and the CS- was operationally defined as the 
less preferred solution containing a different NS (e.g. grape Kool Aid) paired with one UCS 
(saccharin: having only orosensory consequences).  Thus, the “CS-” is not a negative stimulus, 
but rather a “less-preferred” stimulus.  In fat-CFP studies, the CS+ was operationally defined as 
the more preferred solution containing one NS (e.g. cherry Kool Aid) paired with one UCS with 
a higher (3.5%) concentration of corn oil and the CS- was operationally defined as the less 
preferred solution containing a different NS (e.g. grape Kool Aid) paired with one UCS with a 
lower (0.9%) concentration of corn oil. Previous studies (Dela Cruz et al., 2012a, 2012b) show 
that rats consume less of the 0.9% concentration relative to the 3.5% concentration of corn oil.  
In quinine-CFA studies the CS+ was operationally defined as the less preferred solution 
containing one NS (e.g. cherry Kool Aid) paired with three UCSs (quinine + fructose + 
saccharin) and the CS- was operationally defined as the more preferred solution containing a 
different NS (e.g. grape Kool Aid) paired with two UCSs (fructose + saccharin).  Therefore, we 
operationally define the CS+ as the more preferred solution and the CS- as the less preferred 
solution in CFP studies, while we operationally define the CS+ as the less preferred solution and 
CS- as the more preferred solution in CFA studies. 
 The primary purpose of the present series of studies was to analyze the pharmacology of 
CFP and CFA. Therefore, given the short-term (~2 h) effects of the drugs, it was imperative that 
we utilized a conditioning procedure in which rats were exposed to solutions for multiple 
sessions of short durations (~1h).  It should be noted that for the development of fat and 
carbohydrate flavor preferences, paradigms using short-term (30min) or long-term (22h) training 
session lengths have been done (Lucas & Sclafani, 1999). They found that intake and/or 
preference could vary depending on the duration of the subsequent choice tests (either 30min or 
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22h), and that this influenced the extent to which carbohydrates were preferred over fats, and 
vice versa (Lucas & Sclafani, 1999).  Thus, short-term choice tests do not always predict the 
long-term intakes and preferences for fats and carbohydrates, thereby limiting our 
pharmacological findings to only short-term tests. 
1B. Fat-CFP 
 Rodents are also attracted to the flavor of fat (e.g., corn oil) which may be partly 
mediated by taste receptors for fatty acids (Ackroff and Sclafani, 2007; Ackroff and Sclafani, 
2009; Passilly-Degrace et al., 2009), as well as rewarding post-ingestive and orosensory 
properties (Ackroff and Sclafani, 2009; Sclafani, 1999; Sclafani, 2004).  Prior studies have 
shown that in addition to carbohydrates such as sugars, fats are also capable of eliciting robust 
and stable flavor-flavor and flavor-nutrient CFPs in rats (Dela Cruz et al., 2012a; 2012b; Lucas 
and Sclafani, 1989; Lucas and Sclafani, 1999).  With respect to fat “Pavlovian-like” associative 
processes, similar distinctions between the capability of certain sugars (e.g., fructose vs. glucose) 
to condition flavor preferences via either orosensory or post-ingestive processes have been 
demonstrated utilizing varying methodologies, fats as unconditioned stimuli, and CS-US delay 
intervals (Ackroff and Sclafani, 2009).  Accordingly, sham-feeding studies comparing nutritive 
and nonnutritive oil (corn oil and mineral oil, respectively) intake and preferences suggest that 
while both oils are capable of eliciting intake via their palatable orosensory properties, intake of 
nutritive oils are preferred during oil-oil choice testing (Mindell et al., 1990) and are preferred 
during separate oil emulsion-saccharin choice testing in food-restricted rats (Elizade and 
Sclafani, 1990).  Accordingly, Specific Aims 2 and 4 expand our knowledge of the 
pharmacological substrates of fat (e.g., corn oil) flavor-flavor conditioning. 
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2. Pharmacological and Neuroanatomical Substrates of CFP: 
2A. Acquisition and Expression of Fructose-CFP 
The pharmacological substrates of conditioned flavor preferences (CFP) initially focused 
on brain DA and opioid systems (see reviews: Sclafani et al., 2011; Touzani et al., 2010a). Sweet 
taste activated mesolimbic and mesocortical DA circuits involved in the mediation of natural as 
well as drug rewards (e.g., Genn et al., 2004; Hajnal et al., 2003). DA receptor antagonism also 
suppressed the intake of sweet solutions in rats (Geary and Smith, 1985; Muscat and Willner, 
1989; Xenakis and Sclafani, 1981).   
As previously mentioned, flavor-flavor conditioning has been studied for sucrose in 
sham-feeding rats (Yu et al. 1999; 2000a; 2000b), and for fructose in real-feeding rats (Baker et 
al., 2003; 2004), given the inability of fructose to condition preferences after IG administration 
(Sclafani and Ackroff, 1994; Sclafani et al., 1993; 1999).  Research was then aimed to assess the 
underlying pharmacological and neuroanatomical substrates moderating these distinct behavioral 
phenomena.  Accordingly, systemic administration of DA D1 (SCH23390) or D2 (raclopride) 
receptor antagonists eliminated both acquisition and expression of fructose-CFP in real-feeding, 
food-restricted rats and sucrose-CFP in sham-feeding, food-restricted rats (Baker et al., 2003; 
Hsiao and Smith, 1995; Yu et al., 2000a; 2000b). 
A critical role of the mesocorticolimbic DA system has been identified in reward 
processes and reward-related learning (Berridge and Robinson, 1998; Salamone and Correa, 
2012; Smith, 2004; Wise, 2008). In this system, DA neurons located in the VTA project to 
cortical and limbic structures including the NAc, AMY and the mPFC (Swanson, 1982). Another 
brain DA system implicated in flavor learning (Caulliez et al., 1996) includes the A13 DA 
neurons located in the zona incerta that innervate the lateral hypothalamus (LH) (Wagner et al., 
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1995). Central DA receptor mediation of the acquisition of fructose-CFP is controlled by the 
AMY and mPFC (Bernal et al., 2009; Malkusz et al., 2012).  Central DA receptor mediation of 
the expression of fructose-CFP is controlled by the NAc, AMY, medial orbital frontal cortex 
(mOFC) and LH (Amador et al., 2014; Bernal et al., 2008; Bernal et al., 2009; Malkusz et al., 
2015). 
 In addition to DA, the roles of other neurotransmitter systems in mediating forms of CFP 
have been evaluated.  For example, although it has been demonstrated that naloxone, a general 
opioid receptor antagonist, treatment during a flavor and glucose training session prevented rats 
from acquiring a preference for a glucose-paired flavor (Mehiel, 1996), subsequent studies 
demonstrated that systemic administration of NTX reduced sweet intake, but failed to alter 
acquisition or expression of flavor-flavor-mediated sugar-CFP induced by sucrose in sham-
feeding rats or fructose in real-feeding rats (Baker et al., 2004; Yu et al., 1999). Central 
injections of NTX into the NAc, mPFC, AMY or LH also failed to affect fructose-CFP 
expression (Bernal et al., 2010; Malkusz et al., 2014). Systemic administration of NMDA 
receptor antagonists (MK-801) eliminated acquisition, but not expression of fructose-CFP 
(Golden and Houpt, 2007). Further, systemic administration of cannabinoid (CB1) receptor 
inverse agonists (AM251) reduced expression, but not acquisition of fructose-CFP (Miner et al., 
2008). Therefore, DA D1, DA D2, NMDA and CB1, but not opioid receptor signaling is required 
for the full learning (acquisition) and maintenance (expression) of fructose-CFP, apparently in 
limbic sites associated with reward. 
2B. Acquisition and Expression of Corn Oil-CFP 
 DA mediation of the rewarding effect of fat flavor is suggested by the findings that corn 
oil sham-feeding promotes NAc DA release (Liang et al., 2006), and DA D1 and D2 antagonists 
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suppress the sham feeding response to corn oil and real-feeding of fats in rats (Baker et al., 2001; 
Davis et al., 2006; Rao et al., 2008; Weatherford et al., 1988; 1990). DA D2, but not D1 
antagonism also suppressed operant responding for corn oil in mice (Yoneda et al., 2007).  In 
inbred mice, strain differences were observed in the ability of the D1 antagonist, SCH23390 to 
significantly reduce fat intake whereas the D2 antagonist, raclopride, had minimal effects on fat 
intake (Dym et al., 2010). 
The opioid system has been implicated in the mediation of fat appetite and intake. In 
particular, there are many reports of opioid receptor antagonists suppressing fat intake in rats and 
mice (Cole et al., 1995; Dym et al., 2010; Glass et al., 2000; Higgs and Cooper, 1998; Islam and 
Bodnar, 1990; Marks-Kaufman et al., 1985; Naleid et al., 2007; Sahr et al., 2008). In addition, 
administration of the mu-selective opioid agonist, D-Ala2-NMe-Phe4-Glyol5-enkephalin 
(DAMGO) into the NAc stimulated high-fat intake in rats (Zhang et al., 1998). Place preferences 
conditioned by oral intake of corn oil or a high-fat snack food are also attenuated by NTX 
administration (Jarosz et al., 2006; Shide and Blass, 1991). Finally, it was demonstrated that the 
opioid system contributes to the acquisition for dietary fat but is not required for its maintenance 
and the reinforcement for fat intake and quantity consumed are differentially moderated by this 
system (Sakamoto, 2015). 
Glutamate signaling has been shown to play a crucial role in learning and memory and 
the underlying synaptic plasticity (Rezvani, 2006). More specifically, glutamate receptor 
activation is required for food-related incentive learning. That is, glutamate antagonism within 
the AMY and NAc impaired appetitive instrumental learning (Hernandez et al., 2005; Kelley et 
al., 1997). Glutamate antagonism within the AMY also impaired both the acquisition and 
expression of conditioned taste avoidance (Yasoshima et al., 2000). Within the VTA, glutamate 
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antagonists impaired cue-sucrose learning and DA release in the NAc elicited by the sucrose-
predictive cue (Stuber et al., 2008; Zellner et al., 2009; Zweifel et al., 2009). Interestingly, 
glutamate receptor antagonism by systemic administration of MK-801 blocked the acquisition of 
fructose-CFP (Golden and Houpt, 2007). 
In contrast to the pronounced pharmacological effects observed on the acquisition and 
expression of fructose-CFP, the acquisition and expression of CO-CFP was only attenuated by 
DA D1 and D2 (Dela Cruz et al., 2012a), but not opioid receptor antagonism (Dela Cruz et al., 
2012b), while the non-competitive NMDA receptor antagonist (MK-801) eliminated only the 
acquisition of CO-CFP (Dela Cruz et al., 2012b). 
3. Potential Roles of Cholinergic Receptor Systems in Mediating CFP: 
3A. Cholinergic Systems and Fructose-CFP (Specific Aim 1) 
Ach has been implicated in food intake, particularly the “addictive” aspects of excessive 
sugar intake, by its interactions with brain DA systems (Avena and Rada 2012). 
Neuroanatomical interactions presumably occur through Ach inputs from the pedunculopontine 
and laterodorsal tegmental (PPT/LDT) nuclei to VTA DA cells (Holmstrand and Sesack, 2011; 
Maskos, 2008; Omelchenko and Sesack, 2005; Woolf et al., 1990) or through Ach or DA 
terminal innervation of Ach-containing interneurons in the NAc (Dautan et al., 2014; de Rover et 
al., 2002; Witten et al., 2010; Zhou et al., 2002). These interactions are integral in the 
formulation of central mechanisms involved in food reward (see reviews: Avena and Rada, 2012; 
Kelley et al., 2005; Laurent et al., 2014; Mark et al., 2011; McFadden et al., 2014; Nunes et al., 
2013).  Additionally, food intake increases Ach release in the AMY (Hajnal et al., 1998) and 
NAc (Avena et al., 2006; 2008a; 2008b; 2008c; Mark et al., 1992; Mark et al., 1995). Moreover, 
central studies of food and drug reward suggests that these brain DA-Ach systems interact to 
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modulate medium spiny GABAergic output within the NAc (Hoebel et al., 2007) as well as 
DAergic output within the VTA (Mark et al., 2011; Mifsud et al., 1989; Schilstrom et al., 1998; 
Schmidt et al., 2011).  Additionally, muscarinic receptor antagonism with SCOP in the NAc 
reduced both deprivation-induced feeding (Pratt and Blackstone, 2009) and NAc DAMGO-
induced feeding (Perry et al., 2009), and NAc sites at which SCOP suppressed feeding and 
DAMGO-induced feeding overlapped (Perry et al., 2014). DAMGO-induced increases in high-
fat feeding were blocked by NTX and SCOP, but not by antagonists of DA, glutamate or 
nicotinic receptors (Will et al., 2006). VTA muscarinic receptor blockade also mediated cue-
related responses to feeding such that SCOP administered into the VTA disrupted free-feeding 
and acquisition, but not the maintenance of food-related learning (Sharf and Ranaldi, 2006). 
SCOP administered into the NAc core induced avoidance to flavor and spatial cues (Pratt et al., 
2007). SCOP administered into the ventral hippocampus impaired memories for socially-
transmitted food preferences (Carballo-Marquez et al., 2009). To determine cholinergic 
involvement in the development of sugar preferences, one of our preliminary studies (Rotella et 
al., 2015) demonstrated that SCOP, but not MEC completely blocked the acquisition of fructose-
CFP. Also, both SCOP and MEC significantly reduced, but failed to block the expression of 
fructose-CFP.  
3B. Cholinergic Systems and Corn Oil-CFP (Specific Aim 2) 
Cholinergic receptor signaling have been implicated in the mediation of fat intake.  
Consumption of a high-fat diet for one week reduced acetylcholinesterase activity in the frontal 
cortex, hypothalamus and midbrain, as well as increased both β2-nAchR binding in the medial 
prefrontal cortex and substantia nigra, in addition to α7-nAchR binding in the lateral and 
ventromedial hypothalamus. MEC blocked the enhancements in exploratory and novelty-seeking 
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behaviors induced by high-fat consumption (Morganstern et al., 2012). Chronic nicotine reduced 
body weight in mice, particularly those maintained on a high-fat diet, an effect blocked by MEC 
co-treatment (Mangubat et al., 2012). Accumbal microinjections of SCOP markedly reduced fat 
intake elicited by accumbal administration of the mu-opioid receptor agonist, DAMGO, and also 
reduced food intake in food-deprived rats (Perry et al., 2009; Will et al., 2006). However, 
accumbal SCOP failed to affect fat intake itself (Will et al., 2006). 
4. Potential Roles of the GABAB System in Mediating CFP: 
4A. GABAB Systems and Fructose-CFP (Specific Aim 3) 
Given the involvement of the DA or Ach systems in mediating fructose-CFP as well as 
other forms of NAc GABA-mediated food and drug related learning, another potential candidate 
neurotransmitter system which has not been evaluated in the modulation fructose-CFP is the 
GABAergic system.  As previously mentioned in Specific Aim 3 we chose to limit our 
investigation to GABAB receptors given evidence supporting the potential confounding 
behavioral, pharmacological and cognitive effects of systemic administration of GABAA receptor 
agonists (e.g., muscimol) in similar learning paradigms (Salinas and McGaugh, 1995; Castellano 
and McGaugh, 1990; DiSorbo et al., 2009; Kuba et al., 2000; see review: Johnston, 2014), as 
well as research suggesting the possible lack of GABAA involvement in the DA system (Miner et 
al., 2010; Sugita et al. 1992; Churchill et al., 1992; Margreta-Mitrovic et al., 1999; Wirtshafter 
and Sheppard, 2001) and evidence supporting the specific involvement of GABAB signaling in 
animal psychopathological models of food intake dysregulation (e.g., binge-eating: Berner et al., 
2009; Broft et al., 2007; Buda-Levin et al., 2005; Corwin et al., 2012; de Beaurepatre et al., 
2015; Wojnicki et al., 2006). 
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Correspondingly, systemic administration of the GABAB agonist, baclofen, has been 
shown to influence the intake of both solid and liquid diets (Ebenezer, 1995), fats and sugars 
(Avena et al., 2014; Berner et al., 2009; Ebenezer and Pringle, 1992), and modulate short-term 
food intake (Patel and Ebenezer, 2010) as a function of texture (Wojnicki et al., 2013).  
Additionally, a systemic study comparing GABAB mediated alterations of food intake supported 
a primarily central role in baclofen’s effects, as 3-aminopropylphosphinic acid (3-APA), also a 
GABAB agonist but is impermeable to the blood-brain barrier, failed to alter food intake 
(Ebenezer and Patel, 2004).  Moreover, central studies implicate GABA receptor involvement at 
limbic and hypothalamic structures in increasing food intake (Echo et al., 2002; Khaimova et al., 
2004; Miner et al., 2010; Stratford and Kelley, 1997).  As mentioned, however, it should be 
noted that BAC-induced modulations to food, sugar, and fat intake vary widely as a function of 
time of feeding (Ebenezer and Patel, 2011), route of administration (Bains and Ebenezer, 2013; 
Ebenezer and Prabhaker, 2007; Patel and Ebenezer, 2008a; 2008b), homeostatic state (Budna-
Levin et al., 2005; Rao et al., 2008; Sato et al., 2007; Wang et al., 2011; Wojnicki et al., 2014), 
and acute tolerance (Bains and Ebenezer, 2013) rendering it’s exact effects inconclusive.  Given 
the evidence describing the mixed effects of BAC on intake per se, it is hypothesized that 
systemic GABAB agonist administration will alter the acquisition and expression of fructose-
CFP. 
4B. GABAB Systems and Corn Oil-CFP (Specific Aim 4) 
GABAB receptor signaling has also been implicated in the mediation of fat intake. BAC 
administered into limbic and hypothalamic sites increased food intake (e.g., Arnt and Scheel-
Kruger, 1979; Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 
1993), and was reported to be mediated through GABA receptor interactions between the ventral 
  24 
 
tegmental area and nucleus accumbens (Miner et al., 2010). Systemic BAC increased fat intake 
under normal conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), but 
suppressed fat intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; 
Buda-Levin et al., 2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; 
Wong et al., 2009).  Additionally, the reinforcing effects of primary rewarding and conditioned 
stimuli mediated by mesolimbic circuitry was found to be modulated by GABAB receptor 
activation in optogenetic studies of food intake (van Zessen et al., 2012). 
5. Conditioned Flavor-Flavor Avoidances (CFA): 
5A. Quinine-CFA: Parallels of Fructose-CFP 
 Flavor–taste avoidance learning, occurs when an arbitrary flavor (CS) is paired with a 
naturally non-preferred taste (US, e.g., bitter, quinine).  Fanselow and Birk (1982) originally 
reported that rats learned to avoid a flavor (e.g., almond) mixed into a quinine solution although 
their study was not a pure CFA because the animals had a second flavor (e.g., vanilla) mixed into 
a preferred saccharin solution.  More recently, Dwyer (2011) trained rats to drink a CS+ flavor 
(e.g., cherry) added to a quinine solution and a CS− flavor (e.g., grape) added to water in 
separate sessions.  In a subsequent two-bottle choice test, the rats avoided the CS+ when both CS 
flavors were presented in plain water. 
 Previous studies elicited quinine-CFA by employing a paradigm in which thirsty rats 
were trained to drink flavored water adulterated with quinine (Dwyer, 2011; Harris and 
Westbrook, 1998). Specific Aim 5 utilizes a different design to match that used in our flavor–
taste preference conditioning studies in which hungry rats were trained with a flavored fructose 
and saccharin solution and a less preferred flavored saccharin solution (Baker et al., 2003). In 
this case, hungry rats are trained with two differently flavored fructose and saccharin (FS) 
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solutions with one adulterated with quinine.  We examine a range of quinine concentrations to 
determine a concentration that is able to condition a flavor avoidance comparable in magnitude 
to the preference obtained in earlier fructose-CFP studies (Baker et al., 2003; 2004; Bernal et al., 
2008; 2009; 2010; Golden and Houpt, 2007; Malkusz et al., 2012). 
5B. Potential Pharmacological Substrates of Quinine-CFA (Specific Aim 5) 
Conditioned flavor avoidances (CFA) can be induced by either ingested toxins that 
induce gastrointestinal distress (flavor–toxin learning; see review: Freeman and Riley, 2009) or 
by aversive tastes (flavor-taste learning; e.g., Dwyer, 2011; Fanselow and Birk, 1982). 
Pharmacological analyses have examined DA D1, DA D2, NMDA and opioid 
antagonists in flavor-toxin CFA learning. DA D1, but not D2 antagonism disrupted the 
acquisition of a LiCl-induced CFA following systemic administration, and following central 
administration into the LH or NAc shell (Caulliez et al., 1996; Fenu et al., 2001; 2005; 2009). 
Blockade of NMDA, α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
metabotropic glutamate receptors in the AMY disrupted LiCl-induced CFA (Yasoshima et al., 
2000). Naloxone enhanced taste aversions elicited by LiCl (Davis et al., 2009; Miceli et al., 
1979; Smurthwaite et al., 1992).  Given this as well as the differential effects of DA D1, DA D2, 
NMDA and opioid receptor signaling on flavor-flavor learning elicited by the palatability of 
fructose and corn oil, Specific Aim 5 assesses the potential role of these receptor candidates in 
modulating the acquisition and expression of flavor-flavor CFP elicited by the unpalatability of 
quinine. 
5C. Cholinergic Systems and Quinine-CFA (Specific Aim 6A) 
Cholinergic receptors have also been previously implicated in certain forms of CFA. In 
flavor-toxin CFA learning, SCOP attenuated LiCl-induced CFA without altering aversion to 
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quinine (Coil et al., 1978). SCOP and nicotine are capable of eliciting flavor-taste CFAs with the 
former abolished and the latter enhanced by lesions placed in the area postrema (Ossenkopp et 
al., 1986; Ossenkopp and Gugno, 1990). A possible role for cholinergic receptors in flavor-taste 
CFA is supported by the ability of quinine to inhibit Ach currents in alpha-9-alpha-10-containing 
nicotinic Ach receptors in Xenopus oocytes (Ballestero et al., 2005), and adrenal catecholamine 
secretion evoked by Ach stimulation of muscarinic and nicotinic receptors (Jang et al., 2001). In 
turn, nicotine depressed quinine-evoked responses in the nucleus tractus solitarius that were 
blocked by MEC (Simons et al., 2006). Nicotine and quinine CFA generalized to each other in 
three mouse strains (Gyekis et al., 2012), with MEC blocking this ability in behavioral and 
electrophysiological assays (Oliveira-Maia et al., 2009). Thus, these data appear to implicate 
cholinergic receptor signaling in flavor-taste CFA and as a result, Specific Aim 6A addresses the 
roles of muscarinic and nicotinic cholinergic receptor signaling in mediating quinine-induced 
CFA. 
5D. GABA Systems and Quinine-CFA (Aim 6B)  
 A role for GABAB receptor systems in conditioned aversions is supported by the ability 
of the GABAB agonist, BAC, but not the GABAB antagonist, saclofen, to suppress saccharin-
induced drinking following pairing (Echo et al., 2002; Wilson et al., 2011). However, another 
study using a similar dose range found that systemic BAC failed to induce an aversion or affect 
ethanol-induced aversions (Chester and Cunningham, 1999).  Further, although systemic BAC 
failed to alter operant responding to quinine-adulterated solutions (Petry and Heyman, 1997), it 
did enhance the discriminative abilities of D-amphetamine in a conditioned taste aversion 
procedure (Miranda et al., 2009).  Accordingly, Specific Aim 6B tests the involvement of 
GABAB receptor signaling in quinine-CFA. 
  27 
 
6. Organization of the Studies: 
 The six specific aims of this dissertation research are systematically examined in four 
major documents that have successfully undergone peer review and have indeed been published.  
For ease of presentation, Chapters 3-6 present the four papers in the order that they were 
published.   Thus, Dissertation Research Paper 1 (Chapter 3) addresses Specific Aim 5, 
Dissertation Research Paper 2 (Chapter 4) addresses Specific Aims 1 and 6A, Dissertation 
Research Paper 3 (Chapter 5) addresses Specific Aims 3 and 6B, and Dissertation Research 
Paper 4 (Chapter 6) addresses Specific Aims 2 and 4. 
 Dissertation Research Paper 1: The goals of Specific Aim 5 were to determine whether 
DA D1, DA D2, opioid and NMDA receptors, involved in mediating appetitive associative 
learning processes (e.g., sugar- and fat-CFP), would similarly moderate underlying associative 
processes contributing to the behavioral effects of CFA associative learning processes induced 
by primary aversive stimuli (e.g., quinine). Thus, we addressed the pharmacology of flavor-taste 
CFA by examining the roles of DA D1, DA D2, NMDA and opioid receptor signaling in flavor 
avoidance conditioned by the bitter taste of quinine. This paper, entitled “Role of NMDA, opioid 
and dopamine D1 and D2 receptor signaling in the acquisition of a quinine-conditioned flavor 
avoidance in rats”, was published in Physiology and Behavior (128, 133-140, 2014) (Chapter 3).    
 Dissertation Research Paper 2: The goals of Specific Aim 1 were to determine whether 
muscarinic or nicotinic cholinergic receptor antagonism mediates the acquisition and expression 
of sugar (fructose)-CFP. Further, one goal of Specific Aim 6 determines whether muscarinic or 
nicotinic receptor antagonism mediate quinine-CFA. Therefore, we evaluate the ability of SCOP 
and MEC for their effects upon the acquisition and expression of fructose-CFP (Specific Aim 1) 
and acquisition of quinine-CFA (Specific Aim 6A). This paper, entitled “Muscarinic and 
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nicotinic cholinergic receptor antagonists differentially mediation acquisition of fructose-
conditioned flavor preference and quinine-conditioned flavor avoidance in rats”, was published 
in Neurobiology of Learning and Memory (123, 239-249, 2015) (Chapter 4). 
Dissertation Research Paper 3: The goal of Specific Aim 3 was to determine whether 
systemic pharmacological stimulation of GABAB receptors influence the acquisition and 
expression of sugar (fructose)-CFP. Further, a second goal of Specific Aim 6 determines whether 
stimulation of GABAB receptors mediate quinine-CFA. Therefore, we evaluate the ability of 
BAC for its effects upon the acquisition and expression of fructose-CFP (Specific Aim 3) and 
acquisition of quinine-CFA (Specific Aim 6B). This paper, entitled “Baclofen differentially 
mediates fructose-conditioned flavor preference and quinine-conditioned flavor avoidance in 
rats”, was published in European Journal of Pharmacology (775, 15-21, 2016a) (Chapter 5). 
 Dissertation Research Paper 4:  The goals of Specific Aim 2 were to determine whether 
muscarinic or nicotinic cholinergic receptor antagonism mediates the acquisition and expression 
of fat (corn oil)-CFP. Similarly, the goal of Specific Aim 4 determines whether stimulation of 
GABAB receptors antagonism mediate the acquisition and expression of fat-CFP. Therefore, we 
evaluate the ability of SCOP and MEC (Specific Aim 2) as well as BAC (Specific Aim 4) for 
their effects upon the acquisition and expression of fat-CFP. This paper, entitled “Muscarinic, 
nicotinic and GABAergic receptor signaling differentially mediate fat-conditioned flavor 
preference in rats”, was published in Pharmacology, Biochemistry, and Behavior (150-151, 14-
21, 2016b) (Chapter 6). 
  29 
 
Chapter 3: Role of NMDA, opioid and dopamine D1 and D2 receptor signaling in the 
acquisition of a quinine-conditioned flavor avoidance in rats 
1. Introduction: 
 Animals use flavor cues (taste, odor, texture) to guide their selection of nutritious foods 
and avoidance of toxic foods (or fluids) with learning shaping this selection (Capaldi, 1996; 
Sclafani, 1995). Four common types of food learning have been identified: CFP induced by the 
orosensory (flavor-taste learning; e.g., (Baker et al., 2004; Baker et al., 2003, Holman, 1975, 
Sclafani, 1995; Sclafani & Ackroff, 1994; Sclafani et al., 1993; Sclafani et al., 1999; Yu et al., 
1999; 2000a; 2000b)) and/or the post-oral (flavor-nutrient learning; e.g., (Azzara et al., 2000; 
2001; Touzani et al., 2008)) reinforcing properties of foods such as sugars, and CFA induced by 
either ingested toxins that induce gastrointestinal distress (flavor-toxin learning; see review: 
(Freeman & Riley, 2009)) or an aversive taste (flavor-taste learning; e.g., (Dwyer,  2011; 
Fanselow & Birk, 1982)). This paper is using the term, avoidance rather than aversion, as we did 
not measure taste reactivity following CFA and to allow consistency throughout the text. The 
fourth and least studied type of food learning, flavor-taste avoidance learning, occurs when an 
arbitrary flavor (CS) is paired with a naturally unpreferred taste (US, e.g., bitter quinine). 
Fanselow and Birk (1982) originally reported that rats learned to avoid a flavor (e.g., almond) 
mixed into a quinine solution although their study was not a pure CFA because the animals had a 
second flavor (e.g., vanilla) mixed into a preferred saccharin solution. More recently, Dwyer 
(2011) trained rats to drink a CS+ flavor (e.g., cherry) added to a quinine solution and a CS- 
flavor (e.g., grape) added to water in separate sessions. In a subsequent two-bottle choice test, the 
rats avoided the CS+ when both CS flavors were presented in plain water.  
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Numerous studies have investigated the neurochemical substrates of flavor-taste and 
flavor-nutrient CFP as well as flavor-toxin CFA using DA, NMDA and opioid receptor 
antagonists. In CFP studies, systemic treatment with DA D1 and D2 receptor antagonists 
attenuated the acquisition and expression of a flavor-taste CFP produced by the sweet taste of 
sucrose or fructose (Baker et al., 2003; Yu et al., 2000a; 2000b). In contrast, systemic DA D1 but 
not D2 antagonism blocked the acquisition, and to a lesser degree the expression of a flavor-
nutrient CFP elicited by IG sucrose infusions (Azzara et al., 2001). Brain sites involved in DA 
modulation of flavor-taste and flavor-nutrient CFP by sugar include the NAc (Bernal et al., 2008; 
Touzani et al., 2008), AMY (Bernal et al., 2009; Touzani et al., 2009) and mPFC (Malkusz et al., 
2012; Touzani et al., 2010). In flavor-toxin CFA studies, systemic DA D1, but not D2 
antagonism disrupted the acquisition of a LiCl-induced CFA (Fenu et al., 2005; 2009). Central 
drug studies revealed that DA D1 receptor antagonists administered into either the LH (Caulliez 
et al., 1996) or shell of the NAc (Fenu et al., 2001) disrupted the acquisition of a LiCl-induced 
CFA. 
In NMDA receptor signaling studies, the acquisition, but not the expression of flavor-
taste mediated fructose-CFP was blocked by systemic treatment with the non-competitive 
NMDA antagonist, MK-801 (Golden & Houpt, 2007). Blockade of NMDA, AMPA and 
metabotropic glutamate receptors in the AMY disrupted LiCl-induced CFA (Yasoshima et al., 
2000), and blockade of NMDA receptors in the AMY eliminated the acquisition of flavor-
nutrient- CFP (Touzani et al., 2013). In contrast to DA and glutamate involvement, systemic or 
central administration of the general opioid antagonist, NTX had little or no effect on flavor 
preference conditioning by the taste or nutritive actions of sugar (Azzara et al., 2000; Baker et 
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al., 2004; Bernal et al., 2010; Yu et al., 1999). However, naloxone enhanced taste aversions 
elicited by LiCl (Davis et al., 2009; Miceli et al., 1979; Smurthwaite et al., 1992). 
Flavor-taste CFA learning has not been the subject of pharmacological analysis, and the 
present study addressed this gap by examining the roles of DA D1, DA D2, NMDA and opioid 
receptor signaling in flavor avoidance conditioned by the bitter taste of quinine.  In two prior 
studies, CFA was produced by training thirsty rats to drink flavored water adulterated with 
quinine (Dwyer, 2011; Harris & Westbrook, 1998). Here we used a different design to match that 
used in our flavor-taste preference conditioning studies in which hungry rats were trained with a 
flavored fructose + saccharin solution and a less preferred flavored saccharin solution (Baker et 
al., 2003). In this case, hungry rats were trained with two differently flavored fructose + 
saccharin (FS) solutions with one adulterated with quinine. The first experiment examined a 
range of quinine concentrations to determine a concentration that conditioned a flavor avoidance 
comparable in magnitude to the preference obtained in earlier fructose-CFP studies (Baker et al., 
2004; 2003; Bernal et al., 2008; 2009; 2010; Golden & Houpt, 2007; Malkusz et al., 2012). The 
second experiment examined the systemic effects of DA D1 (SCH23390), D2 (raclopride), 
NMDA (MK-801) and opioid (naltrexone) receptor antagonists on the acquisition of the quinine-
induced CFA. In these experiments, the avoidance of the quinine-paired CS+ flavor was 
evaluated in two-bottle tests with both flavored FS solutions presented without quinine. To 
determine if the high palatability of the FS solutions used in the choice tests may weaken the 
expression of the quinine conditioned avoidance, a third experiment was conducted in which the 
rats were given two-bottle tests using flavored saccharin solutions without fructose.  
 
 
  32 
 
2.  Methods: 
2.1. Subjects:  Male Sprague-Dawley rats (n=138, 250-275 g), obtained from Charles 
River Laboratories (Wilmington, MA), were housed individually in wire mesh cages and 
maintained on a 12:12 h light/dark cycle with chow (5001, PMI Nutrition International, 
Brentwood, MO) and water available ad libitum for the first week. All animals were then food-
restricted to 85-90% of their body weight throughout behavioral testing. Food rations were 
provided 1 h after the end of daily training and testing sessions. The experimental protocols in 
the three experiments were approved by the Queens College Institutional Animal Care and Use 
Committee certifying that all subjects and procedures are in compliance with the National 
Institutes of Health Guide for Care and Use of Laboratory Animals. 
2.2. Test Solutions and Initial Training: The training solutions contained 8% fructose 
(Sigma Chemical Co., St. Louis, MO) and 0.2% sodium saccharin (Sigma Chemical Co.) with or 
without quinine (0.001-0.06%: Sigma Chemical Co.), each flavored with 0.05% unsweetened 
grape or cherry Kool-Aid (General Foods, White Plains, NY). Fructose rather than sucrose or 
glucose was used because, unlike these other sugars, fructose has minimal post-oral flavor 
conditioning effects (Sclafani & Ackroff, 1994; Sclafani et al., 1993; 1999). Half of the rats in 
each group had the cherry flavor added to the FS solution and the grape flavor added to the 
fructose + saccharin + quinine (FSQ) solution; the flavors were reversed for the remaining rats. 
In the two-bottle choice tests, the cherry and grape flavors were presented in either 8% fructose + 
0.2% saccharin (Experiments 1 and 2) or 0.2% saccharin (Experiment 3) solutions. The flavored 
fructose + saccharin + quinine solution is referred to as the CS+/FSQ, and the flavored fructose + 
saccharin solution as the CS-/FS; and the same flavors used in the two-bottle tests are referred to 
as CS+ and CS-, respectively.  All testing took place in the rat’s home cage during the mid-light 
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phase of the light:dark cycle. The food-restricted rats were initially trained to drink an unflavored 
8% fructose and 0.2% saccharin solution from sipper tubes during five daily 1-h sessions. The 
sipper tube was mounted on the front of the cage held by a taut steel spring, and was positioned 
3-6 cm above the cage floor.  
2.3. Procedure: Rats were trained over eight one-bottle training sessions (1 h) to drink 
the CS-/FS solution on odd-numbered days, and the CS+/FSQ solution on even-numbered days. 
The eight training trials were divided into four pairs of sessions with a one-day break between 
each pair. In the first three training pairs, only one bottle was presented. In the fourth pair of 
training sessions (days 7 and 8), a second sipper tube containing water was also presented to 
acclimate the rats to the presence of two sipper tubes used during the choice tests; water intake 
was negligible in these training trials. The left-right position of the CS and water sipper tubes 
was counterbalanced over the two days. Training intakes were limited to 16 ml/session to 
correspond with the training procedure used in our prior fructose-CFP studies (Baker et al., 2003; 
2004; Bernal et al., 2008; 2009; 2010; Malkusz et al., 2012). Following training, the rats were 
given six two-bottle choice test sessions (1 h) with unlimited access to the CS+ and CS- 
solutions. The position of the two bottles were left (L)-right (R)-R-L-L-R in half of the animals, 
and R-L-L-R-R-L in the remaining half. Solution intakes during the training and testing were 
measured by weighing (0.1 g) the bottles before and after the 1 h sessions. 
2.4. Experiment 1: Quinine Concentration and CFA: Seven groups (n=6/7 each) of food-
restricted rats, matched for unflavored fructose+ saccharin intakes, were tested in the 
conditioning procedure described above in which one of the following quinine concentrations 
was included in the CS+FSQ solution during one-bottle training: 0.001%, 0.002%, 0.004%, 
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0.008%, 0.012%, 0.016% and 0.030%. The animals then received six two-bottle tests with the 
CS+ and CS- flavors mixed in 8% fructose + 0.2% saccharin solutions. 
2.5. Experiment 2: Pharmacological Effects on Acquisition of Quinine-CFA: Five groups 
of food-restricted rats received systemic injections of a) vehicle (VEH group, n=13; 1 ml 0.9% 
normal saline/kg body weight, ip), b) MK-801 (MK801 group, n=11; 100 ug/kg, ip, Sigma 
Chemical Co.), c) SCH23390 (SCH group, n=12; 200 nmol/kg, ip, Sigma Chemical Co.), d) 
raclopride (RAC group, n=11; 200 nmol/kg, ip, Sigma Chemical Co.) or naltrexone (NTX group, 
n=12; 1 mg/kg, ip, Sigma Chemical Co.) 30 min prior to each of eight one-bottle training 
sessions with the CS-/FS solution on odd-numbered days and  CS+/FSQ (0.030% concentration) 
on even-numbered days. The doses of MK-801, SCH, RAC and NTX were chosen based on their 
use in prior studies investigating the acquisition of fructose-CFP (Baker et al., 2003; 2004; 
Golden & Houpt, 2007). To assess whether drug effects were functionally equivalent to 
increasing the quinine concentration, a sixth group of rats (VEH.06% group, n=12)  received 
vehicle injections followed 30 min later with the CS-/FS solution or a CS+/FSQ solution 
containing 0.06% quinine. Following training, all groups received six two-bottle sessions with 
the CS+and CS- flavors mixed in 8% fructose + 0.2% saccharin solutions. 
2.6. Experiment 3: To assess whether the highly palatable 8% fructose + 0.2% saccharin 
solution used in two-bottle testing in Experiments 1 and 2 influenced the expression of the 
quinine conditioned flavor avoidance, two groups of rats received either vehicle or SCH (200 
nmol/kg) 30 min prior to each of eight one-bottle training sessions with the CS-/FS and 
CS+/FSQ (0.030% concentration). However, in the six two-bottle choice sessions, the CS+ and 
CS- flavors were presented in 0.2% saccharin solutions. 
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2.7. Data analysis: In each experiment, training intakes were averaged over the four 
CS+/FSQ and four CS-/FS sessions and were analyzed with a two-way randomized-blocks 
ANOVA (CS conditions x Groups). Intakes during the preference tests were averaged over 
sessions 1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3) to control for side position effects. A 
three-way randomized-blocks ANOVA compared the CS intakes of the concentration groups in 
Experiment 1 (Group x CS x Test), and the CS intakes of the drug groups in Experiments 2 and 3 
(Group x CS x Test). Separate two-way ANOVAs evaluated total CS intakes and percent CS+/s 
intakes of the different groups in the three experiments. When main or interaction effects were 
found, Bonferroni corrected comparisons (p<0.05) detected significant effects. 
3. Results: 
3.1. Quinine Concentration and CFA:  During one-bottle training, the mean intake of the 
CS-/FS solution significantly exceeded that of the CS+/FSQ solution (14.7 vs. 11.9 g/1 h, 
F(1,36)= 111.82, p<0.0001), and significant differences were also observed across the seven 
quinine concentrations (F(6,36)= 15.99, p<0.0001) and for the interaction between CS and 
concentration (F(6,36)= 22.63, p<0.0001).  As indicated in Figure 1A, one-bottle training intakes 
of the CS-/FS and CS+/FSQ solutions failed to differ at quinine concentrations 0.001%, 0.002%, 
004% and 0.008%. CS+/FSQ intakes were significantly lower than CS-/FS intakes with the 
0.012%, 0.016% and 0.03% quinine concentrations (Figure 1A). 
In the two-bottle choice tests, overall, CS+ intakes (13.9 g) failed to differ from CS- 
intakes (14.5 g). However, significant differences were observed among tests (F(2,72)= 5.68, 
p<0.018) and for the interaction between quinine concentration and tests (F(12,72)= 6.16, 
p<0.047). Figure 1B depicts CS- and CS+ intakes in Test 1 across the seven training quinine 
concentrations. Whereas the six lower quinine concentrations elicited similar CS- and CS+  
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Figure 1. Elicitation of Quinine-conditioned flavor avoidance (CFA) is dependent on quinine 
concentration. Panel A: One-bottle training intakes (mean +SEM, g/60 min) of CS+/FSQ and 
CS-/FS solutions in separate groups of animals given CS+/FSQ solutions containing 0.001%, 
0.002%, 0.004%, 0.008%, 0.012%, 0.016% or 0.030% quinine. Panel B. Two-bottle choice Test 
1 intakes (mean +SEM, g/60 min) of the CS+ flavor and CS- flavor presented in FS solutions. 
The percentages of CS+ intake over total intake are denoted above each pair of values. 
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intakes, rats trained with the highest (0.03%) quinine concentration displayed significantly lower 
CS+ intake than CS- intake, indicative of an avoidance of the flavor associated with the FSQ 
solution. This effect was transitory in that this group and all other groups failed to display any 
differences in CS+ and CS- intakes in Tests 2 and 3 (data not shown). Evaluation of the percent 
CS+ intakes failed to reveal any differences among concentrations, tests or their interaction. 
Thus, the 29% CS+ percent intake of the 0.03% group was lower, but not significantly so, than 
those (48-54%) of the other six quinine groups. 
3.2. Pharmacological effects on Quinine-CFA:  In the one-bottle training sessions, 
overall, CS-/FS intake significantly exceeded CS+/FSQ intake (12.7 vs. 2.0 g/1 h, F(1,60)= 
1303.21, p<0.0001), there were significant group differences (F(5,60)= 13.11, p<0.0001), and 
there was a significant interaction between groups and CS (F(5,60)= 3.31, p=0.011). CS-/FS 
intake for all six groups was significantly higher than CS+/FSQ intake (Figure 2), demonstrating 
the ability of quinine at concentrations of 0.03% and 0.06% (VEH.06% group) to reduce intake. 
CS-/FS intake was significantly lower in the SCH and NTX groups relative to VEH group; the 
MK-801, RAC and VEH groups did not differ significantly in their CS-/FS intakes (Figure 2). 
CS+/FSQ intake was significantly lower in MK801, SCH and NTX groups relative to the VEH 
group; the RAC and VEH groups did not differ in CS+/FSQ intakes (Figure 2). The CS+/FSQ 
intake of the VEH.06% group was significantly lower than that of the VEH group trained with 
0.03% quinine (Figure 2). 
In the two-bottle choice tests, there were significant differences in the overall CS+ (8.8 g) 
and CS- (15.5 g) intakes (F(1,19)= 359.90, p<0.0001), as well as for the interactions between 
groups and tests (F(10,120)= 5.12, p<0.043) and tests and CS (F(2,120)= 3.71, p<0.039). Within-
group comparisons revealed that VEH rats consumed more CS- than CS+ only during Test 1  
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Figure 2. (Experiment 2): One-bottle training intakes (mean +SEM, g/60 min) of CS+/FSQ and 
CS-/FS solutions during training sessions 30 min following systemic administration of vehicle 
(VEH group), MK-801 (MK801 group), SCH23390 (SCH group), raclopride (RAC group) or 
naltrexone (NTX group). These groups were trained witih a CS+/FSQ solution containing 0.03% 
quinine whereas the VEH.06% group was trained w ith a CS+/FSQ solution containing 0.06% 
quinine. Significant differences are denoted between CS+/FSQ and CS-/FS intake are denoted 











  39 
 
(Figure 3A), consistent with the results of Experiment 1. In contrast, the MK801, SCH and NTX 
groups consumed more CS- than CS+ in all three tests (Figure 3B, C, E), indicating that the 
NMDA, DA D1 and opioid antagonists prolonged the CFA effects of quinine. In contrast, the 
RAC group, like the VEH group, consumed more CS- than CS+ in Test 1 only (Figure 3D). The 
three drug groups (SCH, MK801, NTX) that displayed a persistent CS+ avoidance (Figure 
3B,C,E), were the groups that also showed significantly reduced CS+/FSQ intake during training 
relative to the VEH group (Figure 2). In contrast, the RAC group was similar to the VEH group 
in its training and test intakes. The persistent quinine-induced CFA in rats trained with MK-801, 
SCH and NTX was unexpected, and therefore, an additional vehicle control group was added to 
determine whether the effects of these drugs were behaviorally and functionally equivalent to 
increasing the concentration of quinine during training. This explanation appeared to be plausible 
in that the VEH.06% group trained with a 0.06% quinine solution in the CS+/FSQ consumed 
significantly more CS- than CS+ in Test 1 and 2 although not in Test 3 (Figure 3F). 
Analysis of the percent CS+ intake data revealed significant differences across tests 
(F(2,120)= 4.13, p<0.029), but not among groups  or for the interaction between groups and 
tests. Trends in the data indicate that the avoidance in all five groups were comparable (30-37%) 
for the first test pair in animals exposed to the 0.03% quinine solution, and were lower (23%) for 
the first test pair in animals exposed to the 0.06% quinine solution (Figure 3). However, whereas 
vehicle-trained (43-50%) and RAC-trained (40-46%) rats displayed increasing indifference to 
thetwo flavors in the second and third test pairs, rats trained with MK-801 (32-33%), SCH (35-
36%) and NTX (29-39%) displayed persistent quinine-induced CFA during the second and 
thirdtest pairs (Figure 3). Finally, vehicle-treated rats exposed to 0.06% quinine showed a 
steadyerosion of the avoidance in the second (34%) and third (40%) test pairs (Figure 3). 
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Figure 3. (Experiment 2): Two-bottle choice test intakes (mean +SEM, g/60 min) of the CS+ 
flavor and CS- flavor presented in fructose+saccharin solutions in Tests 1-3 in groups trained 
with vehicle (A), MK-801 (B), SCH23390 (C), raclopride (D), naltrexone (E) or VEH and a 
CS+/FSQ solution containing 0.06% quinine (F). The percentages of CS+/FSQ intake over total 
intake are denoted above each pair of values. Significant differences are denoted between 
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3.3. Quinine-Induced CFA expressed with Saccharin Solutions: To test the possibility 
that the transitory nature of quinine-induced CFA in the VEH group was due to “masking” 
effects of the very palatable FS solution used in two-bottle testing, this experiment employed an 
identical paradigm in vehicle-trained rats except that the CS+ and CS- flavors were mixed in a 
0.2% saccharin solution during the two-bottle test. A SCH group was similarly trained and tested 
to determine if the testing with CS flavors in 0.2% saccharin solutions influenced the results 
obtained with vehicle and SCH23390 injections.  In the one-bottle training sessions, overall, CS-
/FS intake significantly exceeded CS+/FSQ intake (10.6 vs. 2.5 g/1 h, F(1,9)= 769.41, 
p<0.0001), the two groups significantly differed from each other (F(1,9)= 286.26, p<0.0001), 
and there was a significant interaction between groups and CS (F(1,9)= 6.31, p=0.033). CS-/FS 
intake in both groups was significantly higher than CS+/FSQ intake (Figure 4A). SCH-trained 
rats displayed significantly less CS-/FS intake relative to vehicle-trained rats; CS+/FSQ intakes 
failed to differ between groups (Figure 4A).   
In the two-bottle choice tests, there were significant differences in the overall CS+ (6.3 g) 
and CS- (13.9 g) intakes (F(1,9)= 19.03, p<0.002), as well as for the interaction between tests 
and CS (F(2,180)= 3.69, p<0.045) but not between groups or for the interaction between groups 
and tests.  Within-group comparisons revealed that VEH rats consumed significantly more CS- 
than CS+ only in Test 1(Figure 4B), demonstrating an identical avoidance pattern to that 
observed with rats tested with the CS+ and CS- flavors presented in FS solutions in Experiments 
1 and 2. In contrast, the SCH rats consumed significantly more CS- than CS+ in all three Tests 
(Figure 4C) as observed in Experiment 2. Analysis of the percent CS+ intake data revealed 
significant effects across tests (F(2,18)= 4.02, p<0.036), but not between groups and for the 
interaction between groups and tests. Trends in the data indicate that the avoidances in the  
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Figure 4. (Experiment 3. Panel A): One-bottle training intakes (mean +SEM, g/60 min) of 
CS+/FSQ and CS-/FS solutions during training sessions 30 min following systemic 
administration of vehicle (VEH group) or SCH23390 (SCH group). Two-bottle choice test 
intakes (mean +SEM, g/60 min) of the CS+ flavor and CS- flavor presented in 0.2% saccharin 
solutions in Tests 1-3 in VEH group (B) and SCH group (C). The percentages of CS+/FSQ 
intake over total intake are denoted above each pair of values. Significant differences are denoted 
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vehicle (26%) and SCH (19%) groups were comparable for the first test pair (Figure 4). 
However, whereas vehicle-trained rats (40-49%) displayed increasing indifference to the two 
flavors in the second and third test pairs, rats trained with SCH displayed persistent quinine-
induced CFA during the second (28%) and third (25%) test pairs (Figure 4). 
4. Discussion: 
  The present study examined the roles of DA, NMDA and opioid receptor signaling in  
the acquisition of a flavor-taste CFA induced by the bitter taste of quinine added to a flavored 
fructose+saccharin solution. This was of interest given that the acquisition of a flavor-taste CFP 
induced by the sweet taste of fructose is blocked by systemic or central administration of DA D1, 
DA D2, NMDA, but not opioid receptor antagonists (Baker et al., 2003; 2004; Bernal et al., 
2008; 2009; 2010; Golden & Houpt, 2007; Malkusz et al., 2012). 
The results of Experiment 1 demonstrated that a CFA could be produced by adulterating 
a fructose+saccharin solution with quinine depending upon the concentration of the bitterant. At 
very low concentrations (0.001-0.008%), the added quinine failed to reduce CS+FSQ training 
intake relative to the CS-FS, and did not produce significant differences in CS+ and CS- intakes 
in the two-bottle choice tests. Although adulteration with 0.012% or 0.016% quinine 
significantly depressed CS+/FSQ training intake, it was insufficient to produce a CFA in the 
two-bottle tests. However, when the quinine concentration was raised to 0.03%, CS+/FSQ intake 
was significantly reduced relative to CS-/FS intake in one-bottle training trials, and a quinine 
CFA was observed in two-bottle Test 1 but not in Tests 2 and 3. The transitory nature of the 
0.3% quinine-induced CFA was also observed in the VEH groups of Experiments 2 and 3 that 
were tested with CS flavors presented in fructose+saccharin and saccharin-only solutions, 
respectively. The data from Experiment 3 indicates that the transitory quinine CFA observed in 
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the first two experiments was not due to the use of palatable fructose+saccharin solutions in the 
choice tests. Instead, the quinine CFA was found to be related to the concentration of the bitter 
adulterant. The VEH.06% rats trained with a CS+FSQ containing 0.06% quinine consumed less 
solution during training and displayed a more persistent CS+ avoidance (Tests  1 and 2) than did 
the VEH rats with the CS+FSQ containing 0.03% quinine (Test 1 only), indicating that the 
persistence of the quinine CFA could be increased by increasing quinine concentration.  
Our observation of a quinine-induced CFA in hungry rats trained with fructose-saccharin 
solutions extends a prior report of quinine-induced CFAs in thirsty rats trained with flavored 
water using the same grape and cherry CS flavors (Dwyer, 2011). Note that this and prior studies 
evaluated quinine-induced CFA in only one or two two-bottle choice sessions (Dwyer, 2011; 
Fanselow & Birk, 1982; Harris & Westbrook; 1998) unlike the six test sessions of the present 
study, and thus provide no data on the persistence of the CFA in thirsty rats.  In studies of 
fructose-CFP, the conditioned preference persisted over 6 to 10 two-bottle test sessions which 
indicates that at least some forms of flavor-taste learning are resistant to extinction (Baker et al., 
2003; 2004; Bernal et al., 2008; 2009; 2010; Malkusz et al., 2012). 
 The prior sugar-conditioned flavor-taste preference studies revealed that flavor 
conditioning was dependent of upon intact DA D1 and D2 (Baker et al., 2003; Yu et al., 2000a; 
2000b) and NMDA (Golden & Houpt, 2007), but not opioid (Baker et al., 2004; Yu et al., 1999) 
receptor signaling. That is, systemic administration of SCH23390, raclopride and MK-801, but 
not naltrexone, during flavor training reduced or eliminated the learning of the sweet taste based 
CS+ preference. This is in marked contrast to the present findings that the same doses of 
SCH23390, MK-801, and naltrexone, but not raclopride, enhanced the quinine-CFA as indicated 
by the more persistent CS+ avoidance displayed by the SCH, MK801 and NTX groups compared 
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to the VEH group. The effects of SCH23390, MK-801 and naltrexone on the quinine-based CFA 
were behaviorally similar to that produced by increasing the quinine concentration (from 0.03 to 
0.06%) in the CS+FSQ training solution. That is, the rats trained with the 0.06% quinine 
adulterated CS+FSQ solution underconsumed the solution to the same degree as the SCH, 
MK801, and NTX groups trained with the 0.03% quinine-adulterated CS+FSQ solution, and they 
showed a more persistent CS+ avoidance (Tests 1 and 2) approaching that of the drug groups. 
Thus it is possible that SCH233890, MK-801, and naltrexone injections enhanced the quinine-
CFA by increasing the aversiveness of the FSQ training solution, although the mere observation 
of behavioral equivalence of the antagonist effects on the one hand, and the increased 
concentration effects on the other does not specify that  identical mechanisms of action are 
involved. Further studies are needed to address this issue. 
 4.1 DA D1 and D2 Antagonist Effects: In CFP studies, systemic DA D1and D2 
antagonists reduce the acquisition of flavor-taste sugar preferences (Baker et al., 2003; Hsiao & 
Smith, 1995; Yu et al., 2000a; 2000b), whereas only DA D1 antagonists reduce the acquisition of 
flavor-nutrient sugar preferences (Azzara et al., 2001). These DA antagonist effects involve 
central sites of action, notably the NAc, AMY and mPFC (Bernal et al., 2008; 2009; Malkusz et 
al., 2012; Touzani et al., 2008; 2009a; 2010 ).  One interpretation of how DA antagonists block 
sugar-based CFPs is that the drugs reduce the reward value of the sweet taste or post-oral actions 
of sugars. An extension of this hypothesis would be that DA antagonists also reduce the negative 
reward value of aversive tastes or post-oral aversive states.  In fact, DA D1 receptor antagonists 
administered into either the LH (Caulliez et al., 1996) or shell of the NAc (Fenu et al., 2001) 
disrupted the acquisition of a flavor-toxin CFA induced by LiCl in a manner similar to 
reductions in the acquisition of flavor-nutrient CFP elicited by IG glucose infusions (Touzani et 
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al., 2008; 2009b). The selective effects of SCH23390, but not raclopride injections on quinine-
induced CFA is similar to reports that only SCH23390 altered flavor-toxin avoidance produced 
by LiCl injections (Fenu et al., 2005; 2009). However, whereas SCH23390 blocked the 
development of the LiCl-CFA, the drug enhanced the quinine-CFA in the present study. The 
quinine and LiCl conditioning procedures differed in several important respects which 
complicate comparisons between the different drug effects. Note, in particular, that in one 
experiment, SCH23390 significantly attenuated a LiCl-induced CFA when injected 5 min after 
the CS training sessions but not when injected 30 min prior to the CS training sessions as in the 
present study (Fenu et al., 2001). Thus, to determine if SCH23390, or other drugs, differentially 
influence the learning of a bitter taste (quinine) or toxic drug (LiCl) CFA, it is essential to use 
similar training paradigms (drug dose, injection timing, CS flavor, etc.).  
 Conceivably, DA D1 antagonism may enhance quinine-conditioned flavor avoidance 
because it selectively increases the aversiveness of bitter adulterants. However, there is little 
evidence concerning the impact of systemic SCH23390 on quinine avoidance; indeed, one study 
reported that SCH microinfusions into the ventral pallidum suppressed saccharin, but not quinine 
intake (Shimura et al., 2006). In Experiments 2 and 3, SCH23390 reduced the intake of both the 
FS and FSQ solutions so the drug effect on quinine avoidance per se cannot be differentiated. 
The failure of raclopride injections to alter CS+FSQ training intake or CS+ preference, relative 
to the vehicle treatment, is consistent with one report that this DA D2 antagonist did not alter 
quinine solution intake in rats (Phillips et al., 1991). 
 4.2 NMDA Antagonist Effects: In a CFP study, systemic NMDA receptor antagonism 
eliminated the acquisition, but not expression of a flavor-taste fructose preference (Golden & 
Houpt, 2007). Blockade of NMDA, AMPA and metabotropic glutamate receptors in the AMY, 
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but not the LH or parabrachial nucleus, also disrupted a flavor-LiCl CFA (Tucci et al., 1998; 
Vales et al.; 2006; Yasoshima et al., 2000), whereas blockade of NMDA receptors in the AMY 
eliminated the acquisition of flavor-nutrient-CFP (Touzani et al., 2013). Yet the present study 
demonstrated that systemic treatment with MK-801 significantly prolonged the flavor-taste CFA 
induced by quinine. During training, MK-801-treated rats displayed significant reductions in 
CS+FSQ, but not CS-FS intake as compared to VEH-treated rats, suggesting that it enhanced the 
avoidance of the quinine adulterated solution. Yet, a previous study (Vardigan et al., 2010) 
reported that systemic MK-801 did not reduce quinine solution intake in thirsty rats. Golden and 
Houpt (2007) hypothesized that NMDA receptor signaling mediates the learning process by 
which a flavor CS is associated with the reward value of a gustatory US. Thus, it is not clear why 
systemic NMDA receptor antagonism with MK-801 blocks a fructose-CFP (Golden & Houpt, 
2007), but enhances a quinine-CFA. CFA is induced by MK-801 as well as other NMDA 
antagonists (Fowler et al., 2011; Jackson & Sanger, 1989; Traverso et al., 2003; 2012; Turgeon 
et al., 2000), and it enhances ethanol-induced CFA (Blenkowski et al., 1998).  
 4.3 Opioid Antagonist Effects: In CFP studies, neither systemic nor central (NAc) opioid 
receptor antagonism altered the acquisition or expression of flavor-taste or flavor-nutrient sugar 
preferences (Azzara et al., 2000; Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). Yet the 
present study demonstrated that NTX significantly prolonged the flavor-taste CFA induced by 
quinine. This effect may be related to the finding that opioid antagonism increased quinine 
aversion in rats (Cagniard & Murphy, 2013; Le Magnen et al., 1980; Siviy & Reid, 1983), 
although this is not a consistent result (Ferraro et al., 2002; Goodwin et al., 2001; Levine et al., 
1982; Parker et al., 1992). Opioid receptor antagonism with naloxone is also reported to enhance 
taste aversions elicited by LiCl (Davis et al., 2009; Micelli et al., 1979; Smurthwaite et al., 
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1992). NTX as well as delta-opioid agonists and antagonists produce conditioned flavor 
avoidance by themselves (Hutchinson et al., 2000; Kautz et al., 1989; Parker & Rennie, 1992). 
Yet, opioid antagonism blocks morphine-induced taste aversions (Fox et al., 2006; Stevenson et 
al., 1992).  
 4.4 Do antagonists prolong flavor-taste quinine CFA by eliciting CFA themselves: The 
ability of NTX and MK-801 to induce a CFA when paired with unflavored saccharin or sucrose 
raises the question as to whether aversive drug effects contributed to the enhanced quinine-CFA 
observed in the present study.  However, Golden and Houpt (2007) did not find any evidence 
that MK-801 at the dose used in the present study induces a conditioned flavor avoidance.  To 
our knowledge, there are no reports that systemic SCH23390 conditions sweet taste avoidance; 
one study found that systemic SCH failed to produce a saccharin avoidance (Fenu et al., 2001).  
It is worth noting the features of the conditioning paradigm used in the present study that differ 
from the typical drug-induced CFA procedures.  In particular, in the present study, the antagonist 
drugs were administered before the presentation of the CS flavor, whereas in standard CFA 
studies the drug is administered after the CS flavor is consumed.  Nevertheless, it is possible that 
taste avoidance can occur in such a "backward" conditioning preparation if the drug onset is slow 
enough to functionally occur simultaneous with or after the presentation of the CS flavor. A 
second more important difference between the present paradigm and the typical CFA procedure 
is that the antagonist drugs were given prior to both the CS- and the CS+ solutions during 
training sessions so that both flavors were associated with the aversive effects, if any, of the 
drugs.  In the typical drug CFA procedure, only CS+ is paired with the drug and the CS- is paired 
with a vehicle treatment. The critical importance of this design feature is indicated by early 
studies of opioid antagonist effects on sugar-conditioned flavor preferences. In particular, one 
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study (Mehiel, 1996) reported that naloxone blocked a sugar CFP when the drug was 
administered prior to CS+ training sessions only, whereas other studies reported that naltrexone 
did not block a sugar CFP when the drug was administered prior to both CS+ and CS- training 
sessions (Azzara et al., 2000; Yu et al., 1999). Thus, it is not certain that drug-induced aversive 
effects contributed to the prolonged quinine-CFA observed in the present study, but this issue 
certainly requires further analysis.  
 In summary, whereas DA D1, DA D2 and NMDA, but not opioid receptor antagonism 
blocks the acquisition of sweet taste-based CFP, DA D1, NMDA and opioid, but not DA D2 
receptor antagonism enhances a bitter taste-based CFA. 
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Chapter 4: Muscarinic and nicotinic cholinergic receptor antagonists differentially mediate 
acquisition of fructose-conditioned flavor preference and quinine-conditioned flavor 
avoidance in rats. 
1. Introduction: 
 Sugar-CFPs are based on learned associations between food flavor elements (flavor-
flavor conditioning) as well as between flavor and post-ingestive consequences (flavor-nutrient 
conditioning) (Sclafani, 1995). Flavor-flavor conditioning has been studied for sucrose in sham-
feeding rats (Yu et al., 1999, 2000a, 2000b), and for fructose in real-feeding rats (Baker al., 
2003, 2004) given the inability of fructose to condition preferences after IG administration 
(Sclafani and Ackroff, 1994; Sclafani et al., 1993, 1999). In contrast, glucose is capable of 
producing CFP following oral and IG administration (Dela Cruz et al., 2014; Sclafani and 
Ackroff, 1994; Sclafani et al., 1993, 1999). Previous pharmacological analyses have evaluated 
the neurochemical substrates of the acquisition (learning) and expression (maintenance) of the 
flavor-flavor component of sugar-CFP. Systemic administration of either DA D1 (SCH23390) or 
D2 (raclopride) receptor antagonists eliminated both acquisition and expression of fructose-CFP 
in real-feeding, food-restricted rats and sucrose-CFP in sham-feeding, food-restricted rats (Baker 
et al., 2003; Hsiao and Smith, 1995; Yu et al., 2000a, 2000b). Central DA receptor mediation of 
the acquisition and expression of fructose-CFP is differentially controlled by the NAc, AMY, 
mPFC, mOFC, and LH (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 2012, 
2015). Systemic administration of NMDA receptor antagonists (MK-801) eliminated the 
acquisition, but not the expression of fructose-CFP (Golden and Houpt, 2007). However, 
systemic administration of cannabinoid (CB1) receptor inverse agonists (AM251) reduced the 
expression, but not the acquisition of fructose-CFP (Miner et al., 2008). In contrast, systemic and 
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NAc administration of NTX reduced sweet intake, but failed to alter flavor-flavor-mediated 
sugar-CFP (Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). Therefore, DA D1, DA D2, 
NMDA and CB1, but not opioid receptor signaling is required for the full learning (acquisition) 
and maintenance (expression) of fructose-CFP, apparently in limbic sites associated with reward. 
CFA can be induced by either ingested toxins that induce gastrointestinal distress (flavor–
toxin learning; see review: Freeman and Riley, 2009) or by an aversive taste (flavor-taste 
learning; e.g., Dwyer, 2011 Fanselow and Birk, 1982). Pharmacological analyses have examined 
DA D1, DA D2, NMDA and opioid antagonists in flavor-toxin CFA learning. DA D1, but not 
D2 antagonism disrupted the acquisition of a LiCl-induced CFA following systemic 
administration, and following central administration into the LH or NAc shell (Caulliez et al., 
1996; Fenu et al., 2001, 2005, 2009). Blockade of NMDA, AMPA and metabotropic glutamate 
receptors in the amygdala disrupted LiCl-induced CFA (Yasoshima et al., 2000). Naloxone 
enhanced taste aversions elicited by LiCl (Davis et al., 2009; Miceli et al., 1979; Smurthwaite et 
al., 1992). Our laboratory (Rotella et al., 2014) previously examined the pharmacological 
substrates of flavor-taste CFA learning using a design to match that used in our flavor–flavor 
CFP studies. In this case, food-restricted rats were trained with two differently flavored fructose 
+ saccharin (FS) solutions with one adulterated with quinine (0.03%: FSQ). In contrast to the 
greater persistence of fructose-CFP over a week or more of testing (Baker et al., 2003, 2004), 
quinine (0.03%)-CFA typically lasts for one pair of sessions. However, the persistence of 
quinine-CFA was significantly enhanced by systemic administration of DA D1, NMDA and 
opioid, but not DA D2 receptor antagonists administered during training (Rotella et al., 2014). 
Thus, whereas DA D1, DA D2 and NMDA, but not opioid receptor antagonism blocks the 
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acquisition of sweet taste-based CFP, DA D1, NMDA and opioid, but not DA D2 receptor 
antagonism enhanced the duration of a bitter taste-based CFA.    .      
Avena and Rada (2012) have implicated acetylcholine (Ach) in the mediation of food 
intake, particularly the “addictive” aspects of excessive sugar intake, by its interactions with 
brain DA systems. One Ach-DA neuroanatomical interaction presumably occurs through Ach 
inputs from the PPT/LDT nuclei to identified DA cells in the VTA (Holmstrand and Sesack, 
2011; Maskos, 2008; Omelchenko and Sesack, 2005; Woolf et al., 1990). The second Ach-DA 
interaction presumably occurs through DA terminal innervation of Ach-containing interneurons 
in the NAc (de Rover et al., 2002; Witten et al., 2010; Zhou et al., 2002), although cholinergic 
PPT/LDT innervation is found there as well (Dautan et al., 2014). NAc cholinergic-DA 
interactions act through local DA D2 receptors (Alcantara et al., 2003), mediate accumbal DA 
release that also involves glutamate signaling (Cachope et al., 2012; Chuhma et al., 2014; 
Threlfell and Cragg, 2011), and provide feedback control of VTA DA release (Rahman and 
McBride, 2002). These interactions are integral in the formulation of central mechanisms 
involved in food reward (see reviews: Avena and Rada, 2012; Kelley et al., 2005; Laurent et al., 
2014; Mark et al., 2011; McFadden et al., 2014; Nunes et al., 2013), and suggest that cholinergic 
receptor mechanisms may also play a role in acquisition and expression of fructose-CFP 
mediated by systemic (Baker et al., 2003; Yu et al., 2000a, 2000b) and accumbal (Bernal et al., 
2008; Malkusz et al., 2012) DA. NAc cholinergic interneurons play a role in regulation of body 
weight and metabolism (Hajnal et al., 2000). Food intake increases Ach release in the AMY 
(Hajnal et al., 1998) and the NAc (Mark et al., 1992, 1995). Sugar intake under bingeing 
conditions potently increases NAc Ach release that is mediated by deprivation, sham intake and 
weight of the animals (Avena et al., 2006, 2008a, 2008b, 2008c). Further, VTA Ach and NAc 
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DA are concomitantly released by the orexigenic peptide, ghrelin (Jerlhag et al., 2012), and 
activity of dorsomedial hypothalamic cholinergic neurons increases following overnight food 
deprivation (Groessl et al., 2013). Although food intake was significantly reduced by chronic 
nicotine (Dandekar et al., 2011), the nicotinic cholinergic receptor antagonist, MEC suppressed 
ghrelin-induced food intake (Dickson et al., 2010), and chronic 18-methoxycoronaridine reduced 
long-term sucrose intake (Taraschenko et al., 2011). Pilocarpine, a muscarinic cholinergic 
receptor agonist, administered into the NAc core increased chow intake (Nunes et al., 2013). 
Muscarinic receptor antagonism with SCOP in the NAc reduced both deprivation-induced 
feeding (Pratt and Blackstone, 2009) and NAc DAMGO-induced feeding (Perry et al., 2009), 
and NAc sites at which SCOP suppressed feeding and DAMGO induced feeding overlapped 
(Perry et al., 2014). DAMGO-induced increases in high-fat feeding were blocked by NTX and 
SCOP, but not by antagonists of DA, glutamate or nicotinic receptors (Will et al., 2006). 
Muscarinic receptor blockade also mediated cue-related responses to feeding such that SCOP 
administered into the VTA disrupted food-related learning (Sharf and Ranaldi, 2006). SCOP 
administered into the NAc core induced avoidance to flavor and spatial cues (Pratt et al., 2007). 
SCOP administered into the ventral hippocampus impaired memories for socially-transmitted 
food preferences (Carballo-Marquez et al., 2009). Thus, these data appear to implicate the 
cholinergic receptor system in a limbic circuit that mediates not only food intake per se, but is 
also involved in the development of preferences. 
Cholinergic receptors have also been previously implicated in certain forms of CFA. In 
flavor-toxin CFA learning, SCOP attenuated LiCl-induced CFA without altering aversion to 
quinine (Coil et al., 1978). SCOP and nicotine are capable of eliciting flavor-taste CFAs with the 
former abolished and the latter enhanced by lesions placed in the area postrema (Ossenkopp et 
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al., 1986, Ossenkopp and Gugno, 1990). A possible role for cholinergic receptors in flavor-taste 
CFA is supported by the ability of quinine to inhibit Ach currents in alpha-9-alpha-10-containing 
nicotinic Ach receptors in Xenopus oocytes (Ballestero et al., 2005), and adrenal catecholamine 
secretion evoked by Ach stimulation of muscarinic and nicotinic receptors (Jang et al., 2001). In 
turn, nicotine depressed quinine-evoked responses in the nucleus tractus solitarius that were 
blocked by MEC (Simons et al., 2006). Nicotine and quinine CFA generalized to each other in 
three mouse strains (Gyekis et al., 2012), with MEC blocking this ability in behavioral and 
electrophysiological assays (Oliveira-Maia et al., 2009). Thus, these data appear to implicate 
cholinergic receptor signaling in flavor-taste CFA.     
Much of the evidence implicating cholinergic involvement in complex aspects of food 
intake appears to be due to activity in a limbic circuit (specifically the VTA and NAc) in which 
cholinergic signaling can act directly upon preferences and avoidances either in and of itself, or 
through interactions with brain DA. Therefore, the present study investigated the role of 
muscarinic and nicotinic cholinergic receptor signaling in mediating the expression and 
acquisition of flavor preferences conditioned by fructose in rats. Our previous evaluation of DA 
receptor involvement in fructose-CFP initially examined systemic receptor-selective antagonist 
effects (Baker et al., 2003; Yu et al., 2000a, 2000b) followed by antagonist administration into 
central candidate limbic sites (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 
2012). Hence, the present study initially employed a systemic approach in examining the dose-
dependent effects of muscarinic (SCOP) or nicotinic (MEC) cholinergic receptor antagonists 
upon the expression and acquisition of fructose-CFP. A parallel study then examined whether 
systemic SCOP or MEC altered the acquisition of quinine-CFA in a fructose-saccharin solution.   
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2. Methods: 
2.1 Subjects:  Male Sprague-Dawley rats (n=124, 250-275 g), obtained from Charles 
River Laboratories (Wilmington, MA), were housed individually in wire mesh cages, maintained 
on a 12:12 h light/dark cycle (lights on: 7 AM, lights off: 7 PM) at a constant ambient 
temperature of 22°C with chow (5001, PMI Nutrition International, Brentwood, MO) and water 
available ad libitum for the first week. All animals were then food-restricted to 85-90% of their 
body weight throughout behavioral testing to insure short-latency responses to presentation of 
the training and test solutions. Food rations were provided 1 h after the end of daily training and 
testing sessions. The experimental protocols were approved by the Queens College Institutional 
Animal Care and Use Committee (Protocol 69) certifying that all subjects and procedures are in 
compliance with the National Institutes of Health Guide for Care and Use of Laboratory 
Animals.  
2.2 Fructose-CFP Initial Training and Test Solutions: During initial training in the 
fructose-CFP paradigm, rats were trained to drink an unflavored 0.2% sodium saccharin (Sigma 
Chemical Co., St. Louis, MO) solution during five daily 1-h sessions to guarantee sampling as 
previously described (Baker et al., 2003, 2004); this initial unflavored training solution was the 
same concentrations as the flavored CS- solution used in the subsequent conditioning paradigms. 
The sipper tube was mounted on the front of the cage held by a taut steel spring, and was 
positioned 3-6 cm above the cage floor. Solution measurement (0.1 ml gradations and accuracy) 
was insured by using a retrofitted testing sipper tube that has been previously validated (Baker et 
al., 2003, 2004; Rotella et al., 2014; Yu et al., 1999, 2000a, 2000b). This training procedure was 
repeated daily until all rats approached the sipper tubes with short (< 1 min) latency, typically 
within three days. The limited food rations were given 1 h after each training session. 
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The two training solutions in the fructose-CFP expression and acquisition studies were a 
8% fructose + 0.2% saccharin solution and a saccharin (0.2%) solution, each flavored with 
0.05% unsweetened grape or cherry Kool-Aid (General Foods, White Plains, NY). The 8% 
fructose + 0.2% saccharin-paired flavor is referred to as the CS+/Fs, and the 0.2% saccharin-
paired flavor as the CS-/s (Baker et al., 2003, 2004; Yu et al., 1999, 2000a, 2000b). Half of the 
rats in each drug paradigm had the cherry flavor added to the CS+/Fs solution and the grape 
flavor added to the CS-/s solution; flavors were reversed for the remaining rats. In all two-bottle 
preference choice tests for fructose-CFP, the cherry and grape flavors were presented in 0.2% 
saccharin solutions (CS+, CS-). All training and testing in both paradigms took place in the rat’s 
home cage during the mid-light phase (~11 AM- 4 PM) of the light:dark cycle. 
2.3 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP 
Expression: Thirty-one rats were given ten daily 1-bottle training sessions (0.5 h/day) with 16 ml 
of the CS+/Fs solution presented on odd-numbered days, and 16 ml of the CS-/s solution 
presented on even-numbered days. On days 9 and 10, the rats had access to a second sipper tube 
containing water.  This familiarized the rats to the presence of two sipper tubes used during the 
choice tests; water intake was negligible in these training trials. The left-right position of the CS 
and water sipper tubes was counterbalanced over the two days. The order of presentation of the 
CS+/Fs first followed by subsequent presentation of the CS-/s solution during training was 
identical to that used in our and other previous studies examining the pharmacological substrates 
of fructose-CFP in real-feeding rats (Baker et al., 2004; Golden & Houpt, 2007) and sucrose-
CFP in sham-feeding rats (Yu et al., 2000a, 2000b). Following training, the rats were given eight 
2-bottle choice test sessions (0.5 h/day) with unlimited (~45 ml) access to the CS+ and CS- 
flavors mixed in 0.2% saccharin solutions. Solution intakes during training and testing were 
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measured by weighing (0.1 g) the bottles before and after the 1 h sessions. The animals were 
limited to eight 2-bottle sessions because previous research (Baker et al., 2003, 2004; Yu et al., 
2000a, 2000b) demonstrated that the magnitude of the preference did not change during this 
testing interval. Therefore, each animal received vehicle, and three doses of either the muscarinic 
or nicotinic cholinergic receptor antagonist.  All 31 rats initially received a pair of vehicle 
injections that were used to match the animals into muscarinic and nicotinic groups as well as to 
match them as a function of receiving three of the five doses. Following vehicle treatment, the 
first group of fifteen rats received pairs of three doses of SCOP injections at 0.1 (n=7), 1 (n=7), 
2.5 (n=8), 5 (n=8) and 10 (n=15) mg/kg 30 min prior to the two-bottle choice test. Following 
vehicle treatment, the second group of sixteen rats received pairs of three doses of MEC 
injections at 1 (n=7), 2 (n=7), 4 (n=16), 6 (n=9) and 8 (n=9) mg/kg 30 min prior to the two-bottle 
choice test. The 30-min interval for systemic administration of the muscarinic and nicotinic 
cholinergic receptor antagonists prior to the experimental condition in this and the other two 
paradigms was based on this commonly-used interval in many other systemic studies. Thus, all 
groups of rats were tested in two consecutive daily sessions at vehicle and three drug doses with 
the left–right position of the CS+ and CS- solutions counterbalanced across sessions to control 
for position effects. Half of the rats in each group were tested with an ascending drug dose order, 
and the remaining rats were tested with a descending drug dose order. 
2.4 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP 
Acquisition: Six groups of rats, matched for their intakes of the unflavored 0.2% saccharin 
solution prior to training, were given ten 1-bottle training sessions (1 h/day) with 16 ml of the 
CS+/Fs solution presented on odd-numbered days, and 16 ml of the CS-/s solution presented on 
even-numbered days. The first group (VEH) of eight rats received daily vehicle injections 30 
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min prior to each training session. The second (SCOP 1) and third (SCOP 2.5) groups received 
daily injections of SCOP at doses of 1 (n=8) and 2.5 (n=8) mg/kg respectively 30 min prior to 
each training session. The fourth (MEC 4) and fifth (MEC 6) groups received daily injections of 
MEC at doses of 4 (n=8) and 6 (n=7) mg/kg respectively 30 min prior to each training session. 
The sixth (n=6) group received daily injections of vehicle 30 min prior to each training session, 
but were limited in CS+ and CS- intakes to the reduced levels observed during training in the 
drug groups (LMTD VEH). Following training, all groups were given six daily 2-bottle choice 
sessions (1 h/day) with unlimited (~45 ml) access to the CS+ and CS- flavors mixed in 0.2% 
saccharin solutions; no drugs were administered prior to these sessions. The positions of the CS+ 
and CS- solutions were counterbalanced across sessions.   
2.5 Quinine-CFA Initial Training and Test Solutions: During initial training in the 
quinine-CFA paradigm, rats were trained to drink an unflavored 8% fructose (Sigma Chemical 
Co.) and 0.2% sodium saccharin solution as previously described (Rotella et al., 2014); this 
initial unflavored training solution was the same concentrations as the flavored CS- solution used 
in the subsequent conditioning paradigms. Initial training was otherwise identical to the fructose-
CFP paradigm. The two training solutions in the quinine-CFA acquisition study were 8% 
fructose + 0.2% saccharin with or without quinine (0.03%: Sigma Chemical Co.). Each solution 
was flavored with 0.05% unsweetened grape or cherry Kool-Aid (Rotella et al., 2014). Half of 
the rats in each group had the cherry flavor added to the fructose + saccharin solution and the 
grape flavor added to the fructose + saccharin + quinine solution; the flavors were reversed for 
the remaining rats. In the two-bottle choice tests, the cherry and grape flavors were presented in 
8% fructose + 0.2% saccharin solutions. The flavored fructose + saccharin + quinine solution is 
referred to as the CS+/FSQ, and the flavored fructose + saccharin solution as the CS-/FS; and the 
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same flavors used in the two-bottle tests are referred to as CS+ and CS-, respectively (Rotella et 
al., 2014). All training and testing in this paradigm took place in the rat’s home cage during the 
mid-light phase (~11 AM- 4 PM) of the light:dark cycle. 
2.6 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Quinine-CFA 
Acquisition: Rats were trained over eight one-bottle training sessions (1 h) to drink 16 ml of the 
CS-/FS solution on odd-numbered days, and 16 ml of the CS+/FSQ solution on even-numbered 
days. The CS-/FS solution was presented first to minimize potential potent neophobic effects of 
the fructose-saccharin solution adulterated by quinine (CS+/FSQ), and encourage intake as 
performed previously (Rotella et al., 2014). The eight training trials were divided into four pairs 
of sessions with a one-day break between each pair (Rotella et al., 2014). In the first three 
training pairs, only one bottle was presented. In the fourth pair of training sessions (days 7 and 
8), a second sipper tube containing water was also presented to acclimate the rats to the presence 
of two sipper tubes used during the choice tests; water intake was negligible in these training 
trials. The left-right position of the CS and water sipper tubes was counterbalanced over the two 
days. The first group (VEH) of eighteen rats received daily vehicle injections 30 min prior to 
each training session. The second (SCOP 1) and third (SCOP 2.5) groups received daily 
injections of SCOP at doses of 1 (n=7) and 2.5 (n=8) mg/kg respectively 30 min prior to each 
training session. The fourth (MEC 4) and fifth (MEC 6) groups received daily injections of MEC 
at doses of 4 (n=8) and 6 (n=7) mg/kg respectively 30 min prior to each training session. 
Because the two SCOP and the two MEC groups displayed comparable CS-/F and CS+/FSQ 
intakes during training, an additional limited vehicle group was not employed in this study. 
Following training, all groups received six two-bottle sessions with the CS+ and CS- flavors 
mixed in 8% fructose + 0.2% saccharin (FS) solutions (unlimited ~45 ml) access). The position 
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of the two bottles were left (L)-right (R)-R-L-L-R in half of the animals, and R-L-L-R-R-L in the 
remaining half. Solution intakes during the training and testing were measured by weighing (0.1 
g) the bottles before and after the 1 h sessions. 
2.7 Statistics: In fructose-CFP expression studies, training intakes were averaged over the 
five CS+/Fs and five CS-/s sessions and evaluated by a t-test. Intakes during the two-bottle 
preference tests were averaged over the two sessions at each dose and evaluated with two-way 
repeated-measures analyses of variance (ANOVA, CS condition vs. Dose) for each group. 
Separate ANOVAs evaluated percent CS+/g intakes and total intake as a function of dose for the 
three groups. In fructose-CFP acquisition studies, training intakes were averaged over the five 
CS+/Fs and CS-/s sessions and were analyzed with a two-way randomized-blocks ANOVA (CS 
conditions x Groups). Intakes during the two-bottle preference tests were averaged over sessions 
1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3) to control for side position effects. A three-way 
randomized-blocks ANOVA compared the CS intakes of the six groups (Group x CS x Test). A 
separate two-way ANOVA evaluated percent CS+ intakes and total intakes of the six groups 
across the three tests. In quinine-CFA acquisition studies, training intakes were averaged over 
the four CS+/FSQ and CS-/FS sessions and were analyzed with a two-way randomized-blocks 
ANOVA (CS conditions x Groups). Intakes during the preference tests were averaged over 
sessions 1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3) to control for side position effects. A 
three-way randomized-blocks ANOVA compared the CS intakes of the five groups (Group x CS 
x Test). A separate two-way ANOVA evaluated percent CS+ intakes and total intakes of the five 
groups across the three tests. When main or interaction effects were observed in any ANOVA, 
Bonferroni corrected comparisons (p<0.05) detected significant effects. Drug-induced changes  
in acquisition or expression preferences were operationally defined as a significant change in 
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percent CS+ intakes relative to vehicle, and/or a failure to observe significant differences 
between CS+ and CS- intakes in the two-bottle preference tests. 
3. Results: 
3.1 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP 
Expression: During 1-bottle training, CS+/Fs intake (12.6 g (SEM: +0.3)) significantly exceeded 
(t(30)= 3.77, p<0.0005) CS-/s intake (11.1 g (SEM: +0.4)). In the 2-bottle preference tests 
conducted following SCOP treatment, overall, CS+ (6.6 g) intakes significantly exceeded CS- 
(1.4 g) intakes (F(1,14)= 102.13, p<0.0001), and intakes significantly differed as functions of 
SCOP dose (F(5,70)= 65.29, p<0.0001) and for the interaction between conditions and doses 
(F(5,70)= 42.25, p<0.0001). CS+ intake was significantly higher than corresponding CS- intake 
following vehicle and all SCOP doses (Figure 5A, *). All SCOP doses significantly reduced 
CS+, but not CS- intake relative to vehicle (Figure 5A, +). Percent CS+ preferences significantly 
differed (F(5,54)= 5.16, p<0.0006) as a function of SCOP dose with the three highest (2.5 (65%), 
5 (65%), 10 (68%) mg/kg) doses significantly reducing percent CS+ preferences relative to 
vehicle (90%) (Figure 5A, +). Although significant fructose-CFP preferences were noted across 
all SCOP doses after learning of the preference had taken place, these data indicate a dose-
dependent ability of SCOP to significantly reduce, but not eliminate the magnitude of the 
expression of CS+ preferences at the three highest doses.  
In the 2-bottle preference tests conducted following MEC treatment, overall, CS+ (7.1 g) 
intakes significantly exceeded CS- (1.2 g) intakes (F(1,15)= 570.01, p<0.0001), and intakes 
significantly differed as functions of MEC doses (F(5,75)= 197.16, p<0.0001) and for the 
interaction between conditions and doses (F(5,75)= 104.40, p<0.0001). CS+ intake was 
significantly higher than CS- intake following vehicle and all MEC doses (Figure 5B, *). MEC 
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Figure 5. (Cholinergic receptor antagonists and fructose-CFP expression): Intakes (mean +SEM, 
g/30 min) of CS+ and CS- solutions in two-bottle preference tests in animals pretreated (30 min) 
with systemic scopolamine (Panel A) or mecamylamine (Panel B). Significant differences are 
denoted between CS+ and CS- intake within an injection condition (*) as well as drug-induced 
effects upon CS+ and CS- intake relative to corresponding vehicle values (+). The percentages of 
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doses between 2 and 8 mg/kg, but not 1 mg/kg significantly reduced CS+, but not CS- intake 
relative to vehicle (Figure 5B, +). Percent CS+ preferences significantly differed (F(5,58)= 7.75, 
p<0.0001) as a function of MEC dose with the three highest (4 (68%), 6 (67%), 8 (73%) mg/kg) 
doses significantly reducing percent CS+ preferences relative to vehicle (89%) (Figure 5B. +). 
Although significant fructose-CFP preferences were noted across all MEC doses after learning of 
the preference had taken place, these data indicate a dose-dependent ability of MEC to 
significantly reduce, but not eliminate the magnitude of the expression of CS+ preferences at the 
three highest doses. 
3.2 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP 
Acquisition: During  1-bottle training, overall CS+/Fs intake (6.0 g) significantly (F(1,7)= 26.58, 
p<0.0013) exceeded CS-/s intake (4.1 g), and there were significant differences among groups 
(F(5,35)= 21.54, p<0.0001) and for the interaction between groups and conditions (F(5,35)= 
3.02, p<0.023). CS+/Fs and CS-/s intakes of the SCOP 1, SCOP 2.5, MEC 4 and MEC 6 groups 
were significantly lower than corresponding training intakes of the VEH group (Figure 6, +). 
However, training intakes of all drug groups failed to differ from corresponding LMTD VEH 
group intakes, except for lower CS-/s intake in the SCOP 2.5 group (Figure 6). 
Following training, the rats were given three pairs of two-bottle preference tests without 
drug treatment.  Significant differences were observed among groups (F(5,35)= 3.42, p<0.013), 
among tests (F(2,14)= 4.44, p<0.032), between CS+ and CS- conditions (F(1,7)= 57.24, 
p=0.0001), and for the interactions between groups and tests (F(10,70)= 9.59, p<0.017), groups 
and conditions (F(5,35)= 5.99, p<0.0004), and among groups, tests and times (F(10,70)= 2.59, 
p<0.01), but not for the interaction between tests and conditions (F(2,14)= 1.36, ns). Within-
group comparisons revealed that CS+ intake was significantly greater than CS- intake in 
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Figure 6. (Cholinergic receptor antagonists and fructose-CFP acquisition training): Intakes 
(mean +SEM, g/60 min) of CS+/Fs and CS-/s solutions during one-bottle training sessions in 
animals receiving vehicle (VEH), scopolamine at doses of 1 (SCOP 1) or 2.5 (SCOP 2.5) mg/kg, 
mecamylamine at doses of 4 (MEC 4) or 6 (MEC 6) mg/kg, or vehicle, but limited to drug-
induced intakes (LMTD VEH) 30 min prior to each training session. Significant differences are 
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Tests 1-3 in the VEH (Figure 7A, *), MEC 4 (Figure 7D, *), MEC 6 (Figure 7E, *) and LMTD 
VEH (Figure 7F, *) groups. CS+ and CS- intakes failed to differ in any of the tests in the SCOP 
1 (Figure 7B) and SCOP 2.5 (Figure 7C) groups. The SCOP 1 group displayed significantly 
lower CS+ intake in all three tests and significantly higher CS- intake in the last two tests relative 
to VEH (Figure 7B, +), whereas the SCOP 2.5 group displayed significantly lower CS+, but not 
CS- intake in the first two tests relative to VEH (Figure 7C, +). Comparisons with the LMTD 
VEH group revealed significantly lower CS+ intake across all three tests for the SCOP 1 and 
SCOP 2.5 groups, and significantly higher CS- intakes in the last two tests in the SCOP 1 group. 
Significant differences in the percent CS+ intake were observed among groups (F(5,35)= 6.48, 
p<0.0002) and for the interaction between groups and tests (F(10,70)= 2.98, p<0.035), but not 
among tests (F(2,14)= 0.15, ns). The percent CS+ intakes were stable across the three tests in the 
VEH (85-92%, Figure 7A), MEC 4 (82-83%, Figure 7D), MEC 6 (67-75%, Figure 7E) and 
LMTD VEH (74-88%, Figure 7F) groups. In contrast, the SCOP 1 (40-54%, Figure 7B) and the 
SCOP 2.5 (45-58%, Figure 7C) groups displayed significantly lower percent CS+ preferences 
across all three tests relative to either the VEH or LMTD VEH groups. Thus, these data indicate 
that SCOP, but not MEC, administered during training eliminated the subsequent acquisition of 
fructose-CFP. 
3.3 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Quinine-CFA Acquisition: 
In the one-bottle training sessions, overall, CS-/FS intake significantly exceeded CS+/FSQ intake  
(8.4 vs. 1.7 g/1 h, F(1,17)= 528.14, p<0.0001), there were significant group differences (F(4,68)= 
69.44, p<0.0001), and there was a significant interaction between groups and CS (F(4,68)= 
18.77, p=0.0001). CS-/FS intake for all five groups was significantly higher than CS+/FSQ 
intake (Figure 8A, *), replicating the previously- demonstrated (Rotella et al., 2014) ability of 
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Figure 7. (Cholinergic receptor antagonists and fructose-CFP acquisition testing): Intakes (mean 
+SEM, g/30 min) of CS+ and CS- solutions in three pairs of two-bottle preference tests 
(unlimited (~45 ml) access, Tests 1, 2, 3) in animals that received VEH (Panel A), SCOP 1 
(Panel B), SCOP 2.5 (Panel C), MEC 4 (Panel D), MEC 6 (Panel E) or LMTD VEH (Panel F) 
during training. Significant differences are denoted between CS+ and CS- intake within an 
injection condition (*) as well as drug-induced effects upon CS+ and CS- intake relative to 
corresponding vehicle values (+). The percentages of CS+ intake over total intake are denoted 
above each pair of values with significant effects denoted relative to VEH (+) and LMTD VEH 
(#). 
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Figure 8. (Cholinergic receptor antagonists and quinine-CFA acquisition training and testing. 
Panel A): One-bottle training intakes (mean +SEM, g/60 min) of CS+/FSQ and CS-/FS solutions 
during training sessions in animals receiving systemic administration of VEH, scopolamine at 
doses of 1 (SCOP 1) or 2.5 (SCOP 2.5) mg/kg, or mecamylamine at doses of 4 (MEC 4) or 6 
(MEC 6) mg/kg 30 min prior to each training session. Animals were given 16 ml of solutions 
during training as indicated in the Panel A y-axis. Significant differences are denoted between 
CS+/FSQ and CS-/FS intake are denoted (*) as are any drug effect relative to VEH (+). Two-
bottle choice test intakes (mean +SEM, g/60 min, unlimited (~45 ml) access) of the CS+ and CS- 
flavors presented in fructose+saccharin solutions in Tests 1-3 in groups trained with VEH (Panel 
B), SCOP 1 (Panel C), SCOP 2.5 (Panel D), MEC 4 (Panel E) or MEC 6 (Panel F). Significant 
differences are denoted between CS+/FSQ and CS-/FS intakes within an injection condition (*) 
as well as drug-induced effects upon CS+ and CS- intake relative to corresponding VEH values 
(+). The percentages of CS+/FSQ intake over total intake are denoted above each pair of values. 
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quinine at a 0.03% concentration to reduce intake. CS-/FS and CS+/FSQ intakes were 
significantly lower in the SCOP 1, SCOP 2.5, MEC 4 and MEC 6 groups relative to the 
corresponding VEH group (Figure 8A, +). The SCOP and MEC groups failed to differ from each 
other in CS-/FS and CS+/FSQ intakes. 
In the two-bottle choice tests, there were significant differences in the overall CS+ (6.4 g) 
and CS- (15.4 g) intakes (F(1,17)= 252.39, p<0.0001), as well as significant differences among 
groups (F(4,68)= 11.26, p<0.0001), across tests (F(2,34)= 114.71, p<0.0001), and for the 
interactions between groups and tests (F(8,136)= 7.63, p<0.013), between groups and conditions 
(F(4,68)= 10.07, p<0.0001) and among groups, tests and conditions (F(8,136)= 5.23, p<0.0001), 
but not between tests and conditions (F(2,34)= 0.08, ns). Within-group comparisons revealed 
that the VEH group consumed significantly more CS- than CS+ only during Test 1 (Figure 8B, 
*), consistent with the limited duration of quinine-CFA observed previously (Rotella et al., 
2014). CS- intake was significantly greater than CS+ intake during Tests 1 and 3 in the SCOP 1 
group (Figure 8C, *), and during test 2 in the SCOP 2.5 group (Figure 8D, *). CS- intake was 
significantly greater than CS+ intake across all three tests in the MEC 4 (Figure 8E, *) and MEC 
6 (Figure 8F, *) groups. CS- intake was significantly lower in Test 1 of the SCOP 2.5 group 
relative to corresponding VEH (Figure 8D, +). CS+ intake was significantly lower in Test 2 of 
the MEC 4 group (Figure 8E, +) and in Tests 1 and 2 of the MEC 6 group (Figure 8F, +). 
Analysis of the percent CS+ intake data revealed significant differences among groups (F(4,68)= 
11.43, p<0.0001), across tests (F(2,34)= 10.74, p<0.0002), and for the interaction between 
groups and tests (F(8,136)= 6.27, p<0.0001). The SCOP 1 group displayed significantly greater 
quinine-CFA during Test 1 relative to vehicle (17.0% vs. 33.9%; Figure 8C); all other SCOP 
effects failed to differ from the VEH group. In contrast, MEC treatment during training 
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significantly enhanced the magnitude of quinine-CFA across all three tests in the MEC 4 (Figure 
8E) and MEC 6 (Figure 8F) relative to the VEH group. Thus, these data indicate that MEC, but 
not SCOP, administered during training significantly enhanced and prolonged the subsequent 
acquisition of quinine-CFA. 
4. Discussion: 
 These experiments indicate that systemic pretreatment with muscarinic and nicotinic 
receptor antagonists differentially altered the expression and acquisition of dructose-CFP as well 
as the acquisition of quinine-CFA. 
4.1 Cholinergic Receptor Antagonism and Fructose-CFP Expression: Expression of 
fructose-CFP, defined by significant preferences for the CS+ flavor over the CS- flavor, failed to 
be affected by a wide dose range of the muscarinic antagonist, SCOP or the nicotinic antagonist, 
MEC. However, the magnitude of fructose-CFP expression, defined by changes in percent CS+ 
intake, was significantly reduced by high doses of SCOP (2.5-10 mg/kg: 65-68%) and MEC (4-8 
mg/kg: 67-73%) relative to vehicle (89-90%). These reductions were accompanied by reductions 
in total, and particularly CS+, intake. These intake reductions of saccharin by systemic SCOP 
and MEC correspond to previous reductions of sweet intake following systemic nicotinic 
receptor antagonism (Taraschenko et al., 2011) and chow intake following systemic of 
muscarinic and nicotinic receptor antagonism (Dandekar et al., 2011; Dickson et al., 2010; Perry 
et al., 2009; Pratt and Blackstone, 2009; Will et al., 2006). The very limited inhibition of 
systemic muscarinic or nicotinic cholinergic receptor antagonism of expression of fructose-CFP 
stands in contrast to previously-observed systemic pharmacological effects. Thus, systemic DA 
D1 (SCH23390) or D2 (raclopride) receptor antagonists dose-dependently eliminated the 
expression of both fructose-CFP in real-feeding rats and sucrose-CFP in sham-feeding rats 
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(Baker et al., 2003; Hsiao and Smith, 1995; Yu et al., 2000a, 2000b). Whereas a CB1 receptor 
inverse agonist (AM-251) reduced expression of fructose-CFP (Miner et al., 2008), neither 
NMDA (MK-801) nor opioid (naltrexone) receptor antagonism affected expression of fructose-
CFP (Baker et al., 2004; Bernal et al., 2010; Golden and Houpt, 2007). Thus, muscarinic or 
nicotinic cholinergic receptor santagonism plays a minimal role in the maintenance of an 
already-acquired CFP for fructose. 
4.2 Cholinergic Receptor Antagonism and Fructose-CFP Acquisition: Acquisition of 
fructose-CFP was eliminated by systemic muscarinic (SCOP), but not nicotinic (MEC) 
cholinergic receptor antagonists administered during training. This was demonstrated by the 
failure of two-bottle CS+ and CS- intakes to differ in rats receiving SCOP during training. The 
magnitude of fructose-CFP observed in vehicle-trained (85-92%) rats was eliminated in SCOP-
trained rats receiving 1 (40-54%) and 2.5 (45-58%) mg/kg doses, effects indicative of 
indifference. Because these SCOP doses significantly reduced CS+/Fs and CS-/s intakes during 
training, it is possible that this loss of preference could be alternatively due to specific primary 
actions of muscarinic cholinergic receptor antagonism or to secondary actions of reducing the 
opportunities to learn the preference due to reduced intake per se. The addition of the LMTD 
VEH group receiving vehicle injections, but limited in comparable CS+ and CS- intakes to those 
of the drug groups controlled for this second possibility, and displayed comparable, significant 
fructose-CFP preferences relative to vehicle-trained rats. These data strongly suggest that the 
inability of SCOP-trained rats to display preferences was thus due to its cholinergic receptor 
antagonism. Further, the SCOP doses (1-2.5 mg/kg) capable of eliminating fructose-CFP 
acquisition were incapable of affecting fructose-CFP expression. In contrast, MEC-trained rats 
displayed significant preferences with CS+ intake significantly higher than CS- intake, and 
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comparable percent CS+ intake preferences following the 4 (82-83%) and 6 (67-75%) mg/kg 
doses relative to vehicle- (85-92%) and LMTD VEH- (74-88%) trained groups. This failure of 
systemic nicotinic receptor antagonism to affect fructose-CFP acquisition occurred despite 
MEC’s significant reductions in CS+/Fs and CS-/s intakes during training to levels observed for 
SCOP. Hence, systemic muscarinic (SCOP), but not nicotinic (MEC) receptor antagonism 
administered during training eliminated fructose-CFP acquisition. These data extend the 
circumstances under which muscarinic receptor blockade mediated other cue-related feeding 
responses, including disruptions in food-related learning following VTA administration (Sharf 
and Ranaldi, 2006), avoidance to flavor and spatial cues following NAc core administration 
(Pratt et al., 2007), and memories for socially-transmitted food preferences following ventral 
hippocampal administration (Carballo-Marquez et al., 2009). These effects are also consistent 
with the ability of food, and especially sugars, to increase Ach release in the AMY and the NAc 
(Avena et al., 2006, 2008a, 2008b, 2008c; Hajnal et al., 1998; Mark et al., 1992, 1995). The 
systemic SCOP-induced elimination of fructose-CFP acquisition is similar in magnitude to the 
abilities of systemic DA D1, DA D2 and NMDA receptor antagonists to eliminate fructose-CFP 
acquisition in real-feeding rats (Baker et al., 2003; Golden and Houpt, 2007; Hsiao and Smith, 
1995) and sucrose-CFP acquisition in sham-feeding rats (Yu et al., 2000a, 2000b).  
4.3 Cholinergic Receptor Antagonism and Quinine-CFA Acquisition: Systemic 
administration of nicotinic (MEC), but not muscarinic (SCOP) cholinergic receptor antagonism 
significantly enhanced and prolonged the acquisition of quinine-CFA. Vehicle-trained rats 
displayed a significant, transitory quinine-CFA as demonstrated by a significant aversion 
observed after the first (34%), but not second (48%) or third (47%) pairs of tests. Systemic 
nicotinic cholinergic antagonism significantly increased the magnitude and duration of quinine-
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CFA as indicated by rats trained with the 4 (18-24%) and 6 (11-13%) mg/kg MEC doses. In 
contrast, the SCOP 1 group displayed a significant aversion after the first test pair (17%), but 
failed to differ from vehicle-trained rats thereafter, whereas the SCOP 2.5 group failed to display 
quinine-CFA after any preference test. It should be noted that both systemic SCOP and MEC 
significantly reduced CS-/FS intake and CS+/FSQ intake during training relative to vehicle. This 
raises the possibility that the greater subsequent avoidance responses could be due to non-
specific malaise brought about by pairing the antagonist with the flavored solutions during 
training. Both LiCl-induced conditioned taste aversions and attenuation of neophobic responses 
were blocked by central SCOP pretreatment into the insular cortex (Ferreira et al., 2002; 
Gutierrez et al., 2003a, 2003b; Naor and Dudai, 1996) and NAc shell (Ramirez-Lugo et al., 
2006), but not when SCOP was administered after the presentation of the new taste. Although 
nicotinic receptor antagonists have not been evaluated in this paradigm, galantamine, an 
acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic Ach receptors, 
reduced nicotine seeking without producing malaise (Hopkins et al., 2012). These data suggest 
that systemic nicotinic, but not muscarinic receptor antagonism, enhances and prolongs quinine-
CTA by acting on its specific cholinergic signaling mechanism, and not through non-specific 
malaise-induced effects. Further studies altering the timing of cholinergic antagonist injections 
are necessary to completely rule out participation by this non-specific effect. These effects 
extend our previous (Rotella et al., 2014) findings demonstrating that the persistence of quinine-
CFA was significantly enhanced by systemic administration of DA D1, NMDA and opioid, but 
not DA D2 receptor antagonists administered prior to training. Thus, systemic nicotinic, DA D1, 
NMDA and opioid, but not muscarinic, or DA D2 receptor antagonists administered during 
training enhanced and prolonged the acquisition of quinine-CFA. The inability of SCOP to affect 
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quinine-CFA acquisition is consistent with its previously-described inability to alter quinine 
aversion while attenuating LiCl-induced CFA (Coil et al., 1978). Although systemic SCOP 
elicited a flavor-taste CFA (Ossenkopp et al., 1986), the present data indicate that SCOP- and 
quinine-CFA fail to synergize. The ability of MEC to enhance and prolong quinine-CFA is 
consistent with previous observations that nicotine depressed quinine-evoked responses in the 
nucleus tractus solitarius that were blocked by MEC (Simons et al., 2006), and CFAs induced by 
nicotine and quinine generalized to each other in mice (Gyekis et al., 2012) that were blocked by 
MEC (Oliveira-Maia et al., 2009). However, the ability of MEC to enhance and prolong quinine-
CFA appears specific to this type of “inhibitory” learning. Recent studies demonstrated that 
chronic co-treatment with systemic MEC prevented the occurrence of depressive-like behavior 
elicited by chronic restraint stress as measured by the forced swim test, sucrose preference and 
body weight control (Aboul-Fotouh, 2015). Moreover, whereas nicotine facilitated a version of 
“inhibitory” learning called negative occasion setting, systemic MEC co-treatment extended the 
number of training sessions to elicit this behavior (Meyer et al., 2015). 
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Chapter 5: Baclofen differentially mediates fructose-conditioned flavor preference and 
quinine-conditioned flavor avoidance in rats. 
1. Introduction: 
GABA or its agonists administered into limbic and hypothalamic sites increase food 
intake (e.g., Arnt et al., 1979; Echo et al., 2002; Grandison and Guidotti, 1977; Soderpalm and 
Berridge, 2000; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993). Feeding 
elicited by the GABAB agonist, BAC is mediated through GABA receptor interactions between 
the VTA and NAc (Miner et al., 2010). Indeed, brain dopamine and cholinergic systems 
modulate medium spiny NAc GABA output and VTA dopamine output (see reviews: Avena & 
Rada, 2012; Hoebel et al., 2007). Although peripheral BAC increased rodent chow and fat intake 
under specific dose regimens and intake conditions (e.g., Bains and Ebenezer, 2013; Ebenezer 
and Patel, 2011), it decreased food intake in diabetic and diet-induced obese mice (Sato et al., 
2007). Peripheral BAC also selectively reduced fat intake under normal, limited-access and 
“binge-type” conditions (; as well as intakes of pure fat or a sugar-fat mixture (Avena et al., 
2014; Berner et al., 2009; Buda-Levin et al., 2005; Corwin et al., 2009; Rao et al., 2008; 
Wojnicki et al., 2006; Wong et al., 2009 but see Covelo et al., 2014). Given the complex effects 
of GABAB receptor signaling on feeding, the present study investigated whether systemic BAC 
mediated expression and acquisition of fructose-CFP as well as quinine-CFA in rats.    
2. Methods: 
2.1 Subjects: Male Sprague-Dawley rats (n=74, 250-275 g), obtained from Charles River 
Laboratories (Wilmington, MA), were housed individually in wire mesh cages, maintained on a 
12:12 h light/dark cycle (lights on: 7 AM, lights off: 7 PM) at a constant ambient temperature of 
22°C with chow (5001, PMI Nutrition International, Brentwood, MO) and water available ad 
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libitum for the first week. All animals were then food-restricted to 85-90% of their body weight 
throughout behavioral testing to insure short-latency responses to presentation of the training and 
test solutions. Food rations were provided 1 h after the end of daily training and testing sessions. 
The experimental protocols were approved by the Queens College Institutional Animal Care and 
Use Committee certifying that all subjects and procedures are in compliance with the National 
Institutes of Health Guide for Care and Use of Laboratory Animals.  
2.2 Fructose-CFP Initial Training and Test Solutions: During initial training in the 
fructose-CFP paradigm, rats were trained to drink an unflavored 0.2% sodium saccharin (Sigma 
Chemical Co., St. Louis, MO) solution during five daily 1-h sessions to guarantee sampling as 
previously described (Baker et al., 2003, 2004); this initial unflavored training solution was the 
same concentration as the flavored CS- solutions used in the subsequent conditioning paradigms. 
The sipper tube was mounted on the front of the cage held by a taut steel spring, and was 
positioned 3-6 cm above the cage floor. Solution measurement (0.1 ml gradations and accuracy) 
was insured by using a retrofitted testing sipper tube that has been previously validated (Baker et 
al., 2003, 2004; Rotella et al., 2014, 2015; Yu et al., 1999, 2000a). This training procedure was 
repeated daily until all rats approached the sipper tubes with short (< 1 min) latency, typically 
within three days. The limited food rations were given 1 h after each training session. 
The two training solutions in the fructose-CFP expression and acquisition studies were 
an 8% fructose + 0.2% saccharin solution and a saccharin (0.2%) solution, each flavored with 
0.05% unsweetened grape or cherry Kool-Aid (General Foods, White Plains, NY). The 8% 
fructose + 0.2% saccharin-paired flavor is referred to as the CS+/Fs, and the 0.2% saccharin-
paired flavor as the CS-/s. Half of the rats in each drug paradigm had the cherry flavor added to 
the CS+/Fs solution and the grape flavor added to the CS-/s solution; flavors were reversed for 
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the remaining rats. In all two-bottle preference choice tests for fructose-CFP, the cherry and 
grape flavors were presented in 0.2% saccharin solutions (CS+, CS-). All training and testing in 
both paradigms took place in the rat’s home cage during the mid-light phase (~11 AM- 4 PM) of 
the light/dark cycle. 
2.3 BAC and Fructose-CFP Expression: Seventeen rats were given ten daily 1-bottle 
training sessions (0.5 h/day) with 16 ml of the CS+/Fs solution presented on odd-numbered days, 
and 16 ml of the CS-/s solution presented on even-numbered days. On days 9 and 10, the rats had 
access to a second sipper tube containing water. This familiarized the rats to the presence of two 
sipper tubes used during the choice tests; water intake was negligible in these training trials. The 
left-right position of the CS and water sipper tubes was counterbalanced over the two days. The 
order of presentation of the CS+/Fs first followed by subsequent presentation of the CS-/s 
solution during training was identical to that used in our and other previous studies examining 
the pharmacological substrates of fructose-CFP (Baker et al., 2004; Golden and Houpt, 2007). 
Following training, the rats were given eight 2-bottle choice test sessions (0.5 h/day) with 
unlimited (~45 ml) access to the CS+ and CS- flavors mixed in 0.2% saccharin solutions. 
Solution intakes during training and testing were measured by weighing (0.1 g) the bottles before 
and after the sessions. The animals were limited to eight 2-bottle sessions because previous 
research (Baker et al., 2003, 2004; Yu et al., 2000) demonstrated that the magnitude of the 
preference did not change during this testing interval. Therefore, each animal received VEH, and 
three BAC doses. All 17 rats initially received a pair of VEH injections that were used to match 
the animals across subsequent pairs of BAC doses of 0.5 (n=14), 1.5 (n=15), 3 (n=14) and 5 
(n=8) mg/kg 30 min prior to the two-bottle choice test. The 30-min interval for systemic BAC 
administration prior to the experimental condition in this and the other two paradigms was based 
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on this commonly-used interval in many other systemic studies. Thus, all groups of rats were 
tested in two consecutive daily sessions at VEH and three drug doses with the left–right position 
of the CS+ and CS- solutions counterbalanced across sessions to control for position effects. To 
control for drug dose order effects, half of the rats in each group were tested with an ascending 
dose order, and the remaining rats were tested with a descending dose order. 
2.4 BAC and Fructose-CFP Acquisition: Three groups of rats, matched for their intakes 
of the unflavored 0.2% saccharin solution prior to training, were given ten 1-bottle training 
sessions (1 h/day) with 16 ml of the CS+/Fs solution presented on odd-numbered days, and 16 
ml of the CS-/s solution presented on even-numbered days. The first group (VEH) of eight rats 
received daily VEH injections 30 min prior to each training session. The second (BAC 3) and 
third (BAC 5) groups received daily injections of BAC at doses of 3 (n=7) and 5 (n=7) mg/kg 
respectively, 30 min prior to each training session. Following training, all groups were given six 
daily 2-bottle choice sessions (1 h/day) with unlimited (~45 ml) access to the CS+ and CS- 
flavors mixed in 0.2% saccharin solutions; no drugs were administered prior to these sessions. 
The positions of the CS+ and CS- solutions were counterbalanced across sessions. 
2.5 Quinine-CFA Initial Training and Test Solutions: During initial training in the 
quinine-CFA paradigm, rats were trained to drink an unflavored 8% fructose (Sigma Chemical 
Co.) and 0.2% sodium saccharin solution as previously described (Rotella et al., 2014, 2015); 
this initial unflavored training solution was the same concentrations as the flavored CS- solution 
used in the subsequent conditioning paradigms. Initial training was otherwise identical to the 
fructose-CFP paradigm. The two training solutions in the quinine-CFA acquisition study were 
8% fructose + 0.2% saccharin with or without quinine (0.03%: Sigma Chemical Co.). Each 
solution was flavored with 0.05% unsweetened grape or cherry Kool-Aid (Rotella et al., 2014). 
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Half of the rats in each group had the cherry flavor added to the fructose + saccharin solution and 
the grape flavor added to the fructose + saccharin + quinine solution; the flavors were reversed 
for the remaining rats. In the two-bottle choice tests, the cherry and grape flavors were presented 
in 8% fructose + 0.2% saccharin solutions. The flavored fructose + saccharin + quinine solution 
is referred to as the CS+/FSQ, and the flavored fructose + saccharin solution as the CS-/FS; and 
the same flavors used in the two-bottle tests are referred to as CS+ and CS-, respectively (Rotella 
et al., 2014). All training and testing in this paradigm took place in the rat’s home cage during 
the mid-light phase (~11 AM- 4 PM) of the light/dark cycle.   
2.6 BAC and Quinine-CFA Acquisition: Rats were trained over eight one-bottle training 
sessions (1 h) to drink the CS-/FS solution (16 ml) on odd-numbered days, and the CS+/FSQ 
solution (16 ml) on even-numbered days. The CS-/FS solution was presented first to minimize 
potential potent neophobic effects of the fructose-saccharin solution adulterated by quinine 
(CS+/FSQ), and encourage intake as performed previously (Rotella et al., 2014, 2015). The eight 
training trials were divided into four pairs of sessions with a one-day break between each pair. In 
the first three training pairs, only one bottle was presented. In the fourth pair of training sessions 
(days 7 and 8), a second sipper tube containing water was also presented to acclimate the rats to 
the presence of two sipper tubes used during the choice tests; water intake was negligible in these 
training trials. The left-right position of the CS and water sipper tubes was counterbalanced over 
the two days. The first group (VEH) of eighteen rats received daily VEH injections 30 min prior 
to each training session. The second (BAC 3) and third (BAC 5) groups received daily injections 
of BAC at doses of 3 (n=8) and 5 (n=9) mg/kg respectively, 30 min prior to each training 
session. Following training, all groups received six two-bottle sessions with the CS+ and CS- 
flavors mixed in 8% fructose + 0.2% saccharin (FS) solutions (unlimited (~45 ml) access). The 
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left–right position of the CS+ and CS- solutions were counterbalanced across sessions to control 
for position effects. Solution intakes during training and testing were measured by weighing (0.1 
g) the bottles before and after the 1 h sessions. 
2.7 Statistics: In fructose-CFP expression studies, training intakes were averaged over the 
five CS+/Fs and five CS-/s sessions and evaluated by a t-test. Intakes during the two-bottle 
preference tests were averaged over the two sessions (test pairs) at each dose and evaluated with 
two-way repeated-measures analyses of variance (ANOVA, CS condition vs. Dose). Separate 
ANOVAs evaluated percent CS+/g intakes and total intake as a function of dose. In fructose-
CFP acquisition studies, training intakes were averaged over the five CS+/Fs and CS-/s sessions 
and were analyzed with a two-way randomized-blocks ANOVA (CS conditions x Groups). 
Intakes during the two-bottle preference tests were averaged over sessions 1-2, 3-4, and 5-6 
(referred to as Tests 1, 2, and 3) to control for bottle position effects. A three-way randomized-
blocks ANOVA compared the CS intakes of the three groups (Group x CS x Test). A separate 
two-way ANOVA evaluated percent CS+ intakes and total intakes of the three groups across the 
three tests. In quinine-CFA acquisition studies, training intakes were averaged over the four 
CS+/FSQ and CS-/FS sessions and were analyzed with a two-way randomized-blocks ANOVA 
(CS conditions x Groups). Intakes during the preference tests were averaged over sessions 1-2, 3-
4, and 5-6 (referred to as Tests 1, 2, and 3) to control for bottle position effects. A three-way 
randomized-blocks ANOVA compared the CS intakes of the three groups (Group x CS x Test). 
A separate two-way ANOVA evaluated percent CS+ intakes and total intakes of the three groups 
across the three tests. When main or interaction effects were observed in any ANOVA, 
Bonferroni corrected comparisons (P<0.05) detected significant effects. Drug-induced changes  
in acquisition or expression preferences were operationally defined as a significant change in 
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percent CS+ intakes relative to VEH, and/or a failure to observe significant differences between 
CS+ and CS- intakes in the two-bottle preference tests. 
3. Results: 
3.1 BAC and Fructose-CFP Expression: Training intakes of CS+/Fs (11.3 g) and CS- 
(10.5 g) failed to differ (t(16)= 1.19). In the 2-bottle preference tests, overall, CS+ (11.8 g) 
intakes significantly exceeded CS- (3.5 g) intakes (F(1,16)= 349.59, P<0.0001), and intakes 
significantly differed for the interaction between conditions and doses (F(4,64)= 2.88, P<0.03), 
but not among BAC doses (F(4,64)= 0.85). CS+ intake was significantly higher than 
corresponding CS- intake following VEH and all BAC doses (Fig. 9). Percent CS+ preferences 
significantly differed (F(4,64)= 3.22, P<0.02) across BAC doses with the 3.0 mg/kg (66%) dose 
significantly reducing percent CS+ preferences relative to VEH (87%) (Fig. 9). Total saccharin 
intake failed to differ (F(4,64)= 0.31) among the 0.0 (15.7 g), 0.5 (14.6 g), 1.5 (16.1 g), 3.0 (15.7 
g) and 5.0 (14.2 g) BAC doses. 
3.2 BAC and Fructose-CFP Acquisition: Significant differences in training intakes failed 
to occur among groups (F(2,14)= 0.66), between CS+/Fs and CS-/s conditions (F(1,7)= 5.08) or 
for the interaction between groups and conditions (F(2,14)= 3.10): VEH (CS+/Fs: 12.0 g; CS-/s: 
10.0 g), BAC 3 (CS+/Fs: 13.7 g; CS-/s: 10.5 g) and BAC 5 (CS+/Fs: 12.4 g; CS-/s: 12.5 g). The 
two-bottle preference tests produced significant differences among groups (F(2,14)= 3.96, 
P<0.04), among tests (F(2,14)= 3.74, P<0.05), between CS+ and CS- conditions (F(1,7)= 81.99, 
P=0.0001), but not for any of the two-way and three-way interactions. Fig. 10 illustrates the 
similar pattern of effects in CS+ and CS- intakes across the three tests in the VEH (Panel A), 
BAC 3 (Panel B) and BAC 5 (Panel C) groups. Significant differences in percent CS+ intake  
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Figure 9.  (Baclofen effects upon fructose-CFP expression): Intakes (mean ±SEM, g/30 min) of 
CS+ and CS- solutions in two-bottle preference tests in animals pretreated (30 min) with 
systemic BAC. The percentages of CS+ intake over total intake are indicated above each pair of 
values. Significant differences are denoted between CS+ and CS- intake (*) as are significant 
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Figure 10. (Baclofen effects upon fructose-CFP acquisition): Intakes (mean ±SEM, g/30 min) of 
CS+ and CS- solutions in three pairs of two-bottle preference tests (unlimited (~45 ml) access, 
Tests 1, 2, 3) in animals that received vehicle (VEH: Panel A) or baclofen at doses of 3 (BAC 3: 
Panel B) or 5 (BAC 5: Panel C) mg/kg during training. The percentages of CS+ intake over total 
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failed to occur among groups (F(2,14)= 2.31), among tests (F(2,14)= 0.19) or for the interaction 
between groups and tests (F(4,28)= 1.18) (Fig. 10). Total saccharin intake significantly differed 
among groups (F(2,14)= 3.95, P<0.04) and among tests (F(2,14)= 3.77, P<0.05), but not for the 
interaction between groups and tests (F(4,28)= 1.82). Total saccharin intake in the third test was 
significantly higher in the BAC 5 (23.8 g) relative to the VEH (16.2 g) group. 
3.3 BAC and Quinine-CFA Acquisition: In one-bottle training, CS-/FS intake 
significantly exceeded CS+/FSQ intake  (14.1 vs. 2.8 g/1 h, F(1,17)= 1650.40, P<0.0001); there 
were also significant differences among groups (F(2,34)= 18.62, P<0.0001) and for the 
interaction between groups and CS (F(2,34)= 5.53, P=0.008). CS-/FS intake for all groups was 
significantly higher than CS+/FSQ intake (Fig. 11A). CS+/FSQ intake was significantly lower in 
the BAC 5 relative to the VEH group (Fig. 11A). In two-bottle choice tests, there were 
significant differences between CS+ (8.2 g) and CS- (15.9 g) intakes (F(1,17)= 65.47, P<0.0001) 
as well as among groups (F(2,34)= 7.17, P<0.003), across tests (F(2,34)= 97.95, p<0.0001), and 
for the interactions between groups and tests (F(4,68)= 7.54, P<0.01), between groups and 
conditions (F(2,34)= 7.06, P<0.003) and among groups, tests and conditions (F(4,68)= 6.29, 
P<0.0002), but not between tests and conditions (F(2,34)= 0.17). Within-group comparisons 
revealed that the VEH-trained group consumed significantly more CS- than CS+ only during 
Test 1 (Fig. 11B), consistent with the limited duration of quinine-CFA observed previously 
(Rotella et al., 2014, 2015). The BAC 3-trained group consumed significantly more CS- than 
CS+ during Test 3, and this pattern approached significance in Tests 1 and 2 (Fig. 11C). In 
contrast, CS- intake was significantly higher than CS+ intake across all three tests in the BAC 5-
trained group (Fig. 11D). CS+ intake in the BAC 5-trained group was significantly lower than  
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Figure 11. (Baclofen effects upon quinine-CFA acquisition): One-bottle training intakes (mean 
±SEM, g/60 min) of CS+/FSQ and CS-/FS solutions during training sessions (16 ml limit) in 
animals receiving systemic vehicle or baclofen at doses of 3 or 5 mg/kg 30 min prior to each 
training session (Panel A). Significant differences are denoted between CS+/FSQ and CS-/FS 
intake (*) as well as BAC effects relative to vehicle (+). Two-bottle choice test intakes (mean 
+SEM, g/1 h, unlimited (~45 ml) access) of the CS+ and CS- flavors presented in fructose + 
saccharin solutions in Tests 1-3 in groups trained with VEH (Panel B), BAC 3 (Panel C) BAC 5 
(Panel D). The percentages of CS+/FSQ intake over total intake are denoted above each pair of 
values. Significant differences are denoted between CS- and CS+ intakes (*) as well as BAC-
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CS+ intake of the VEH-trained group across all three tests (Fig. 11B, 11D). Significant 
differences in percent CS+ intake were observed among groups (F(2,34)= 10.41, P<0.0003), 
among tests (F(2,34)= 6.51, P<0.004) and for the interaction between groups and tests (F(4,68)= 
2.71, P<0.04). Percent CS+ intakes were significantly lower across all three tests in the BAC 5 
(Fig. 11D) relative to the VEH (Fig. 11B) group. The lower percent CS+ intakes in Tests 2 and 3 
in the BAC 3 group did not differ from VEH (Fig. 11B, 11C). Total fructose and saccharin intake 
significantly differed among groups (F(2,34)= 7.20, P<0.003), among tests (F(2,34)= 98.09, 
P<0.0001) and for the interaction between groups and tests (F(4,68)= 7.58, P<0.0001). Total 
fructose and saccharin intake in the first test was significantly lower in the BAC 3 (20.0 g) and 
BAC 5 (15.6 g) groups relative to the VEH (24.5 g) group. 
4. Discussion 
 The present study examined whether GABAB receptor activation with systemic BAC 
would alter the expression and acquisition of fructose-CFP or the acquisition of quinine-CFA. 
GABA or its agonists administered into limbic and hypothalamic sites increase food intake (e.g., 
Arnt et al., 1979; Echo et al., 2002; Grandison and Guidotti, 1977; Miner et al., 2010; Soderpalm 
and Berridge, 2000; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993). 
Further, whereas peripheral BAC administration increased chow and fat intake in non- deprived 
rats and mice (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), it decreased food 
intake in diabetic and diet-induced obese mice (Sato et al., 2007). Moreover, peripheral BAC 
reduced fat relative to chow intake under normal, limited-access and “binge-type” conditions in 
rats (e.g., Buda-Levin et al., 2005; Rao et al., 2008; Wojnicki et al., 2006), particularly intakes of 
pure fat or a sugar-fat mixture (e.g., Avena et al., 2014; Berner et al., 2009; Corwin et al., 2009; 
Wong et al., 2009).  
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Although the present study focused on the role of BAC in sugar preference and quinine 
avoidance, BAC effects upon total intake could be analyzed for saccharin intake in the fructose-
CFP expression 2-bottle testing paradigm, for fructose + saccharin and saccharin intake in the 
fructose-CFP 1-bottle training paradigm, and for fructose + saccharin and quinine + fructose + 
saccharin intake in the quinine-CFA acquisition 1-bottle training paradigm. In the fructose-CFP 
expression paradigm, systemic BAC failed to alter total saccharin intake across the 0.5-5 mg/kg 
BAC dose range. In the fructose-CFP acquisition paradigm, neither the 3 nor 5 mg/kg doses of 
BAC administered during training significantly altered fructose + saccharin or saccharin intake 
relative animals receiving VEH. The inability of systemic BAC to alter saccharin intake per se is 
in contrast to the ability of the same dose range to impair gustatory discrimination of 0.3% and 
0.6% saccharin solutions (Wilson et al., 2011). In the quinine-CFA paradigm, fructose + 
saccharin intake was similar among the three training groups, but quinine-adulterated fructose 
and saccharin intake was significantly lower in the rats receiving the 5 mg/kg BAC dose during 
training. It should be noted that animals in all three conditioning paradigms were food-restricted 
and received multiple injections of systemic BAC, factors that alter BAC-induced orexigenic 
actions on chow intake (e.g., Patel and Ebenezer, 2008). Thus, these data are in agreement with 
the general failure to observe differences in sweet intake per se following systemic BAC (Avena 
et al., 2014; Berner et al., 2009; Corwin and Wojnicki, 2009). 
 4.1 GABAB Receptor Agonism and Fructose-CFP Expression:  In the fructose-CFP 
expression paradigm, CS+ intake was significantly higher than corresponding CS- intake in the 
two-bottle preference tests following VEH and all (0.5-5 mg/kg) BAC doses. The magnitude of 
the fructose-CFP measured by percent CS+ preference was significantly, but marginally lowered 
by the 3 mg/kg BAC dose (66%) relative to VEH; lower (0.5, 1.5) and higher (5.0) BAC doses 
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failed to exert effects. This marginal reduction in fructose-CFP expression following systemic 
GABAB receptor activation was similar and comparable to that observed following systemic 
administration of AM-251, a cannabinoid CB1 receptor inverse agonist (Miner et al., 2008) and 
muscarinic (scopolamine) and nicotinic (mecamylamine) cholinergic antagonists (Rotella et al., 
2015). In contrast, systemic administration of dopamine D1 (SCH23390) or D2 (raclopride) 
receptor antagonists eliminated expression of fructose-CFP in real-feeding rats and sucrose-CFP 
in sham-feeding rats (Baker et al., 2003; Yu et al., 2000). Further, neither systemic NMDA (MK-
801) nor opioid (naltrexone) receptor antagonism affected expression of fructose-CFP in real-
feeding rats or sucrose-CFP in sham-feeding rats (Baker et al., 2004; Golden and Houpt, 2007; 
Yu et al., 1999). 
 4.2 GABAB Receptor Agonism and Fructose-CFP Acquisition:  In the fructose-CFP 
acquisition paradigm, the patterns of CS+ and CS- intake in all three two-bottle preferences tests 
were similar in rats receiving VEH or the two (3 or 5 mg/kg) BAC doses during training. 
Correspondingly, the magnitude of fructose-CFP measured by percent CS+ intake failed to differ 
among these groups. The inability of systemic GABAB receptor activation to alter the acquisition 
(learning) of fructose-CFP stands in marked contrast to the abilities of systemic administration of 
DA D1, DA D2, NMDA or muscarinic receptor antagonists to eliminate acquisition of fructose-
CFP in real-feeding rats and/or sucrose-CFP in sham-feeding rats (Baker et al., 2003; Golden and 
Houpt, 2007; Rotella et al., 2015; Yu et al., 2000). Rather, the effects of systemic BAC in failing 
to affect fructose-CFP acquisition were similar to that observed following NTX (Baker et al., 
2004; Yu et al., 1999), AM-251 (Miner et al., 2008) or MEC (Rotella et al., 2015). 
 4.3 GABAB Receptor Agonism and Quinine-CFA Acquisition:  In the quinine-CFA 
paradigm, systemic BAC dose-dependently enhanced and prolonged the magnitude of quinine-
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CFA with rats receiving the 5 mg/kg BAC dose during training eliciting significantly higher CS- 
than CS+ intake across all three tests. As observed previously (Rotella et al., 2014, 2015), the 
VEH-trained group consumed significantly more CS- than CS+ only during Test 1. The BAC 3-
trained group consumed significantly more CS- than CS+ during Test 3, and this pattern 
approached significance in Tests 1 and 2. Consequently, the magnitudes of quinine-CFA as 
measured by percent CS+ intake takes were significantly lower across all three tests in rats 
trained with the 5 mg/kg BAC dose (15-20-25%) relative to VEH-trained rats (34-48-47%). The 
dose-dependent ability of systemic GABAB receptor activation to enhance and prolong quinine-
CFA is similar to that observed following systemic dopamine D1, NMDA, opioid or nicotinic, 
but not dopamine D2 or muscarinic antagonists (Rotella et al., 2014, 2015). A role for GABAB 
receptor systems in conditioned aversions is supported by the ability of the GABAB agonist, 
BAC, but not the GABAB antagonist, saclofen, to suppress saccharin-induced drinking following 
pairing (Echo et al., 2002; Wilson et al., 2011). However, another study using a similar dose 
range found that systemic BAC failed to induce an aversion or affect ethanol-induced aversions 
(Chester and Cunningham, 1999). Further, although systemic BAC failed to alter operant 
responding to quinine-adulterated solutions (Petry and Heyman, 1997), it did enhance the 
discriminative abilities of D-amphetamine in a conditioned taste aversion procedure (Miranda et 
al., 2009). The present findings that systemic BAC enhanced and prolonged quinine-CFA 
extends the role of GABAB receptor signaling in both orosensory and post-ingestive processes 
related to avoidance and aversion, respectively. 
In conclusion, these data implicate GABAB receptor signaling in the acquisition of 
quinine avoidance with minimal or no effects upon fructose preferences. Further studies 
investigating systemic BAC effects upon fat-CFP are warranted given the reductions in fat intake 
  89 
 
following systemic administration of GABAB receptor agonists (e.g., Avena et al., 2014; Berner 
et al., 2009; Buda-Levin et al., 2005; Corwin et al., 2009; Rao et al., 2008; Wojnicki et al., 2006; 
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Chapter 6: Muscarinic, nicotinic and GABAergic receptor signaling differentially 
mediate fat-conditioned flavor preferences in rats. 
1. Introduction: 
The pharmacological substrates of the acquisition and expression of sugar- and fat-CFP 
have been examined for DA, opioid and NMDA receptor systems. Systemic administration of 
DA D1 (SCH23390) or D2 (raclopride), but not opioid (naltrexone), receptor antagonists 
eliminated the acquisition and expression of flavor-flavor conditioning studies elicited by 
sucrose in sham-feeding rats (Yu et al., 1999, 2000a, 2000b) or fructose in real-feeding rats 
(Baker et al., 2003, 2004), implicating both DA receptor families, but not opioids in both the 
learning and maintenance of these responses. Yet DA D1, but not D2 or opioid receptor 
antagonists eliminated acquisition, and to a lesser degree, reduced expression of flavor-nutrient 
conditioning elicited by IG sucrose infusions (Azzara et al., 2000, 2001), implicating only the 
DA D1 receptor in the learning of this response. In contrast, fat (CO)-CFP acquisition and 
expression was only attenuated by DA D2, but not D1 or opioid receptor antagonists (Dela Cruz 
et al., 2012a, 2012b), indicating that combined flavor-flavor and flavor-nutrient mechanisms 
reduce the effectiveness of DA antagonism to affect the response. The non-competitive NMDA 
receptor antagonist, MK-801 eliminated the acquisition, but not expression of CFP induced by 
fructose (Golden and Houpt, 2007) or CO (Dela Cruz et al., 2012a), implicating glutamatergic 
signaling in the learning of this response. The more limited pharmacological effects on CO-CFP 
is similar to that observed following glucose that also activates both flavor-flavor and flavor-
nutrient processes. Thus, oral glucose-CFP was significantly though marginally attenuated in 
expression studies by DA D1, DA D2 or NMDA receptor antagonism (Dela Cruz et al., 2014). 
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Cholinergic muscarinic and nicotinic receptor signaling and GABAB receptor signaling 
have been recently implicated in the mediation of fructose-CFP (Rotella et al., 2015, 2016). 
Fructose-CFP expression was significantly reduced by systemic administration of muscarinic 
(SCOP: 2.5-10 mg/kg: 65-68%) and nicotinic (MEC: 4-8 mg/kg: 67-73%) cholinergic receptor 
antagonists, but only at doses that reduced total saccharin intake.   However, this occurred 
despite the fact that CS+ preference intakes were significantly higher than CS- preference 
intakes, indicating minimal actions of cholinergic signaling on expression of this response. 
Further, fructose-CFP acquisition was eliminated by SCOP at doses of 1 (40-54%) and 2.5 (45-
58%) mg/kg, and was accompanied by a failure to observe CS+ and CS- intake differences. On 
the other hand, MEC failed to alter fructose-CFP acquisition, indicating a critical role for 
muscarinic cholinergic receptors in the learning of this response. In contrast, MEC, but not 
SCOP enhanced the magnitude and persistence of quinine-induced conditioned flavor avoidance 
for a fructose solution (Rotella et al., 2015), indicating different cholinergic receptor mechanisms 
in preference and avoidance responses. Whereas systemic administration of the GABAB receptor 
agonist, BAC minimally reduced the expression, but not the acquisition of fructose-CFP, the 
magnitude and persistence of quinine-induced conditioned flavor avoidance for a fructose 
solution was enhanced (Rotella et al., 2016), indicating a limited role for GABAB signaling in 
expression of this response. 
Cholinergic receptor signaling has also been implicated in the mediation of food and fat 
intake. Food increases Ach release in the AMY and the NAc (Avena et al., 2006, 2008a, 2008b, 
2008c; Hajnal et al., 1998; Mark et al., 1992, 1995). Consumption of a high-fat diet for one week 
reduced acetylcholinesterase activity in the frontal cortex, hypothalamus and midbrain, as well as 
increased both β2-nAChR binding in the medial prefrontal cortex and substantia nigra, in 
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addition to α7-nAChR binding in the lateral and ventromedial hypothalamus (Morganstern et al., 
2012). MEC blocked the enhancements in exploratory and novelty-seeking behaviors induced by 
high-fat consumption (Morganstern et al., 2012). Chronic nicotine reduced body weight in mice, 
particularly those maintained on a high-fat diet, an effect blocked by MEC co-treatment 
(Mangubat et al., 2012). Accumbal microinjections of SCOP markedly reduced fat intake elicited 
by accumbal administration of the mu-opioid receptor agonist, DAMGO, and also reduced food 
intake in food-deprived rats (Perry et al., 2009; Will et al., 2006). However, accumbal SCOP 
failed to affect fat intake itself (Will et al., 2006).  
GABAB receptor signaling has also been implicated in the mediation of fat intake. BAC 
administered into limbic and hypothalamic sites increased food intake (e.g., Arnt et al., 1979; 
Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993), and 
was reported to be mediated through GABA receptor interactions between the ventral tegmental 
area and nucleus accumbens (Miner et al., 2010). Systemic BAC increased fat intake under 
normal conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), but suppressed fat 
intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al., 
2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al., 2009). 
Therefore, the present study examined whether systemic administration of muscarinic (SCOP) 
and nicotinic (MEC) cholinergic receptor antagonists and a GABAB receptor agonist (BAC) 
would alter expression and acquisition of fat-CFP elicited ingestion of a flavor (e.g., cherry) 
paired with a higher (3.5%) CO concentration relative to a flavor (e.g., grape) paired with a 
lower (0.9%) CO concentration.  
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2. Methods: 
 2.1 Subjects:  Male Sprague-Dawley rats (260-300 g, Charles River Laboratories, 
Wilmington, MA) were housed individually in wire mesh cages and maintained on a 12:12 h 
light/dark cycle with chow (5001, PMI Nutrition International, Brentwood, MO) and water 
available ad libitum, except as noted below. The experimental protocols were approved by the 
Queens College Institutional Animal Care and Use Committee certifying that all subjects and 
procedures are in compliance with the National Institutes of Health Guide for Care and Use of 
Laboratory Animals. 
 2.2 Test Solutions: The training fluids consisted of 3.5% and 0.9% corn oil (CO: Sigma 
Chemical Co., St. Louis, MO) flavored with 0.05% unsweetened grape or cherry Kool-Aid 
(General Foods, White Plains, NY) and prepared as suspensions using 0.3% xanthan gum 
(Sigma) as described previously (Dela Cruz et al., 2012a, 2012b). Half of the rats in each group 
had the cherry flavor added to the 3.5% CO and the grape flavor added to the 0.9% CO; the 
flavors were reversed for the remaining rats. In the two-bottle preference tests, the 0.05% cherry 
and grape flavors were each presented in similar 0.9% CO + 0.3% xanthan gum suspensions. The 
CO + Kool-Aid + gum mixtures with the flavored training solutions are hereafter referred to as 
CS+/3.5% CO and CS-/0.9% CO, and the flavored 0.9% CO two-bottle test solutions are 
referred to as CS+ and CS-. All testing took place in the rat’s home cage during the mid-light 
phase of the light:dark cycle. In the two weeks prior to testing, the rats were placed on a food 
restriction schedule that maintained their body weights at 85-90% of their ad libitum level to 
increase approach behavior to the solutions. This procedure has been consistently applied in all 
of our and other prior CFP studies using oral intake or intragastric infusions of sugars and fats 
(e.g., Azzara et al., 2000, 2001; Baker et al., 2003, 2004; Dela Cruz et al., 2012a, 2012b; 2014; 
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Golden and Houpt, 2007; Rotella et al., 2015, 2016; Yu et al., 199, 2000a, 2000b). It is important 
to note that examination of these effects in food-deprived rats not only increases motivation to 
drink, but also produces an energy deficit. Many prior studies have explored both taste and 
consumption of palatable diets under both sated and deprived conditions, and have found 
dissociable behavioral and neurochemical processes.  In other words, distinct hedonic and 
homeostatic processes can govern approach and consumption, and can presumably differentially 
alter preference for flavored solutions (see review: Baldo et al., 2013). For instance, 
administration of naloxone into the basolateral nucleus of the amygdala blocked increased fat 
intake induced by accumbal administration of DAMGO, but not increased fat intake induced by 
food deprivation (Parker et al., 2010). In contrast, administration of naloxone into the central 
nucleus of the amygdala blocked food deprivation-induced increases in fat intake, but not fat 
intake induced by accumbal DAMGO (Parker et al., 2014). Further, whereas intra-accumbal 
DAMGO increased c-Fos activation within the hypothalamic perifornical area that was blocked 
by baso-lateral amygdala inactivation, inta-accumbal DAMGO increased c-Fos activation in the 
ventral tegmental area that was unaffected by baso-lateral amygdala inactivation (Parker et al., 
2015). Our laboratory (Yu et al., 1999) performed one CFP study that tested the ability of 
naltrexone to affect acquisition and expression of sucrose intake in sham-feeding rats under sated 
and deprived conditions. We found that the feeding condition failed to alter naltrexone’s inability 
to reduce acquisition or expression of sucrose-CFP in sham-feeding rats. Thus, the fact that these 
studies were done under food restriction should serve as a caveat.     
The rats were initially adapted to drink an unflavored 0.2% saccharin solution from 
sipper tubes during daily 2-h sessions. The sipper tube was mounted on the front of the cage held 
by a taut steel spring, and was positioned 3-6 cm above the cage floor. This training procedure 
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was repeated daily until all rats approached the sipper tubes with short (< 1 min) latency, 
typically within three days. The limited food rations were given 30 min after each training 
session. 
 2.3 Experiment 1: SCOP, MEC and BAC CO-CFP: Expression Study: Twenty-four male 
rats were given ten 1-bottle training sessions (2 h/day) with 24 ml of the CS+/3.5% CO solution 
presented on odd-numbered days, and 24 ml of the CS-/0.9% CO solution presented on even-
numbered days. On days 9 and 10, the rats had access to a second sipper tube containing water. 
This familiarized the rats to the presence of two sipper tubes used during the choice tests; water 
intake was negligible in these training trials. The left-right position of the CS and water sipper 
tubes was counterbalanced over the two days. Following training, all rats were given eight daily 
two-bottle choice test sessions (2 h/day) with the CS+ (45 ml) and CS- (45 ml) solutions. Thirty 
min prior to the first two sessions, all rats were given vehicle injections (1 ml 0.9% saline/kg 
body weight, intraperitoneally (ip)). The animals were then divided into three equal (n=8) groups 
matched for the magnitude of their CO preferences observed following vehicle treatment. The 
SCOP group received three doses (1, 5 and 10 mg/kg, ip, Sigma Chemical Co., St. Louis, MO) 
prior to the remaining six sessions; half of the rats were tested with an ascending dose order, and 
the remaining rats were tested with a descending dose order. The rats were tested in two 
consecutive daily sessions at each drug dose with the left-right position of the CS+ and CS- 
solutions counterbalanced across sessions to control for bottle position effects. The MEC group 
received three doses (1, 6 and 8 mg/kg, ip, Sigma Chemical Co.), and the BAC group received 
three doses (1.5, 3 and 5 mg/kg, ip, Sigma Chemical Co.) prior to the remaining six sessions The 
dose ranges were similar to those used in our prior conditioning studies with sugars (Rotella et 
al., 2015, 2016). Care was taken to minimize spillage due to the fact that some of the effects 
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could be potentially small. After initially weighing each bottle, it was gently shaken to insure 
appropriate flow of the viscous CO solutions. Any effluent from the bottle (~ 0.5-1.0 g) was 
collected and appropriate spillage adjustments were made to obtain an accurate pre-weight 
measurement. The taut steel spring prevented movement of the bottles during the sessions. 
Visual inspection of the bottles during the study revealed minimal if any spillage because of the 
viscosity of the solutions. The session length of 2 h was identical to that previously used in 
assessing fructose-CFP (Baker et al., 2003, 2004), and CO-CFP (Dela Cruz et al., 2012a, 2012b).   
2.4 Experiment 2: SCOP, MEC and BAC and CO-CFP: Acquisition Study. Eight groups 
of naïve male rats were matched for their intakes of an unflavored 0.2% saccharin solution prior 
to training. The rats were given ten 1-bottle training sessions (2 h/day, 24 ml) with the CS+/3.5% 
CO solution presented on odd-numbered sessions, and the CS-/0.9% CO solution presented on 
even-numbered sessions, and all intraperitoneal (ip) injections were administered 30 min prior to 
each training session. Seven of the eight groups  received vehicle (VEH, n=11, 1 ml 0.9% saline/ 
kg body weight), SCOP at doses of 1 (SCOP1, n=10) and 2.5 (SCOP2.5, n=8) mg/kg, MEC at 
doses of 4 (MEC4, n=8) and 6 (MEC6, n=11) mg/kg, BAC at doses of 3 (BAC3, n=8) and 5 
(BAC5, n=8) mg/kg. Because some of the drugs reduced overall CS intakes, an eighth group 
(Limited VEH, n=10) received vehicle injections, and their intakes were limited to approximate 
the reduced intakes observed in the different drug dose groups. These doses were similar to those 
employed in acquisition studies with sugars (Rotella et al., 2015, 2016). Following training, all 
eight groups were given six daily two-bottle choice sessions (2 h/day) with unlimited access to 
the CS+ (45 ml) and CS- (45 ml) solutions; no drugs were administered prior to these sessions. 
The positions of the CS+ and CS- solutions were counterbalanced across sessions. 
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2.5 Data analysis: In the expression studies, training intakes were averaged over the five 
CS+/3.5% CO and five CS-/0.9% CO sessions and evaluated by t-tests. Intakes during the 
preference tests were averaged over the two sessions at each dose and evaluated with two-way 
repeated-measures analyses of variance (ANOVA, CS condition vs. Dose) for the SCOP, MEC 
and BAC groups, respectively. Separate ANOVAs evaluated percent CS+ intakes and total 
intakes as a function of drug doses. In the acquisition study, training intakes were averaged over 
the five CS+/3.5% CO and CS-/0.9% CO sessions, and were analyzed separately in a two-way 
randomized-blocks ANOVA (CS x Groups). Intakes during the preference tests were averaged 
over sessions 1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3). A three-way randomized-blocks 
ANOVA compared the CS intakes of the drug and control groups (Group x CS x Test). Separate 
two-way ANOVAs evaluated percent CS+ intakes and total intakes of the groups. When main or 
interaction effects were found, Bonferroni corrected comparisons (p<0.05) detected significant 
effects. 
3. Results: 
3.1 SCOP, MEC and BAC and expression of CO-CFP: The mean 1-bottle training intake 
of the CS+/3.5% CO (21.8 ±0.3 g/2 h) was significantly greater (t(23)= 4.03, p<0.0005) than the 
CS-/0.9% CO (18.2 ±1.0 g/2 h). In the two-bottle choice tests in SCOP-tested rats, CS+ was 
consumed significantly more (F(1,28)= 72.06, p<0.0001) than CS-, and significant differences 
were observed among doses (F(3,28)= 17.94, p<0.0001) and for the CS x Dose interaction 
(F(3,28)= 22.24, p<0.0001). CS+ intakes significantly exceeded CS- intakes following VEH and 
the 1 and 10, but not the 5 mg/kg SCOP doses (Figure 12A). Rats consumed significantly less 
CS+ at all SCOP doses compared to VEH, whereas CS- intakes failed to be significantly affected 
(Figure 12A). Total intake (g/2 h) significantly (F(3,24)= 24.75, p<0.0001) declined following  
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Figure 12. (Expression Study): Intakes (mean (g/2 h), ±SEM) of CS+ and CS− flavored 0.9% 
corn oil (CO) solutions in two-bottle preference tests in animals receiving systemic injections of 
the muscarinic cholinergic antagonist, scopolamine (SCOP: Panel A), the nicotinic cholinergic 
antagonist, mecamylamine (MEC, Panel B) or the GABAB receptor agonist, baclofen (BAC: 
Panel C) 30 min prior to testing. Significant differences are denoted between CS+ and CS− 
intake within an injection condition (*) and between CS+ intake following a drug dose relative to 
vehicle treatment (+). The percentages of CS+ intake over total intake are denoted above each 
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the 1 (11.3 ±3.5 g), 5 (6.0 ±1.4 g) and 10 (4.6 ±1.3 g) mg/kg SCOP doses relative to VEH (27.6 
±3.3 g). Significant differences in the percent CS+ intakes were observed (F(3,21)= 5.00, 
p<0.009), and the 70% preference at the 5 mg/kg SCOP dose was significantly lower than the 
98% preference following VEH (Figure 12A). Preferences at the 1 (84%) and 10 (82%) mg/kg 
SCOP doses were intermediate, but did not differ from the VEH test. 
In the two-bottle choice tests in MEC-tested rats, CS+ was consumed significantly more 
(F(1,28)= 229.44, p<0.0001) than CS-, and significant differences were observed among doses 
(F(3,28)= 21.52, p<0.0001) and for the CS x Dose interaction (F(3,28)= 30.05, p<0.0001). CS+ 
intakes significantly exceeded CS- intakes following VEH and all three MEC doses (Figure 
12B). Rats consumed significantly less CS+ at the two higher MEC doses compared to VEH, 
whereas CS- intakes were not affected (Figure 12B). Total intake (g/2 h) significantly (F(3,21)= 
43.17, p<0.0001) declined following the 6 (8.4 ±1.3 g) and 8 (8.8 ±1.2 g) mg/kg MEC doses 
relative to VEH (31.8 ±4.0 g). Significant differences in the percent CS+ intakes were observed 
(F(3,21)= 4.62, p<0.01), and the 85% preference at the 8 mg/kg MEC dose was significantly 
lower than the 97% preference following VEH (Figure 12B). Preferences at the 1 (95%) and 6 
(91%) mg/kg MEC doses were intermediate, and did not differ from the VEH test. 
In the two-bottle choice tests in BAC-tested rats, CS+ was consumed significantly more 
(F(1,28)= 37.71, p<0.0001) than CS-, but no differences were observed among doses (F(3,28)= 
0.24) or for the CS x Dose interaction (F(3,28)= 1.08). CS+ intakes significantly exceeded CS- 
intakes following VEH and the 1.5 and 5, but not the 3 mg/kg BAC doses (Figure 12C). BAC-
induced CS+ and CS- intakes did not differ from VEH values (Figure 12C). Total intake (g/2 h) 
also did not differ (F(3,21)= 1.03) across the VEH and BAC conditions.  The percent CS+ 
intakes approached significance (F(3,21)= 2.68, p=0.073), and a post-hoc comparison revealed 
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that the 74% preference at the 3 mg/kg BAC dose was significantly lower than the 97% 
preference following VEH (Figure 12C). Preferences at the 1.5 (85%) and 5 (86%) mg/kg BAC 
doses were intermediate, and did not differ from the VEH test. 
3.2 SCOP, MEC and BAC and acquisition of CO-CFP:  During 1-bottle training, overall 
CS+/3.5% CO intake (13.7 g/2 h) significantly (F(1,132)= 4.23, p<0.0001) exceeded CS-/0.9% 
CO intake (11.6 g/2 h), and significant differences were observed among groups (F(7,132)= 
12.07, p<0.0001) but not for the Group x CS  interaction (F(7,132)= 0.31). Total training intakes 
(2 h/g) were significantly greater in the VEH group (20.3 g) than the LMTD VEH (8.6 g), 
SCOP1 (12.8 g), SCOP2.5 (9.4 g), MEC4 (8.7 g) and MEC6 (6.9 g), but not the BAC3 (18.3 g) 
and BAC5 (16.2 g) groups (Figure 13A). Intakes of the SCOP and MEC groups did not differ 
from the LMTD VEH group. CS+/3.5% CO and CS-/0.9%CO intakes of the SCOP2.5, MEC4, 
MEC6 LMTD VEH groups were significantly lower than the corresponding VEH animals, 
whereas CS+/3.5%CO intake of the SCOP1 group was significantly lower than corresponding 
VEH animals. However, CS+/3.5% CO and CS-/0.9% CO intakes of these groups did not differ 
from those of the LMTD VEH group.  In the two-bottle preference tests, overall, rats consumed 
significantly more (F(1,396)= 538.31, p<0.0001) CS+ than CS- solution, and significant 
differences were observed among the eight groups (F(7,396)= 2.51, p<0.016), and for the Groups 
x CS interaction (F(7,396)= 11.59, p<0.0001), but not among tests (F(2,396)= 0.58) or for the 
Groups x Tests (F(14,128)= 0.42), Tests x CS (F(2,396)= 1.89) and Groups x Tests x CS 
(F(14,396)= 0.52) interactions. CS+ intakes significantly exceeded CS- intakes across all three 
tests in the VEH (Figure 13B), Limited VEH (Figure 13C), SCOP1 (Figure 13D), MEC4 (Figure 
13F), MEC6 (Figure 13G), BAC3 (Figure 13H) and BAC5 (Figure 13I) groups. In contrast, CS+ 
and CS- intakes did not differ across any test in the SCOP2.5 group (Figure 13E). Significant  
  101 
 
 
Figure 13. (Acquisition Study): Training intakes (mean (g/2 h), ±SEM) of rats exposed to ten 1-
bottle sessions of flavored 3.5% corn oil solutions (CS+/3.5% CO, Days 1, 3, 5, 7, 9) or 0.9% 
corn oil solutions (CS-/0.9% CO, Days 2, 4, 6, 8, 10) 30 min following systemic injections of 
vehicle (VEH), a limited vehicle (LTD VEH) control, scopolamine at doses of 1 (SCOP1) or 2.5 
(SCOP2.5) mg/kg, mecamylamine at doses of 4 (MEC4) or 6 (MEC6) mg/kg or baclofen at 
doses of 3 (BAC3) or 5 (BAC5) mg/kg. Significant differences are denoted between CS+/3.5% 
CO or CS-/0.9% CO intake following a drug dose relative to VEH (+) treatment (Panel A). 
Intakes (mean (g/2 h), ±SEM) of CS+ and CS− flavored 0.9% CO solutions in three two-bottle 
preference tests in the VEH (Panel B), LTD VEH (Panel C), SCOP1 (Panel D), SCOP2.5 (Panel 
E), MEC4 (Panel F), MEC6 (Panel G), BAC3 (Panel H) or BAC5 (Panel I) groups. Significant 
differences (*) are denoted between CS+ and CS−intake within each test and each group, and for 
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differences in the percent CS+ intakes were observed among groups (F(7,198)= 19.16, 
p<0.0001), but not among tests (F(2,198)= 2.0), or for the interaction between Groups x Tests  
(F(14,198)= 0.41). Percent CS+ intake were significantly lower in the SCOP2.5 (Figure 13E) 
relative to the VEH group (Figure 13B) in tests 1 (59% vs. 88%), 2 (55% vs. 87%) and 3 (41% 
vs. 84%). All other groups did not differ from VEH values across tests in percent CS+ intake. 
Significant differences in total intake were observed among groups (F(7,198)= 2.36, p<0.024), 
but not among tests (F(2,198)= 0.56), or for the interaction between Groups x Tests  (F(14,198)= 
0.39). Whereas total intake was typically similar for most groups relative to the VEH group, 
significant reductions were noted in the first two tests in the MEC6 group and in the third test in 
the LMTD VEH group. 
4. Discussion: 
 The present study examined whether muscarinic (SCOP) or nicotinic (MEC) cholinergic 
receptor antagonism or GABAB (BAC) receptor activation would alter expression and 
acquisition of fat (CO)-CFP. Using percent CS+ intake as a measure of the magnitude of a 
preference, expression of CO-CFP was significantly, but marginally reduced by the 5 mg/kg 
SCOP dose (70%), by the 8 mg/kg MEC dose (85%) and by the 3 mg/kg BAC dose (74%) 
relative to comparable vehicle values (97-98%). These mild reductions in CO-CFP expression 
occurred despite sizable dose-dependent reductions in total CS intake following SCOP and 
MEC, but not BAC. Acquisition of CO-CFP was selectively and dose-dependently eliminated by 
administration of SCOP, but not MEC or BAC during one-bottle training. Training intakes of the 
CS+ and CS- CO solutions were significantly lower in groups receiving SCOP and MEC, but not 
BAC. To control for the non-specific actions of reduced solution consumption during training, an 
additional Limited VEH group had their intakes limited to approximate the reduced intakes 
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observed in drug groups. In contrast to the robust CO-CFP observed across the three tests in the 
VEH (86%) and Limited VEH (95%) groups, the SCOP2.5 group failed to display differences 
between CS+ and CS- intakes across tests, and their overall percent CS+ intake approached 
indifference (52%). Whereas total intake during the preference tests failed to differ among the 
VEH, Limited VEH and SCOP2.5 groups, the CS+ and CS- intakes respectively decreased and 
increased across preference tests in the SCOP2.5 group, demonstrating a selective loss of the 
salience of the CS+ solution. In contrast, a lower dose of SCOP (SCOP1 group) failed to affect 
the significant CS+ preferences demonstrated by analyses of CS+ and CS- intakes and percent 
CS+ intake (78%). Moreover, neither MEC at doses of 4 or 6 mg/kg nor BAC at doses of 3 or 5 
mg/kg administered during training affected CO-CFP acquisition in analyses of either CS+ and 
CS- intakes or percent CS+ intake. The following sections examine cholinergic and GABAB 
receptor involvement in preference conditioning and palatable intake. 
 4.1 Muscarinic and Nicotinic Cholinergic and GABAB Receptor Involvement in Fat-CFP 
Expression: Expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2015) was 
minimally affected only at certain doses over a wide dose range of either SCOP (fructose-CFP: 
65-68% (2.5-10 mg/kg; CO-CFP: 70% (5 mg/kg)) or MEC (fructose-CFP: 67-73% (4-8 mg/kg); 
CO-CFP: 80% (8 mg/kg)). In both paradigms, these reductions were accompanied by reductions 
in total, and particularly CS+, intake following SCOP and MEC, but not BAC. The intake 
reductions of saccharin CS solutions in the fructose-CFP paradigm by SCOP and MEC are 
similar to reductions of sweet intake following systemic nicotinic receptor antagonism 
(Taraschenko et al., 2011). The intake reductions of 0.9% corn oil CS solutions in the CO-CFP 
paradigm by SCOP and MEC differ from the inability of accumbal SCOP to affect fat intake 
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(Will et al., 2006), but correspond to the finding that accumbal SCOP microinjections reduced 
fat intake elicited by accumbal DAMGO administration (Perry et al., 2009; Will et al., 2006).  
Coincidentally, expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2016), 
was minimally affected only at one dose (3 mg/kg) over a wide dose range of BAC (fructose-
CFP: 66%; CO-CFP: 74%). The inability of the BAC dose range to alter total fat intake in the 
present study stands in contrast to its previously-reported increases in fat intake under normal ad-
libitum conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), and suppression 
of fat intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin 
et al., 2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al., 
2009). This may be due to the fact that animals in the present study were chronically food-
restricted to encourage short latency sampling of the solutions during the preference paradigm. 
 The patterns of very limited inhibition of expression of CO-CFP by muscarinic or 
nicotinic cholinergic receptor antagonism or GABAB receptor agonism are similar to DA D1, DA 
D2, opioid and NMDA receptor antagonism of CO-CFP expression (Dela Cruz et al., 2012a, 
2012b). Despite evaluating a wide dose range (50-800 nmol/kg) of SCH23390 and raclopride, 
CO-CFP expression was reduced only by intermediate (200 nmol/kg) DA D1 (56%) and DA D2 
(61%) antagonist doses. Similarly, despite evaluating a wide naltrexone dose range (0.1-5 
mg/kg), CO-CFP expression was modestly reduced by only the 0.1 (69%) and 1 mg/kg (71%) 
doses. Further, despite evaluating a wide MK-801 dose range (50-200 µg/kg), the loss of 
preference (49%) following the highest NMDA antagonist dose was accompanied by dramatic 
decreases in total fat intake. Antagonist effects upon fructose-CFP are more striking in that 
SCH23390 or raclopride dose-dependently eliminated the expression of both fructose-CFP in 
real-feeding rats and sucrose-CFP in sham-feeding rats (Baker et al., 2003; Hsiao and Smith, 
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1995; Yu et al., 2000a, 2000b). In contrast, neither NMDA nor opioid receptor antagonism 
affected expression of fructose-CFP (Baker et al., 2004; Golden and Houpt, 2007). It is important 
to note that whereas glucose and sucrose are capable of conditioning flavor preferences through 
both flavor-flavor and flavor-nutrient processes, fructose elicits flavor preferences through 
flavor-flavor, but not flavor-nutrient processes in short-term tests (Sclafani and Ackroff, 1994; 
Sclafani et al., 1993, 1999). Therefore, comparisons of the present limited cholinergic and 
GABAB receptor signaling effects on CO-CFP with sugar-CFP may be more pertinent for oral 
glucose-CFP because, like CO, glucose activates both flavor-flavor and flavor-nutrient 
processes. Rats displayed a robust oral glucose-CFP (94-95%) which was significantly though 
marginally attenuated in expression studies by SCH23390 (67-70%), raclopride (77%) or MK-
801 (70%) at doses that also markedly reduced overall CS intake (Dela Cruz et al., 2014). Given 
the imperfection of direct fructose and oil comparisons and given that parallel glucose data using 
the present agents is not yet available, other future studies need to address this issue as well as 
others examining oral only and oral + post-ingestive mechanisms. Finally, other future studies 
should address whether the oral effects of fat are more important in these procedures than fat-
related post-ingestive effects by examining whether pharmacological manipulation of 
preferences elicited by short-term exposure to intragastric oil are similar to or different from that 
of the present data.            
 4.2 Muscarinic and Nicotinic Cholinergic and GABAB Receptor Involvement in Fat-CFP 
Acquisition: Acquisition of CO-CFP was selectively and dose-dependently eliminated by 
administration of SCOP, but not MEC during one-bottle training despite the fact that both 
antagonists lowered training intakes. The SCOP2.5 group failed to display differences between 
CS+ and CS- intakes across tests, and their overall percent CS+ intake approached indifference 
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(52%). CS+ and CS- intakes respectively decreased and increased across preference tests in the 
SCOP2.5 group, demonstrating a selective loss of the salience of the CS+ solution. Further, the 
SCOP dose (2.5 mg/kg) capable of eliminating CO-CFP acquisition is lower than the dose (5 
mg/kg) that only mildly reduced CO-CFP expression. In contrast, the SCOP1, MEC4 and MEC6 
groups failed to display changes in CO-CFP acquisition. The pattern of selective muscarinic, but 
not nicotinic cholinergic receptor involvement parallels the ability of SCOP, but not MEC to 
eliminate fructose-CFP acquisition (Rotella et al., 2015). The selective actions by which 
muscarinic, but not nicotinic cholinergic receptor blockade blocks both CO- and fructose-CFP 
acquisition (Rotella et al., 2015) are similar to other previously-cited cue-related feeding 
responses (Carballo-Marquez et al., 2009; Pratt et al., 2007; Sharf and Ranaldi, 2006). It does not 
appear that SCOP is eliminating fat- and fructose-CFP acquisition through some aversive 
quality. Reasons include that the doses necessary to eliminate acquisition of these responses are 
far lower than the SCOP doses that marginally reduce the maintenance of these responses in 
expression studies. Second, and more importantly, whereas SCOP, but not MEC blocks the 
acquisition of fructose-CFP, MEC, but not SCOP enhances the conditioned flavor avoidance 
induced by quinine adulteration (Rotella et al., 2015). Finally, acquisition of CO-CFP was 
unaffected by administration of BAC at doses of 3 or 5 mg/kg during one-bottle training, and 
these doses also failed to affect training intakes. The inability of GABAB receptor agonism to 
affect CO-CFP acquisition parallels its inability to alter fructose-CFP acquisition (Rotella et al., 
2016). This failure by BAC to affect acquisition of sugar- or fat-CFP stands in contrast to its 
ability to enhance and prolong the magnitude of quinine-CFA (Rotella et al., 2016).    
 The elimination of acquisition of CO-CFP by muscarinic cholinergic antagonism is 
similar to NMDA receptor antagonist effects (Dela Cruz et al., 2012a), and is more potent than 
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DA D1 and D2 receptor antagonist effects (Dela Cruz et al., 2012b). In contrast, the inability of 
nicotinic cholinergic receptor antagonism or GABAB receptor agonism to alter CO-CFP 
acquisition is similar to the relative lack of opioid antagonist effects (Dela Cruz et al., 2012a). 
That GABAB agonists and opioid antagonists similarly fail to affect CO-CFP acquisition stand in 
contrast to the ability of BAC and naltrexone to strongly suppress fat intake under “binge-eating” 
and other similar conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al., 2005; 
Corwin and Wojnicki, 2009; Rao et al., 2008; Wang et al., 2011; Wong et al., 2009). Thus, it 
would appear that the regulatory processes underlying opioid and GABAB regulation of “binge-
eating” is unrelated to the lack of involvement of these systems in the learning of these strong fat 
preferences. 
 The present and previous (Rotella et al., 2015, 2016) data indicate that whereas SCOP, 
MEC and BAC minimally affect fat-CFP expression, SCOP, but not MEC or BAC effectively 
eliminates the acquisition of fructose-CFP and fat-CFP. The use of systemic cholinergic receptor 
antagonist treatment or GABAB agonist treatment in examining fructose- and fat-CFP followed 
our previous strategy of initial systemic evaluation of DA receptor involvement in fructose- and 
fat-CFP (Baker et al., 2003; Dela Cruz et al., 2012a, 2012b Yu et al., 2000a, 2000b) followed by 
DA antagonist administration into central candidate limbic sites for fructose-CFP (Amador et al., 
2014; Bernal et al., 2008, 2009; Malkusz et al., 2012). Much of the evidence implicating 
cholinergic involvement in complex aspects of food intake appears to be due to activity in a 
limbic circuit (specifically the VTA and NAc) in which cholinergic signaling can act directly 
upon sweet preferences and avoidances either in and of itself, or through interactions with brain 
DA. Sweet solutions appear to affect both DA and Ach release, particularly in the NAc and 
related sites. In addition to the ability of general food intake to increase DA and Ach in the NAc 
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shell (Mark et al., 1992), daily bingeing on sugar repeatedly and initially released NAc shell DA 
followed by Ach NAc shell release (Rada et al., 2005). Whereas real-feeding sucrose increased 
NAc DA and Ach, sucrose intake in sham-drinking rats displayed the DA, but not the Ach 
elevations in the NAc (Avena et al., 2006). Correspondingly, increases in NAc DA were 
observed in normal-weight and underweight rats, whereas NAc Ach was increased in the former, 
but not the latter group (Avena et al., 2008c). In contrast, animals trained to binge on a sucrose 
solution display increased Ach and decreased DA release in the NAc shell following food 
deprivation (Avena et al., 2008a). Consistent with the ability of sugars to produce greater CFP 
relative to saccharin, sucrose-predictive cues evoked greater NAc DA release than saccharin-
predictive cues (McCutcheon et al., 2012). Administration of morphine, the mu-opioid agonist, 
DAMGO or galanin into the paraventricular nucleus of the hypothalamus increased DA and 
decreased Ach in the NAc shell (Rada et al., 1998, 2010). A parallel system might be proposed 
for mediation of fat-CFP given the present data, and that accumbal microinjections of SCOP 
markedly reduced fat intake elicited by accumbal administration of the mu-opioid receptor 
agonist, DAMGO, and also reduced food intake in food-deprived rats (Perry et al., 2009; Will et 
al., 2006). However, accumbal SCOP failed to affect fat intake itself (Will et al., 2006). 
Given these relationships, a central site of action at which muscarinic receptor 
antagonism might reduce sugar- and fat-CFP and interact with brain DA is the NAc shell. Such 
Ach-DA interactions would presumably occur through DA terminal innervation of Ach-
containing interneurons in the NAc (de Rover et al., 2002; Witten et al., 2010; Zhou et al., 2002), 
although cholinergic PPT/LDT innervation is found there as well (Dautan et al., 2014). NAc 
cholinergic-DA interactions act through local DA D2 receptors (Alcantara et al., 2003), mediate 
accumbal DA release that also involves glutamate signaling (Cachope et al., 2012; Chuhma et 
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al., 2014; Threlfell and Cragg, 2011), and provide feedback control of VTA DA release (Rahman 
and McBride, 2002). Further studies with accumbal cholinergic receptor antagonists are 
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Chapter 7: General Discussion 
The final chapter will briefly summarize the effects of muscarinic and nicotinic 
cholinergic receptor antagonism on the acquisition and expression of fructose-CFP or CO-CFP 
(e.g., Specific Aims 1 and 2) as well as the effects of GABAB receptor agonism (e.g., Specific 
Aims 3 and 4).  Our novel flavor avoidance paradigm (quinine-CFA) will then be reviewed in 
terms of the effects of DA D1, DA D2, opioid and NMDA receptor antagonism (Specific Aim 5) 
and muscarinic and nicotinic cholinergic receptor antagonism and GABAB receptor agonism 
(Specific Aim 6) on the acquisition of quinine-CFA.  Finally, there will be a general discussion 
of the following topics: A) what is the relationship between preference and avoidance, and how 
theoretically would receptor antagonists affect the two forms of learning, B) future directions on 
the proposed research as well as C) implications of animal based CFP and CFA investigations 
for human consumption behaviors and pathology. 
1A. Summary of Muscarinic and Nicotinic Cholinergic Receptor Antagonism: Fructose- 
and Fat-CFP (Specific Aims 1 & 2)   
The expression of fructose-CFP failed to be affected by a wide dose range of the 
muscarinic antagonist, SCOP or the nicotinic antagonist, MEC. However, the magnitude of 
fructose-CFP expression, defined by changes in percent CS+ intake, was significantly reduced by 
high doses of SCOP (2.5-10 mg/kg: 65-68%) and MEC (4-8 mg/kg: 67-73%) relative to VEH 
(89-90%). These reductions were accompanied by reductions in total, and particularly CS+, 
intake. These intake reductions of saccharin by systemic SCOP and MEC correspond to previous 
reductions of sweet intake following systemic nicotinic receptor antagonism (Taraschenko et al., 
2011) and chow intake following systemic of muscarinic and nicotinic receptor antagonism 
(Dandekar et al., 2011; Dickson et al., 2010; Perry et al., 2009; Pratt and Blackstone, 2009; Will 
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et al., 2006). The very limited inhibition of systemic muscarinic or nicotinic cholinergic receptor 
antagonism of expression of fructose-CFP stands in contrast to previously-observed systemic 
pharmacological effects. Thus, systemic DA D1 (SCH23390) or D2 (raclopride) receptor 
antagonists dose-dependently eliminated the expression of both fructose-CFP in real-feeding rats 
and sucrose-CFP in sham-feeding rats (Baker et al., 2003; Hsiao and Smith, 1995; Yu et al., 
2000a, 2000b). Whereas a CB1 receptor inverse agonist (AM-251) reduced expression of 
fructose-CFP (Miner et al., 2008), neither NMDA (MK-801) nor opioid (naltrexone) receptor 
antagonism affected expression of fructose-CFP (Baker et al., 2004; Bernal et al., 2010; Golden 
and Houpt, 2007). Thus, muscarinic or nicotinic cholinergic receptor antagonism plays a 
minimal role in the maintenance of an already-acquired CFP for fructose.     
 In contrast, acquisition of fructose-CFP was eliminated by systemic SCOP, but not MEC 
administered during training and the magnitude of fructose-CFP relative to VEH-trained (85-
92%) rats was eliminated in SCOP-trained rats receiving 1 (40-54%) and 2.5 (45-58%) mg/kg 
doses, effects indicative of indifference. However, these SCOP doses significantly reduced 
CS+/Fs and CS-/s intakes during training, lending to the possiblity that this loss of preference 
could be due to specific primary actions of muscarinic cholinergic receptor antagonism or to 
secondary actions of reducing the opportunities to learn the preference due to reduced intake per 
se.  To control for this second possibility, the addition of the LMTD VEH group receiving 
vehicle injections, but limited in comparable CS+ and CS- intakes to those of the drug groups, 
displayed comparable, significant fructose-CFP preferences relative to vehicle-trained rats 
suggesting that the inability of SCOP-trained rats to display preferences was thus due to its 
cholinergic receptor antagonism. Further, while lower SCOP doses eliminated fructose-CFP 
acquisition, they failed to affect fructose-CFP expression. In contrast, MEC-trained rats 
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continued to display significant preferences with CS+ intake significantly higher than CS- intake 
despite MEC resulting in significant reductions in CS+/Fs and CS-/s intakes during training to 
levels observed for SCOP.  Hence, systemic muscarinic, but not nicotinic receptor antagonism 
administered during training eliminated fructose-CFP acquisition. The systemic SCOP-induced 
elimination of fructose-CFP acquisition is similar in magnitude to the abilities of systemic DA 
D1, DA D2 and NMDA receptor antagonists to eliminate fructose-CFP acquisition in real-
feeding rats (Baker et al., 2003; Golden and Houpt, 2007; Hsiao and Smith, 1995) and sucrose-
CFP acquisition in sham-feeding rats (Yu et al., 2000a, 2000b).     
 Given the similar, albeit weaker effects of DA D1, DA D2, and NMDA receptor 
antagonists on the acquisition and expression of CO-CFP relative to fructose-CFP (Dela Cruz et 
al., 2012a, 2012b) in addition to the research suggesting interactions amongst these systems and 
the cholinergic system in the mediation of reward and learning (Avena & Rada, 2012), it was 
hypothesized and addressed in Specific Aim 2 that blockade of muscarinic and nicotinic 
cholinergic receptors would also influence the acquisition and expression of CO-CFP, and that 
these effects would be smaller in magnitude relative to the effects observed for fructose-CFP. 
The expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2015) was minimally 
affected only at certain doses over a wide dose range of either SCOP (fructose-CFP: 65-68% 
(2.5-10 mg/kg; CO-CFP: 70% (5 mg/kg)) or MEC (fructose-CFP: 67-73% (4-8 mg/kg); CO-
CFP: 80% (8 mg/kg)). In both paradigms, these reductions were accompanied by reductions in 
total, and particularly CS+, intake following SCOP and MEC. The intake reductions of saccharin 
CS solutions in the fructose-CFP paradigm by SCOP and MEC are similar to reductions of sweet 
intake following systemic nicotinic receptor antagonism (Taraschenko et al., 2011). The patterns 
of very limited inhibition of expression of CO-CFP by muscarinic or nicotinic cholinergic 
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receptor antagonism is similar to DA D1, DA D2, opioid and NMDA receptor antagonism of 
CO-CFP expression (Dela Cruz et al., 2012a, 2012b). Despite evaluating a wide dose range (50-
800 nmol/kg) of SCH23390 and raclopride, CO-CFP expression was reduced only by 
intermediate (200 nmol/kg) DA D1 (56%) and DA D2 (61%) antagonist doses. Similarly, despite 
evaluating a wide NTX dose range (0.1-5 mg/kg), CO-CFP expression was modestly reduced by 
only the 0.1 (69%) and 1 mg/kg (71%) doses. Further, despite evaluating a wide MK-801 dose 
range (50-200 µg/kg), the loss of preference (49%) following the highest NMDA antagonist dose 
was accompanied by dramatic decreases in total fat intake. Antagonist effects upon fructose-CFP 
are more striking in that SCH23390 or raclopride dose-dependently eliminated the expression of 
both fructose-CFP in real-feeding rats and sucrose-CFP in sham-feeding rats (Baker et al., 2003; 
Hsiao and Smith, 1995; Yu et al., 2000a, 2000b). In contrast, neither NMDA nor opioid receptor 
antagonism affected expression of fructose-CFP (Baker et al., 2004; Golden and Houpt, 2007). It 
is important to note that whereas glucose and sucrose are capable of conditioning flavor 
preferences through both flavor-flavor (orosensory) and flavor-nutrient (post-ingestive) 
processes, fructose elicits flavor preferences through flavor-flavor, but not flavor-nutrient 
processes in short-term tests (Sclafani and Ackroff, 1994; Sclafani et al., 1993, 1999). Therefore, 
comparisons of the present limited cholinergic receptor signaling effects on CO-CFP with sugar-
CFP may be more pertinent for oral glucose-CFP because, like CO, glucose activates both 
flavor-flavor and flavor-nutrient processes. Rats displayed a robust oral glucose-CFP (94-95%) 
which was significantly though marginally attenuated in expression studies by SCH23390 (67-
70%), raclopride (77%) or MK-801 (70%) at doses that also markedly reduced overall CS intake 
(Dela Cruz et al., 2014). Given the imperfection of direct fructose and oil comparisons and given 
that parallel glucose data using the present agents is not yet available, other future studies need to 
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address this issue as well as others examining oral only and oral + post-ingestive mechanisms. 
Finally, other future studies should address whether the oral effects of fat are more important in 
these procedures than fat-related post-ingestive effects by examining whether pharmacological 
manipulation of preferences elicited by short-term exposure to intragastric oil are similar to or 
different from that of the present data.                  
 Acquisition of CO-CFP was selectively and dose-dependently eliminated by 
administration of SCOP, but not MEC during one-bottle training despite the fact that both 
antagonists lowered training intakes. The SCOP2.5 group failed to display differences between 
CS+ and CS- intakes across tests, and their overall percent CS+ intake approached indifference 
(52%). CS+ and CS- intakes respectively decreased and increased across preference tests in the 
SCOP2.5 group, demonstrating a selective loss of the salience of the CS+ solution. Further, the 
SCOP dose (2.5 mg/kg) capable of eliminating CO-CFP acquisition is lower than the dose (5 
mg/kg) that only mildly reduced CO-CFP expression. In contrast, the SCOP1, MEC4 and MEC6 
groups failed to display changes in CO-CFP acquisition. The pattern of selective muscarinic, but 
not nicotinic cholinergic receptor involvement parallels the ability of SCOP, but not MEC to 
eliminate fructose-CFP acquisition (Rotella et al., 2015). The selective actions by which 
muscarinic, but not nicotinic cholinergic receptor blockade blocks both CO- and fructose-CFP 
acquisition (Rotella et al., 2015) are similar to other previously-cited cue-related feeding 
responses (Carballo-Marquez et al., 2009; Pratt et al., 2007; Sharf and Ranaldi, 2006). It does not 
appear that SCOP is eliminating fat- and fructose-CFP acquisition through some aversive 
quality. Reasons include that the doses necessary to eliminate acquisition of these responses are 
far lower than the SCOP doses that marginally reduce the maintenance of these responses in 
expression studies. Second, and more importantly, whereas SCOP, but not MEC blocks the 
  115 
 
acquisition of fructose-CFP, MEC, but not SCOP enhances the conditioned flavor avoidance 
induced by quinine adulteration (Rotella et al., 2015).         
 The elimination of acquisition of CO-CFP by muscarinic cholinergic antagonism is 
similar to NMDA receptor antagonist effects (Dela Cruz et al., 2012a), and is more potent than 
DA D1 and D2 receptor antagonist effects (Dela Cruz et al., 2012b).  Thus in relation to Specific 
Aim 2, whereas both SCOP and MEC partially mediate fat-CFP expression, only SCOP is 
involved in the acquisition of fat-CFP.        
1B. Summary of GABAB Receptor Agonism: Fructose- and Fat-CFP (Specific Aims 3 & 4)                                                                                                 
 Although the present study focused on the role of BAC in sugar preference, BAC effects 
upon total intake could be analyzed for saccharin intake in the fructose-CFP expression 2-bottle 
testing paradigm, for fructose + saccharin and saccharin intake in the fructose-CFP 1-bottle 
training paradigm. In the fructose-CFP expression paradigm, systemic BAC failed to alter total 
saccharin intake across the 0.5-5 mg/kg BAC dose range. In the fructose-CFP acquisition 
paradigm, neither the 3 nor 5 mg/kg doses of BAC administered during training significantly 
altered fructose + saccharin or saccharin intake relative animals receiving VEH. The inability of 
systemic BAC to alter saccharin intake per se is in contrast to the ability of the same dose range 
to impair gustatory discrimination of 0.3% and 0.6% saccharin solutions (Wilson et al., 2011). It 
should be noted that animals in these conditioning paradigms were food-restricted and received 
multiple injections of systemic BAC, factors that alter BAC-induced orexigenic actions on chow 
intake (e.g., Patel and Ebenezer, 2008). Thus, these data are in agreement with the general failure 
to observe differences in sweet intake per se following systemic BAC (Avena et al., 2014; 
Berner et al., 2009; Corwin and Wojnicki, 2009). 
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 In the fructose-CFP expression paradigm, CS+ intake was significantly higher than 
corresponding CS- intake in the two-bottle preference tests following VEH and all (0.5-5 mg/kg) 
BAC doses. The magnitude of the fructose-CFP was significantly, but marginally lowered by the 
3 mg/kg BAC dose (66%) relative to VEH; lower (0.5, 1.5) and higher (5.0) BAC doses failed to 
exert effects. This marginal reduction in fructose-CFP expression following systemic GABAB 
receptor activation was similar and comparable to that observed following systemic 
administration of AM-251, a cannabinoid CB1 receptor inverse agonist (Miner et al., 2008) and 
muscarinic (scopolamine) and nicotinic (mecamylamine) cholinergic antagonists (Rotella et al., 
2015). In contrast, systemic administration of dopamine D1 (SCH23390) or D2 (raclopride) 
receptor antagonists eliminated expression of fructose-CFP in real-feeding rats and sucrose-CFP 
in sham-feeding rats (Baker et al., 2003; Yu et al., 2000). Further, neither systemic NMDA (MK-
801) nor opioid (naltrexone) receptor antagonism affected expression of fructose-CFP in real-
feeding rats or sucrose-CFP in sham-feeding rats (Baker et al., 2004; Golden and Houpt, 2007; 
Yu et al., 1999).  
In the fructose-CFP acquisition paradigm, the patterns of CS+ and CS- intake in all three 
two-bottle preferences tests were similar in rats receiving VEH or the two (3 or 5 mg/kg) BAC 
doses during training. Correspondingly, the magnitude of fructose-CFP measured by percent 
CS+ intake failed to differ among these groups. The inability of systemic GABAB receptor 
activation to alter the acquisition of fructose-CFP stands in marked contrast to the abilities of 
systemic administration of dopamine D1, dopamine D2, NMDA or muscarinic receptor 
antagonists to eliminate acquisition of fructose-CFP in real-feeding rats and/or sucrose-CFP in 
sham-feeding rats (Baker et al., 2003; Golden and Houpt, 2007; Rotella et al., 2015; Yu et al., 
2000). Rather, the effects of systemic BAC in failing to affect fructose-CFP acquisition were 
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similar to that observed following NTX (Baker et al., 2004; Yu et al., 1999), AM-251 (Miner et 
al., 2008) or MEC (Rotella et al., 2015).  Thus in relation to Specific Aim 3, while BAC 
marginally reduced fructose-CFP expression, it failed to block fructose-CFP acquisition.   
 The expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2015), was 
minimally affected only at one dose (3 mg/kg) over a wide dose range of BAC (fructose-CFP: 
66%; CO-CFP: 74%). The inability of the BAC dose range to alter total fat intake in these series 
of studies stands in contrast to its previously-reported increases in fat intake under normal ad-
libitum conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), and suppression 
of fat intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin 
et al., 2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al., 
2009). This may be due to the fact that animals in the present study were chronically food-
restricted to encourage short latency sampling of the solutions during the preference paradigm.  
The patterns of very limited inhibition of expression of CO-CFP by GABAB receptor agonism 
are similar to DA D1, DA D2, opioid, NMDA, muscarinic or nicotinic cholinergic receptor 
antagonism on CO-CFP expression (Dela Cruz et al., 2012a, 2012b). It is important to note that 
whereas glucose and sucrose are capable of conditioning flavor preferences through both flavor-
flavor (orosensory) and flavor-nutrient (post-ingestive) processes, fructose elicits flavor 
preferences through flavor-flavor, but not flavor-nutrient processes in short-term tests (Sclafani 
and Ackroff, 1994; Sclafani et al., 1993, 1999). Therefore, comparisons of the present limited 
GABAB receptor signaling effects on CO-CFP with sugar-CFP may be more pertinent for oral 
glucose-CFP because, like CO, glucose activates both flavor-flavor and flavor-nutrient 
processes. Rats displayed a robust oral glucose-CFP (94-95%) which was significantly though 
marginally attenuated in expression studies by SCH23390 (67-70%), raclopride (77%) or MK-
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801 (70%) at doses that also markedly reduced overall CS intake (Dela Cruz et al., 2014). Given 
the imperfection of direct fructose and oil comparisons and given that parallel glucose data using 
the present agents is not yet available, other future studies need to address this issue as well as 
others examining oral only and oral + post-ingestive mechanisms. Finally, other future studies 
should address whether the oral effects of fat are more important in these procedures than fat-
related post-ingestive effects by examining whether pharmacological manipulation of 
preferences elicited by short-term exposure to intragastric oil are similar to or different from that 
of the present data. 
The acquisition of CO-CFP was unaffected by administration of BAC at doses of 3 or 5 
mg/kg during one-bottle training, and these doses also failed to affect training intakes. The 
inability of GABAB receptor agonism to affect CO-CFP acquisition parallels its inability to alter 
fructose-CFP acquisition (Rotella et al., 2016). This failure by BAC to affect acquisition of 
sugar- or fat-CFP stands in contrast to its ability to enhance and prolong the magnitude of 
quinine-CFA (Rotella et al., 2016). 
That GABAB agonists and opioid antagonists similarly fail to affect CO-CFP acquisition 
stand in contrast to the ability of BAC and NTX to strongly suppress fat intake under “binge-
eating” and other similar conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al., 
2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wang et al., 2011; Wong et al., 2009). Thus, 
it would appear that the regulatory processes underlying opioid and GABAB regulation of 
“binge-eating” is unrelated to the lack of involvement of these systems in the learning of these 
strong fat preferences. 
The inability of nicotinic cholinergic receptor antagonism or GABAB receptor agonism to 
alter CO-CFP acquisition is similar to the relative lack of opioid antagonist effects (Dela Cruz et 
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al., 2012a), but differs from the ability of muscarinic cholinergic (Rotella et al., 2016b) and 
NMDA receptor antagonist effects (Dela Cruz et al., 2012a).  Thus, in relation to Specific Aim 
4, these data indicate that BAC minimally affects fat-CFP expression and fails to effectively 
eliminate the acquisition of fructose-CFP and fat-CFP.  
1C. Summary of the Pharmacology of Quinine-CFA (Specific Aims 5 & 6)                                                                                                 
 Under an evolutionary perspective, it could be said that the activation of certain taste 
receptors for sweets and fats and the following “pleasant” perceptions aided in the survival of 
man and many species and thus were selected for and subsequently passed to following 
generations due to the energy and nutrients these substances provided.  By contrast, it could be 
said that the activation of certain taste receptors for bitter toxins and the following “unpleasant” 
perceptions aided in the survival of man and many species and thus were selected for and 
subsequently passed to following generations due to the harm or death that was prevented.  
Those failing to learn to avoid these toxic substances presumably did not survive and the genes 
coding for the taste receptors and underlying neurochemical substrates mediating this learning 
were also not passed down.  Therefore, not only is important to understand the neurochemical 
and/or neuroanatomical substrates mediating these adaptive approach behaviors, but it is equally 
important to understand the same processes underlying adaptive avoidant behaviors.  As such, 
another primary goal of this dissertation was to determine whether the same neurotransmitter 
systems mediating the learning and maintenance of preferences conditioned by primary rewards 
(e.g. sugars and fats) also mediated the underlying learning processes of avoidances conditioned 
by primary aversive stimuli (e.g. bitter taste of quinine).       
 In order to assess the proposed effects on Specific Aim 5, we first demonstrated that a 
CFA could be produced by adulterating a fructose+saccharin solution with quinine depending 
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upon the concentration of the bitterant. At very low concentrations (0.001-0.008%), the added 
quinine failed to reduce CS+FSQ training intake relative to the CS-FS, and did not produce 
significant differences in CS+ and CS- intakes in the two-bottle choice tests. Although 
adulteration with 0.012% or 0.016% quinine significantly depressed CS+/FSQ training intake, it 
was insufficient to produce a CFA in the two-bottle tests. However, when quinine concentration 
was raised to 0.03%, CS+/FSQ intake was significantly reduced relative to CS-/FS intake in one-
bottle training trials, and a quinine-CFA was observed in two-bottle Test 1 but not in Tests 2 and 
3. The transitory nature of the 0.3% quinine-induced CFA was also observed in the VEH groups 
of Experiments 2 and 3 that were tested with CS flavors presented in fructose+saccharin and 
saccharin-only solutions, respectively. The data from Experiment 3 indicates that the transitory 
quinine CFA observed in the first two experiments was not due to the use of palatable 
fructose+saccharin solutions in the choice tests. Instead, the quinine-CFA was found to be 
related to the concentration of the bitter adulterant. The VEH.06% rats trained with a CS+FSQ 
containing 0.06% quinine consumed less solution during training and displayed a more persistent 
CS+ avoidance (Tests  1 and 2) than did the VEH rats with the CS+FSQ containing 0.03% 
quinine (Test 1 only), indicating that the persistence of the quinine-CFA could be increased by 
increasing quinine concentration.  
In CFP studies, systemic DA D1and D2 antagonists reduce the acquisition of flavor-taste 
sugar preferences (Baker et al., 2003; Hsiao & Smith, 1995; Yu et al., 2000a; 2000b), whereas 
only DA D1 antagonists reduce the acquisition of flavor-nutrient sugar preferences (Azzara et 
al., 2001).  One interpretation of how DA antagonists block sugar-based CFPs is that the drugs 
reduce the reward value of the sweet taste or post-oral actions of sugars. An extension of this 
hypothesis would be that DA antagonists also reduce the negative reward value of aversive tastes 
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or post-oral aversive states.  In fact, DA D1 receptor antagonists administered into either the 
lateral hypothalamus (Caulliez et al., 1996) or shell of the NAc (Fenu et al., 2001) disrupted the 
acquisition of a flavor-toxin CFA induced by LiCl in a manner similar to reductions in the 
acquisition of flavor-nutrient CFP elicited by IG glucose infusions (Touzani et al., 2008; 2009b). 
The selective effects of SCH23390, but not raclopride injections on quinine-induced CFA is 
similar to reports that only SCH23390 altered flavor-toxin avoidance produced by LiCl 
injections (Fenu et al., 2005; 2009). However, whereas SCH23390 blocked the development of 
the LiCl-CFA, the drug enhanced the quinine-CFA in the present study. The quinine and LiCl 
conditioning procedures differed in several important respects which complicate comparisons 
between the different drug effects. Note, in particular, that in one experiment, SCH23390 
significantly attenuated a LiCl-induced CFA when injected 5 min after the CS training sessions 
but not when injected 30 min prior to the CS training sessions as in the present study (Fenu et al., 
2001). Thus, to determine if SCH23390, or other drugs, differentially influence the learning of a 
bitter taste (quinine) or toxic drug (LiCl) CFA, it is essential to use similar training paradigms 
(drug dose, injection timing, CS flavor, etc.).  
 Conceivably, DA D1 antagonism may enhance quinine-conditioned flavor avoidance 
because it selectively increases the aversiveness of bitter adulterants. However, there is little 
evidence concerning the impact of systemic SCH23390 on quinine avoidance; indeed, one study 
reported that SCH microinfusions into the ventral pallidum suppressed saccharin, but not quinine 
intake (Shimura et al., 2006). In Experiments 2 and 3, SCH23390 reduced the intake of both the 
FS and FSQ solutions so the drug effect on quinine avoidance per se cannot be differentiated. 
The failure of raclopride injections to alter CS+FSQ training intake or CS+ preference, relative 
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to the vehicle treatment, is consistent with one report that this DA D2 antagonist did not alter 
quinine solution intake in rats (Phillips et al., 1991). 
In a CFP study, systemic NMDA receptor antagonism eliminated the acquisition, but not 
expression of a flavor-taste fructose preference (Golden & Houpt, 2007). Yet the present study 
demonstrated that systemic treatment with MK-801 significantly prolonged the flavor-taste CFA 
induced by quinine. During training, MK-801-treated rats displayed significant reductions in 
CS+FSQ, but not CS-FS intake as compared to VEH-treated rats, suggesting that it enhanced the 
avoidance of the quinine adulterated solution. Yet, a previous study (Vardigan et al., 2010) 
reported that systemic MK-801 did not reduce quinine solution intake in thirsty rats. Golden and 
Houpt (2007) hypothesized that NMDA receptor signaling mediates the learning process by 
which a flavor CS is associated with the reward value of a gustatory US. Thus, it is not clear why 
systemic NMDA receptor antagonism with MK-801 blocks a fructose-CFP (Golden & Houpt, 
2007), but enhances a quinine-CFA. CFA is induced by MK-801 as well as other NMDA 
antagonists (Fowler et al., 2011; Jackson & Sanger, 1989; Traverso et al., 2003; 2012; Turgeon 
et al., 2000), and it enhances ethanol-induced CFA (Blenkowski et al., 1998). 
In CFP studies, neither systemic nor central (NAc) opioid receptor antagonism altered the 
acquisition or expression of flavor-taste or flavor-nutrient sugar preferences (Azzara et al., 2000; 
Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). Yet the present study demonstrated that 
NTX significantly prolonged the flavor-taste CFA induced by quinine. This effect may be related 
to the finding that opioid antagonism increased quinine aversion in rats (Cagniard & Murphy, 
2013; Le Magnen et al., 1980; Siviy & Reid, 1983), although this is not a consistent result 
(Ferraro et al., 2002; Goodwin et al., 2001; Levine et al., 1982; Parker et al., 1992). Opioid 
receptor antagonism with naloxone is also reported to enhance taste aversions elicited by LiCl 
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(Davis et al., 2009; Micelli et al., 1979; Smurthwaite et al., 1992). NTX as well as delta-opioid 
agonists and antagonists produce conditioned flavor avoidance by themselves (Hutchinson et al., 
2000; Kautz et al., 1989; Parker & Rennie, 1992). Yet, opioid antagonism blocks morphine-
induced taste aversions (Fox et al., 2006; Stevenson et al., 1992). 
In relation to Specific Aim 6, the last set of studies addressed the roles of muscarinic, 
nicotinic or GABAB receptor signaling in the acquisition of quinine-CFA.    
Systemic administration of nicotinic (MEC), but not muscarinic (SCOP) cholinergic 
receptor antagonism significantly enhanced and prolonged the acquisition of quinine-CFA. 
VEH-trained rats displayed a significant, transitory quinine-CFA as demonstrated by a 
significant aversion observed after the first (34%), but not second (48%) or third (47%) pairs of 
tests. Systemic nicotinic cholinergic antagonism significantly increased the magnitude and 
duration of quinine-CFA as indicated by rats trained with the 4 (18-24%) and 6 (11-13%) mg/kg 
MEC doses. In contrast, the SCOP 1 group displayed a significant aversion after the first test pair 
(17%), but failed to differ from VEH-trained rats thereafter, whereas the SCOP 2.5 group failed 
to display quinine-CFA after any preference test. It should be noted that both systemic SCOP and 
MEC significantly reduced CS-/FS intake and CS+/FSQ intake during training relative to VEH. 
This raises the possibility that the greater subsequent avoidance responses could be due to non-
specific malaise brought about by pairing the antagonist with the flavored solutions during 
training. Both lithium chloride-induced conditioned taste aversions and attenuation of neophobic 
responses were blocked by central SCOP pretreatment into the insular cortex (Ferreira et al., 
2002; Gutierrez et al., 2003a, 2003b; Naor and Dudai, 1996) and NAc shell (Ramirez-Lugo et 
al., 2006), but not when SCOP was administered after the presentation of the new taste. 
Although nicotinic receptor antagonists have not been evaluated in this paradigm, galantamine, 
  124 
 
an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic Ach receptors, 
reduced nicotine seeking without producing malaise (Hopkins et al., 2012).    
 The inability of SCOP to affect quinine-CFA acquisition is consistent with its previously-
described inability to alter quinine aversion while attenuating LiCl-induced CFA (Coil et al., 
1978). Although systemic SCOP elicited a flavor-taste CFA (Ossenkopp et al., 1986), the present 
data indicate that SCOP- and quinine-CFA fail to synergize. The ability of MEC to enhance and 
prolong quinine-CFA is consistent with previous observations that nicotine depressed quinine-
evoked responses in the nucleus tractus solitarius that were blocked by MEC (Simons et al., 
2006), and CFAs induced by nicotine and quinine generalized to each other in mice (Gyekis et 
al., 2012) that were blocked by MEC (Oliveira-Maia et al., 2009). However, the ability of MEC 
to enhance and prolong quinine-CFA appears specific to this type of “inhibitory” learning. 
Recent studies demonstrated that chronic co-treatment with systemic MEC prevented the 
occurrence of depressive-like behavior elicited by chronic restraint stress as measured by the 
forced swim test, sucrose preference and body weight control (Aboul-Fotouh, 2015). Moreover, 
whereas nicotine facilitated a version of “inhibitory” learning called negative occasion setting, 
systemic MEC co-treatment extended the number of training sessions to elicit this behavior 
(Meyer et al., 2015).         
These data suggest that systemic nicotinic, but not muscarinic receptor antagonism, 
enhances and prolongs quinine-CTA by acting on its specific cholinergic signaling mechanism, 
and not through non-specific malaise-induced effects.   These effects extend our previous 
(Rotella et al., 2014) findings demonstrating that the persistence of quinine-CFA was 
significantly enhanced by systemic administration of DA D1, NMDA and opioid, but not DA D2 
receptor antagonists administered prior to training. Thus, systemic nicotinic, DA D1, NMDA and 
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opioid, but not muscarinic, or DA D2 receptor antagonists administered during training enhanced 
and prolonged the acquisition of quinine-CFA.       
 In the quinine-CFA paradigm, systemic BAC dose-dependently enhanced and prolonged 
the magnitude of quinine-CFA with rats receiving the 5 mg/kg BAC dose during training 
eliciting significantly higher CS- than CS+ intake across all three tests. As observed previously 
(Rotella et al., 2014, 2015), the VEH-trained group consumed significantly more CS- than CS+ 
only during Test 1. The BAC 3-trained group consumed significantly more CS- than CS+ during 
Test 3, and this pattern approached significance in Tests 1 and 2. Consequently, the magnitudes 
of quinine-CFA as measured by percent CS+ intake takes were significantly lower across all 
three tests in rats trained with the 5 mg/kg BAC dose (15-20-25%) relative to VEH-trained rats 
(34-48-47%). The dose-dependent ability of systemic GABAB receptor activation to enhance and 
prolong quinine-CFA is similar to that observed following systemic dopamine D1, NMDA, 
opioid or nicotinic, but not dopamine D2 or muscarinic antagonists (Rotella et al., 2014, 2015). 
A role for GABAB receptor systems in conditioned aversions is supported by the ability of the 
GABAB agonist, BAC, but not the GABAB antagonist, saclofen, to suppress saccharin-induced 
drinking following pairing (Echo et al., 2002; Wilson et al., 2011). However, another study using 
a similar dose range found that systemic BAC failed to induce an aversion or affect ethanol-
induced aversions (Chester and Cunningham, 1999). Further, although systemic BAC failed to 
alter operant responding to quinine-adulterated solutions (Petry and Heyman, 1997), it did 
enhance the discriminative abilities of D-amphetamine in a conditioned taste aversion procedure 
(Miranda et al., 2009). The present findings that systemic BAC enhanced and prolonged quinine-
CFA extends the role of GABAB receptor signaling in both orosensory and post-ingestive 
processes related to avoidance and aversion, respectively. These data implicate GABAB receptor 
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signaling in the acquisition of quinine avoidance and extend our findings to that of systemic 
nicotinic, DA D1, NMDA and opioid, but not muscarinic, or DA D2 receptor antagonism, as 
demonstrated by the enhancement and prolonged duration of the acquisition of quinine-CFA.  
2A. CFP and CFA: Theoretical Perspective of Pharmacological Effects   
The series of studies conducted for this dissertation involved the pharmacological 
substrates of both the learning and maintenance of two forms of food-related preference learning 
in rats, fructose-CFP and corn oil-CFP, as well as the learning of a form of food-related 
avoidance, quinine-CFA.  Much evidence supports the roles of the D1, D2 and NMDA receptor 
antagonism in the acquisition and expression of both fructose- and corn oil-CFP and the present 
series of studies provide even further elucidation of the pharmacology of these learned food-
related preferences.  By contrast, the pharmacological substrates of learned food-related 
avoidances are far less studied, and as a result the series of studies conducted for this dissertation 
extended the pharmacology of learned preferences to learned avoidances, demonstrating stark 
behavioral and pharmacological differences between the two.  These findings are summarized in 
Table 1. 
With respect to learned food-related preferences (fructose-CFP and fat-CFP), we show 
that muscarinic receptor signaling is involved in the associative learning phase of both food-
related preferences that were under investigation, but not the expression phase of this learning:.  
We reported that systemic administration of SCOP eliminated the acquisition of both fructose- 
and corn oil-CFP acquisition, with slightly more robust effects for fructose-CFP (40-54% 
indifference) than CO-CFP (41%-59% indifference).  These results lend behavioral support for a 
cholinergic hypothesis of learning and memory (Hasselmo, 1999, 2006; Hasselmo et al., 2002;  
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Table 1
Summary of systemic pharmacological findings in the fructose-conditioned flavor preference (CFP) expression and acquisition, 
quinine-conditioned flavor avoidance (CFA) acquisition and corn oil-CFP acquisition and expression paradigms.
Paradigm Neurotransmitter system Effect Effect Reference
Receptor sub-type: drug Acquisition Expression
Dose
A. Fructose-CFP Dopamine
DA D1 antagonist (SCH) Blocked Blocked* Baker et al., 2003
DA D2 antagonist (RAC) Blocked Blocked* Baker et al., 2003
Glutamate
NMDA antagonist (MK801) Blocked No Effect Golden & Houpt, 2007
Opioid
General antagonist (NTX) No Effect No Effect Baker et al., 2004
Acetylcholine
mACh antagonist (SCOP) Blocked Attenuated Rotella et al., 2015
nACh antagonist (MEC) No Effect Attenuated Rotella et al., 2015
GABA
GABAB agonist (BAC) No Effect Attenuated Rotella et al., 2016a
B. Quinine-CFA Dopamine
DA D1 antagonist (SCH) Enhanced/prolonged n/a Rotella et al., 2014
DA D2 antagonist (RAC) No Effect n/a Rotella et al., 2014
Glutamate
NMDA antagonist (MK801) Enhanced/prolonged n/a Rotella et al., 2014
Opioid
General antagonist (NTX) Enhanced/prolonged n/a Rotella et al., 2014
Acetylcholine
mACh antagonist (SCOP) No Effect n/a Rotella et al., 2015
nACh antagonist (MEC) Enhanced/prolonged n/a Rotella et al., 2015
GABA
GABAB agonist (BAC) Enhanced/Prolonged n/a Rotella et al., 2016a
B. Corn oil-CFP Dopamine
DA D1 antagonist (SCH) Attenuated Blocked Dela Cruz et al., 2012a
DA D2 antagonist (RAC) Attenuated Blocked Dela Cruz et al., 2012a
Glutamate
NMDA antagonist (MK801) Blocked Attenuated Dela Cruz et al., 2012b
Opioid
General antagonist (NTX) Attenuated Attenuated Dela Cruz et al., 2012b
Acetylcholine
mACh antagonist (SCOP) Blocked Attenuated Rotella et al., 2016b
nACh antagonist (MEC) No Effect Attenuated Rotella et al., 2016b
GABA
GABAB agonist (BAC) No Effect Attenuated Rotella et al., 2016b
DA: dopamine; NMDA: N-methyl-D-aspartate; SCH; SCH23390; RAC: raclopride; MK801: MK-801; NTX: naltrexone;
SCOP: scopolamine; MEC: mecamylamine, BAC: baclofen.
Blocked: Significant %CS effect present (≈ 50%) absent of significant differences in CS+ and CS- intakes. 
Attenuated: Significant %CS effect present (≈ 50%) including significant differences in CS+ and CS- intakes. 
* Very low CS intakes at higher doses
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Hasselmo & McGaughy, 2004; Klinkenberg & Blokland, 2010; Meeter et al., 2004).  This 
hypothesis proposes that oscillations  in cholinergic activity within a network including the 
entorhinal cortex, dentate gyrus, CA3, CA1 and medial septum (Meeter et al., 2004) shifts to 
allow optimal levels of information encoding, consolidation and retrieval, where decreases in 
cholinergic activity would impair encoding and increases would impair consolidation and 
retrieval.  Our findings lend support to this hypothesis in that SCOP administration differentially 
blocked the acquisition (encoding) phase of fructose- and CO-CFP.  These findings are similar to 
that of other studies demonstrating these effects on learning and memory using SCOP (Winters 
et al., 2007, 2006, 2008; Young et al., 1995); however, theses studies demonstrated that 
consolidation could even be enhanced by SCOP administration, which would suggest an 
enhanced expression of CFP.  Although we failed to demonstrate significant blockade or 
enhacement of expression of CFP in these studies, it could be due to methodological differences 
between the studies.   
Interestingly, these effects on acquisition were also seen for systemic blockade of DA and 
NMDA receptors in rats.  In contrast, nicotinic receptor antagonism or GABAB receptor agonism 
failed to affect either type of preference acquisition.  Given this, it could be hypothesized that 
muscarinic receptor signaling is required for acquiring a food-related association.  However, 
preferences are not the only form of associative learning animals and humans may acquire, 
avoidances are also possible.  Thus, it could be said that if muscarinic blockade simply interferes 
with all forms of food-related learning, it would also block learned food-related avoidances.  The 
current series of studies found a contrasting effect, in which systemically administered SCOP 
failed to affect the acquisition of quinine-CFA.  Therefore, the ability of SCOP to block the 
learning of a food-related association transcends the nutrient used to condition the behavior, but 
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may be related to the hedonic valence of the stimulus used to condition the behavior, where 
fructose and CO act as appetitive stimuli with positive hedonic valence and quinine acts an 
avoidant stimulus with negative hedonic valence. 
 Given these effects, it may be hypothesized that the pharmacological agents administered 
eliminate or reduce the salience of the stimulus used to condition the behavior, leading to 
indifference during extinction testing.  For example, with respect to CFPs, the positive hedonic 
qualities (e.g. sweet taste of fructose or fatty taste/texture of CO) play a role in their ability to 
condition flavor preferences, resulting in significant % CS+ preferences relative to CS-.  The 
current findings support the role of SCOP to eliminate the positive hedonic salience of fructose 
and CO given that administration of the drug blocked their acquisition as measured by 
indifference (about 50% CS+ relative to CS- intake) during two-bottle testing.  If this hypothesis 
were true of food-learning despite hedonic salience, the same would hold for avoidances, leading 
a taste avoidance to shift to indifference.  With respect to quinine-CFA, the negative hedonic 
quality (e.g. bitter taste of quinine) plays a role in its ability to condition a flavor avoidance, 
resulting in significant %CS+ avoidances relative to CS-.  By contrast, the current findings fail to 
support the role of SCOP in its ability to eliminate the negative hedonic salience of quinine by 
shifting the learned avoidance to indifference, given its failure to eliminate quinine-CFA 
acquisition.  Therefore it would seem that the effects of SCOP on food-related learning are 
restricted to conditioning occurring through the pairing of stimuli of positive hedonic salience. 
 Another interesting result was that nicotinic and GABAB receptor signaling, despite 
failing to mediate the acquisition of fructose- and CO-CFP, were found to significantly affect the 
acquisition of quinine-CFA, demonstrating a pharmacological and behavioral distinction 
between these and muscarinic signaling.  Here, we report that systemically administered MEC 
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and BAC significantly prolonged the duration of quinine-CFA.  If the above hypothesis were to 
hold true, it would be assumed that the acquisition of quinine-CFA would be eliminated rather 
than prolonged.  As a result, the totality of our findings does NOT support this hypothesis 
relating to the elimination of the salience of the stimulus used to condition the behavior. 
 A more encompassing hypothesis to the findings reported in this dissertation would be 
that the pharmacological agents administered serve to shift the acquired association in the 
negative direction, such that taste preferences would shift to indifferences and taste avoidances 
would become more avoided.  The results of SCOP administration provide support for this 
hypothesis in that systemic SCOP lead to %CS+ indifference for both fructose- and CO-CFP 
acquisition, also supported by similar effects reported for DA and glutamatergic NMDA receptor 
blockade, but not nicotinic, GABAB or opioid receptor blockade.  On the other hand, while 
systemic MEC or BAC administration caused an already avoided solution to become more 
avoided or avoided for longer periods of time, similar to opioid, DA and glutamatergic NMDA 
receptor blockade, muscarinic receptor blockade failed to affect quinine-CFA acquisition.  Thus 
although not all pharmacological agents administered affected the learning of these behaviors, 
most served to shift the acquired association in the negative direction, leading preferences to 
indifference and avoidances to become more avoided or for increased duration. 
2B. Future Directions of Research       
Cholinergic Effects:  The present data indicate that whereas systemic muscarinic (SCOP) 
and nicotinic (MEC) cholinergic receptor antagonism minimally affects fructose- and fat-CFP 
expression, systemic muscarinic, but not nicotinic cholinergic receptor antagonism effectively 
eliminates the acquisition of fructose- and fat-CFP. In contrast, systemic nicotinic, but not 
muscarinic cholinergic receptor antagonism enhanced and prolonged the acquisition of quinine-
  131 
 
CFA. The use of systemic cholinergic receptor antagonist treatment followed our previous 
strategy of initial systemic evaluation of DA receptor involvement in fructose-CFP (Baker et al., 
2003; Yu et al., 2000a, 2000b) followed by antagonist administration into central candidate 
limbic sites (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 2012).  Thus, we 
propose the central candidate sites for muscarinic receptor antagonist effects on fructose- and fat- 
CFP acquisition and nicotinic receptor antagonists for quinine-CFA acquisition.  
Muscarinic Acetylcholine Effects:  Much of the evidence implicating cholinergic 
involvement in complex aspects of food intake appears to be due to activity in a limbic circuit 
(specifically the VTA and NAc) in which cholinergic signaling can act directly upon preferences 
and avoidances either in and of itself, or through interactions with brain DA. Sweet solutions 
appear to affect both DA and Ach release.  One Ach-DA neuroanatomical interaction 
presumably occurs through Ach inputs from the PPT/LDT nuclei to identified DA cells in the 
VTA (Holmstrand and Sesack, 2011; Maskos, 2008; Omelchenko and Sesack, 2005; Woolf et 
al., 1990). The second Ach-DA interaction presumably occurs through DA terminal innervation 
of Ach-containing interneurons in the NAc (de Rover et al., 2002; Witten et al., 2010; Zhou et 
al., 2002), although cholinergic PPT/LDT innervation is found there as well (Dautan et al., 
2014). NAc cholinergic-DA interactions act through local DA D2 receptors (Alcantara et al., 
2003), mediate accumbal DA release that also involves glutamate signaling (Cachope et al., 
2012; Chuhma et al., 2014; Threlfell and Cragg, 2011), and provide feedback control of VTA 
DA release (Rahman and McBride, 2002).        
In addition to the ability of general food intake to increase DA and Ach in the NAc shell 
(Mark et al., 1992), daily bingeing on sugar repeatedly and initially released NAc shell DA 
followed by Ach NAc shell release (Rada et al., 2005).  Whereas real-feeding sucrose increased 
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NAc DA and Ach, sucrose intake in sham-drinking rats displayed the DA, but Ach elevations in 
the NAc (Avena et al., 2006). Correspondingly, increases in NAc DA were observed in normal-
weight and underweight rats, whereas NAc Ach was increased in the former, but not the latter 
group (Avena et al., 2008c). In contrast, animals trained to binge on a sucrose solution display 
increased Ach and decreased DA release in the NAc shell following food deprivation (Avena et 
al., 2008a). Consistent with the ability of sugars to produce greater CFP relative to saccharin, 
sucrose-predictive cues evoked greater NAc DA release than saccharin-predictive cues 
(McCutcheon et al., 2012). Administration of morphine, a mu-opioid agonist, DAMGO or 
galanin into the paraventricular nucleus of the hypothalamus increased DA and decreased Ach in 
the NAc shell (Rada et al., 1998, 2010). VTA Ach and NAc DA are concomitantly released by 
the orexigenic peptide, ghrelin (Jerlhag et al., 2012).  Given these relationships, a central site of 
action at which muscarinic receptor antagonism might reduce fructose- and fat-CFP and interact 
with brain DA is the NAc shell. 
 Furthermore, multiple studies implicate the VTA as a potential site in which muscarinic 
antagonist effects may block the acquisition of CFPs, given not only the interaction of DA and 
Ach here, but also NMDA receptors.  NMDA receptor antagonism by MK-801 was found to 
block both fructose- (Golden & houpt, 2007) and fat-CFP (Dela Cruz et al., 2012b) and (2R)-
amino-5-phosphonopentanoate (AP-5) in the VTA impaired acquisition of lever pressing for 
food, but not when injected dorsal to the VTA suggesting region specificty (Zellner et al., 2009).  
Further, VTA NMDA receptor stimulation is necessary for both the acquisition of reward-related 
learning and acquisition by the CS to activate dopamine terminal regions, as measured by c-fos 
expression in forebrain structures such as prefrontal cortex area 2, nucleus accumens core and 
shell as well as medial and lateral caudate (Ranaldi et al., 2011).  It has also been reported that 
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primary rewarding UCSs activate VTA DA neurons and NSs associated with these UCSs acquire 
the ability to act as CSs since they also come to acquire the ability to activate VTA DA neurons 
through NS-UCS associations (Zellner & Ranaldi, 2010), as measured by c-fos activity in the 
VTA (Kest et al., 2012). 
This dissertation reported that systemic antagonism of muscarinic cholinergic receptors 
blocks the acquisition of both fructose- and corn oil-CFP, but failed to affect the acquisition of 
quinine-CFA suggesting that SCOP primarily interferes with reward-related learning.  These 
effects are support by studies demonstrating that SCOP in the VTA blocks the acquisition of 
reward-related learning in the absence of performance deficits (Galaj et al., 2017).  Similar 
effects were reported for the ability of VTA SCOP to block the acquisition of food-related 
learning (Sharf & Ranaldi, 2006) or the acquisition of food-rewarded operant responding, but not 
the performance of the task in rats as measured by a failure to affect lever pressing break points 
under a progressive ratio schedule of reinforcement (Sharf et al., 2006).  Taken together, these 
findings suggest that SCOPs ability to block acquisition of fructose- and corn oil-CFP may be 
due to interfering with the ability of the NSs to acts as CSs by preventing the CS to either 
activate VTA DA on its own or to prevent NMDA-dependent VTA DA activation.  Thus, 
muscarinic cholinergic receptor activation is necessary for a NS to acquire the ability to act as a 
CS through associating with a UCS in the absence of performance deficits. 
Given the pronounced effects of muscarinic cholinergic receptor antagonism on the 
acquisition of fructose-CFP, the process whereby these effects occurred may be discussed in 
relation to whether SCOP blocked the rewarding effects of fructose, or whether SCOP blocked 
the learned association.  A recent study reported that SCOP significantly reduced intakes of both 
a more preferred 16% sucrose solution as well as a less preferred 0.2% saccharin solution in 
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C57BL/6 and BALB/c mice, but not SWR mice (Olsson et al., 2017), suggesting not only a 
genetic difference in the extent to which muscarinic cholinergic receptor blockade influences 
sweet intake, but more importantly that SCOPs effects on intake did not depend on the rewarding 
quality of the stimulus in C57BL/6 and BALB/c mice.  Additionally, whereas SCOP dose-
dependently reduced the expression of sucrose-CFP in C57BL/6 and BALB/c mice it failed to 
affect expression in SWR mice, and while SCOP dose-dependently reduced the acquisition of 
sucrose-CFP in BALB/c mice it marginally affected acquisition in C57BL/6 and SWR mice 
(Bourie et al., 2017).  Therefore, the reductions induced by SCOP on acquisition and expression 
of sugar-CFP particularly in SWR mice appear due to interferrcnce with the associative process 
underlying the behavior (Bourie et al., 2017), and not the inherent reward value of the UCS 
(Olsson et al., 2017). Further studies are necessary to examine this “reward” vs. “learning” issue. 
 Nicotinic Acetylcholine Effects:  With respect to avoidances, DA D1, but not D2 
antagonism disrupted the acquisition of a LiCl-induced CFA following systemic administration, 
and following central administration into the LH or NAc shell (Caulliez et al., 1996; Fenu et al., 
2001, 2005, 2009), sites also involved in preference–related learning.  Blockade of NMDA, 
AMPA and metabotropic glutamate receptors in the AMY disrupted LiCl-induced CFA 
(Yasoshima et al., 2000).  SCOP and nicotine are capable of eliciting flavor-taste CFAs with the 
former abolished and the latter enhanced by lesions placed in the area postrema (Ossenkopp et 
al., 1986, Ossenkopp and Gugno, 1990). Further, nicotine depressed quinine-evoked responses in 
the nucleus tractus solitarius that were blocked by MEC (Simons et al., 2006).  Given these 
relationships, central sites of action at which nicotinic receptor antagonism might enhance 
quinine-CFA is through either by mediation of brain DA reward circuitry, acting within the NAc 
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shell, or by mediation of medullary toxin-detecting structures, acting within the area postrema or 
solitary nucleus.    
It is possibile that the greater subsequent avoidance responses could be due to non-
specific malaise brought about by pairing the antagonist with the flavored solutions during 
training.  Both LiCl-induced conditioned taste aversions and attenuation of neophobic responses 
were blocked by central SCOP pretreatment into the insular cortex (Ferreira et al., 2002; 
Gutierrez et al., 2003a, 2003b; Naor and Dudai, 1996) and NAc shell (Ramirez-Lugo et al., 
2006), but not when SCOP was administered after the presentation of the new taste. Although 
nicotinic receptor antagonists have not been evaluated in this paradigm, galantamine, an 
acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic Ach receptors, 
reduced nicotine seeking without producing malaise (Hopkins et al., 2012). These data suggest 
that systemic nicotinic, but not muscarinic receptor antagonism enhances and prolongs quinine-
CTA by acting on its specific cholinergic signaling mechanism, and not through non-specific 
malaise-induced effects. Further studies altering the timing of cholinergic antagonist injections 
are necessary to completely rule out participation by this non-specific effect.   
 GABAB Effects:  The present data indicate that whereas systemic BAC administration 
failed to significantly affect fructose- and fat-CFP, it enhanced and prolonged the acquisition of 
quinine-CFA. The use of systemic GABAB receptor agonist treatment followed our previous 
strategy of initial systemic evaluation of DA receptor involvement in fructose-CFP (Baker et al., 
2003; Yu et al., 2000a, 2000b) followed by antagonist administration into central candidate 
limbic sites (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 2012).  Thus, we 
propose the central candidate central sites for GABAB receptor agonist effects for quinine-CFA 
acquisition.            
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BAC administered into limbic and hypothalamic sites increased food intake (e.g., Arnt et 
al., 1979; Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 
1993), and was reported to be mediated through GABA receptor interactions between the VTA 
and NAc (Miner et al., 2010).  Feeding elicited by the GABAB agonist, BAC is mediated through 
GABA receptor interactions between the VTA and NAc (Miner et al., 2010). Indeed, brain DA 
and cholinergic systems modulate medium spiny NAc GABA output and VTA DA output (see 
reviews: Avena & Rada, 2012; Hoebel et al., 2007).  Given these relationships, a central site of 
action at which GABAB receptor agonism might enhance quinine-CFA is the VTA.  A summary 
of the proposed neuroanatomical system mediating sugar-CFP is presented in Figure 14. 
2C. Clinical Implications           
Food-Related Pathology:  Although the etiology of obesity is complex, including both 
environmental and genetic factors, obesity in humans tends to occur where cheap, highly 
palatable, and energy-dense foods are readily available (Dragone, 2009).  Furthermore, it has 
been proposed that the apparent bias in favor of weight gain rather than weight loss may be a 
result of not the body’s energy homeostasis sysems, but instead due to a bias towards meal 
initiation as a result of learning, sensory and emotional cues as well as certain societal variables 
(Saper et al., 2002; Schwartz et al., 2003).   As such, sensory, emotional and societal stimuli 
associated with palatable foods can activate potent reward systems that can override the 
homestatic energy system and lead to over-consumption.  Thus, understanding of the behavioral 
pharmacology of learned food preferences and avoidances may be translatable to human 
ingestive studies with the goal of determining the correct drug targets for therapeutic intervention 
in indiviuals with obesity or other food-related behavioral pathology.  Accordingly, muscarinic  
 




Figure 14. A model neuroanatomical system of a “distributed brain network” mediating the 
pharmacological effects of sugar-CFP. The model system begins with the ventral tegmental area 
(VTA) and its two major dopamine (DA) projections through the meso-limbic and meso-cortical 
pathways. In this model, the meso-limbic DA projection terminates in the nucleus accumbens 
(NAC) and amygdala (AMY) both of which possess DA D1 and D2 receptors (D1/2 R). The 
meso-cortical DA projection terminates in the medial prefrontal cortex (mPFC) and medial 
orbital frontal cortex (MOFC) both of which possess D1/2 R. The NAC sends GABA projections 
to the mPFC and MOFC, and in turn receives glutamate (Glu) projections from those cortical 
sites. Major Glu projections reciprocally innervate the AMY with the mPFC and MOFC. Further, 
mixed GABA/Glu projections reciprocally innervate 5the NAC and AMY. Finally, the VTA 
receives input from the NAC through the ventral pallidum (VP), from the AMY through a GLU 
pathway, and from the lateral hypothalamus (LH) through an orexin (Or) projection that is in 
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receptor antagonists such as SCOP may be used to help reduce the associations made between 
unhealthy foods or their associated environmental cues and their rewarding flavors in patients 
diagnosed with pre-diabetic symptoms.  Further, nicotinic receptor antagonists and GABAB 
receptor agonists may be used to help enhance the negative qualities or environmental cues 
associated with binge- or over-eating, effectively combatting the development of diabetes. 
 Food and Addictions:  Animal models of consumption have shown that high-fat and/or 
high-sugar foods lead to neurobiological and behavioral changes that are similar to those due to 
consumption of addictive drugs including their associations with reward dysfunction (Gearhardt 
et al., 2011; Davis et al., 2013) and behavioral factors such as craving and impulsivity (Murphy 
et al., 2014; Meule & Kubler, 2012; Meule & Gearhardt, 2014).  Accordingly, although the 
behaviors assessed in this dissertation involved primarily orosensory properties, similar 
associative processes play a role in the development of various addictions, for example, 
alcholism.  BAC (Colombo et al., 2004) or GABAB positive allosteric modulators (Maccioni et 
al., 2015) were reported to suppress the acquisition and maintenance of alchol self-administration 
in rats by reducing their reinforcing properties.  Further, BAC has been reported to be effective 
in reducing the craving aspect of alcohol addiction in a clinical study of men (Rozatkar et al., 
2016).  In our studies, we found that while BAC administration failed to affect preference 
learning, it significantly enhanced and prolonged quinine-CFA, suggesting its role was to 
increase quinine’s avoidant properties.  Given this, perhaps this dissertation research can help 
explain BAC’s effectiveness in reducing alchol self-administration by means of enhancing 
avoidance to the negative and toxic qualities of alcohol.     
 With respect to nicotine addiction, MEC has been reported to increase cessation rates in 
smokers most effectively when combined with a nicotine patch (Lancaster & Stead, 2000).  We 
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report here that while MEC administration failed to affect preference learning, it significantly 
enhanced and prolonged quinine-CFA, demonstrating the pharmacological difference between 
cholinergic receptor subtype on behavior type.  Our results suggest that MEC’s role was to 
increase quinine’s avoidant properties, thus enhancing and prolonging the avoidance.  Together 
these findings suggest that MEC is a potential pharmacological agent to aid in smoking cessation 
during periods of reduced intake and that this behavioral result could be also due to MEC 
enhancing the negative and toxic qualities of nicotine when paired with a nicotine patch, such 
that it may act to enhance the actions of the nicotine patch without having to apply it as often or 
in higher doses.      
In addition, a recent study reported that ADX71441, a novel GABAB receptor positive 
allosteric modulator, decreased alcohol self-administration preferentially in alcohol-dependent 
versus non-dependent rats and further blocked cue- and stress- induced relapse (Augier et al., 
2017), which are a result of underlying associative processes with alcohol consumption.  In 
comparison to BAC, ADX71441 achieved these effects in the absence of significant secondary 
non-specific effects.  Given the similaries in the effects of BAC versus ADX71441 in alcohol-
related behaviors, but the benefit of ADX71441’s lack of secondary non-specific effects, it 
would be interesting to see how ADX71441 influences the orosensory learning procedures we 
evaluated in this dissertation.  If the secondary non-specific effects of BAC were interfereing 
with its central effects on learning, use of ADX71441 may help to rule out this issue.  
In conclusion, the results from our series of studies suggest that whereas muscarinic 
cholinergic receptor signaling mediates acquisition of preferences associated with sweet and 
fatty tastants, nicotinic cholinergic receptor signaling mediates acquisition of avoidances 
associated with bitter tastants, in addition to GABAB receptor signaling.  These results expand on 
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previous literature supporting the roles of DA D1, D2 and NMDA receptor signaling in the 
acquisition of preferences associated with sweet and fatty tastants and the roles of DA D2, 
NMDA and opioid receptor signaling in the acquisition of avoidances associated with bitter 
tastants, ultimately lending support for theories proposing the interaction of these major 
neurotransmitter systems in the development of food-related learning behaviors.  Interestingly, 
none of the antagonists administered significantly affected the expression of these preferences or 
avoidances, similar to more sparse effects for DA, glutamate and opioid systems, suggesting that 
the maintenance of these learned effects maybe be more isolated with respect to neurochemistry.  
Although these series of studies are limited in the extent that they examined pharmacological 
effects rather than anatomical effects, they do provide support for future studies in which 
anatomical substrates may be targeted.  Much of the underlying processes of learning and 
memory remain unclear, but it can be thought that these processes are mediated by a distributed 
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